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Abstract - Influenza in Vulnerable Populations 
Influenza is a ubiquitous virus that results in thousands of deaths annually, particularly in 
susceptible people. Vulnerability is manifested in two different scenarios, with circumstances 
that render the whole population vulnerable i.e. when resistant or novel strains start to 
circulate or predominate; and in those prone to influenza, such as the extremes of age, 
colonised populations, and those with chronic diseases. The first three chapters address 
situations that have a population impact. Chapter 1 reviews literature on oseltamivir-
resistance. Current circulating strains are susceptible, albeit with clusters of oseltamivir-
resistance. In the recent past, oseltamivir resistant strains predominated, highlighting the 
need for alternative strategies. Chapter 2, a randomized controlled trial, demonstrated no 
clinical or virological advantage of double dose versus standard dose oseltamivir. Chapter 3 
reviews the application of polyclonal antibodies to neglected diseases including avian 
influenza, with promising results in terms of safety and immunogenicity. Chapters 4, 5 and 6 
turn attention to those demographically at risk of influenza. Chapter 4 aims to discover which 
antiviral strategies works best to prevent and manage influenza outbreaks in aged care 
facilities. A protocol for treatment alone versus treatment plus prophylaxis is proposed. The 
issue of how to obtain participation consent remains unresolved. In chapter 5, oseltamivir 
pharmacokinetics in infants is presented, with a paucity of published data. Our results 
support current dose recommendations. Chapter 6 examines the intersection of higher rates 
of both background chronic conditions and severe influenza during the 2009 pandemic 
amongst Indigenous Australians. The first age-standardised national analysis of government-
collected data is presented. There was no clear correlation between background chronic 
disease and influenza in Indigenous Australians. This suggests other factors resulting from 
colonisation are responsible for higher influenza rates.
I would like to acknowledge the traditional Aboriginal and Torres Strait Islander
owners of Australia and commit to working with their interests in mind.
Rashmi Dixit
PhD Student
Faculty of Medicine
Sydney University
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1. Influenza in Vulnerable Populations - Introduction
1.1 Motivation for this PhD Thesis 
As an infectious diseases specialist with an interest in the health of vulnerable populations, I 
undertook this PhD thesis in influenza, as it is not only a ubiquitous respiratory virus, but varies in its 
clinical impact, depending on the underlying health of the patient. Whilst influenza causes annual 
seasonal epidemics in temperate climates, certain populations are more prone to severe or intractable 
disease. This thesis examines the impact of influenza and its antiviral management in vulnerable 
populations: those who are particularly susceptible to influenza and its complications. These include 
circumstances where antiviral-resistant strains of influenza are circulating such that treatment options 
become limited, the elderly, the very young, those with compromised immune responses (particularly 
due to pre-existing organ system diseases), and Indigenous peoples of colonised countries (1–5). 
Serological naivety to circulating strains also predisposes the population to infection. This is 
particularly evident during influenza pandemics, such as the 2009 influenza A H1N1 'swine flu' 
pandemic, which mostly affected the younger population due to pre-existing immunity from prior 
exposure to related influenza strains in the older demographic, especially in those over 75 years (6,7). 
It is also of concern in the event of circulation of new reassorted influenza viruses, such as various 
avian influenza strains. I have an interest in the intersection between and communicable and non-
communicable diseases, the latter which can be the result of proximal social, economic, 
environmental, and ‘lifestyle’ determinants, such as diet, human movement culture, travel, poverty 
and health infrastructure and access. 
1.2 Thesis Aims 
The aims of this thesis are: 
1. To examine the extent of influenza antiviral resistance in circulating strains, which place
immunologically vulnerable populations at risk – e.g. due to reduced vaccine response 
2. To examine strategies to prevent or overcome antiviral resistance – e.g. different dosing
regimens and novel antiviral strategies, such as antibody therapies 
3. To examine the use of antivirals in the vulnerable extremes of age – infants, about whom
there is a paucity of pharmacological data; and the elderly in aged care facilities, in whom 
immune responses to vaccines are suboptimal and in whom outbreaks occur 
4. To examine whether the vulnerability of Indigenous Australians to higher rates of influenza
and its complications is due to the health gap between Indigenous and non-Indigenous 
Australians in chronic conditions 
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1.3 Introductions to Each Chapter 
1.3.1 CHAPTER 1 – A Historical Review of Oseltamivir Resistance 
My first paper is a published review of the emergence of oseltamivir resistance in influenza strains 
that predominantly circulated before, during and soon after the 2009 H1N1 influenza A ‘swine flu’ 
pandemic (8). Antiviral resistance is relevant in two settings of population vulnerability: when influenza 
immunisations are less reliable, and when there is serological naivety in the whole population due to a 
reasserted, novel virus. Effective antiviral agents are an essential part of the influenza management 
armament because vaccination, the most important strategy for influenza prophylaxis, has limitations. 
Firstly, the annual influenza vaccine is based on a prospective prediction of the circulating influenza 
strains, an imperfect science (9). Mismatch between vaccine strains and those that ultimately circulate 
can result in population vulnerability to influenza. Secondly, vaccine effectiveness is determined by 
the immune response in the recipient. The same immunocompromising factors that predispose 
vulnerable people to severe influenza can reduce biological responses to the vaccine, particularly old 
age and immunodeficiencies (10). Thus, the main additional protective measures for these individuals 
in whom the vaccine may, afford only partial protection are high levels of community vaccination 
conferring a ‘herd immunity’ effect; and antiviral medications (11). Herd immunity is limited by the 
influenza vaccine not being funded for all individuals in Australia by the Pharmaceutical Benefits 
Scheme; and by lack of vaccine promotion and uptake in those for whom it is funded (12,13). 
The main current antivirals recommended for influenza treatment by the World Health Organization 
(WHO) are the neuraminidase inhibitors oral oseltamivir, inhaled zanamivir, and IV peramivir (14). 
Neuraminidase inhibitors (NAI) were introduced in 1999, and are the only specific anti-influenza 
antivirals currently registered in Australia. Other antiviral classes such as the adamantanes 
(amantadine and rimantadine) now lack utility due to fairly rapid development of resistance amongst 
influenza A viruses: more than 99% resistance to influenza A (H3N2 and H1N1), and inherent 
inactivity against influenza B. Thus, continuous vigilance is required to anticipate development of the 
same fate for NAIs.  
I performed a literature search of all reports of resistance rates to oseltamivir in circulating viruses 
over the last several influenza seasons. Being aware of patterns such as the rate of development of 
resistance and the geographical distribution of resistant strains provides information to health 
authorities and the pharmaceutical industry to enable both accurate planning and development of 
alternative anti-influenza measures. These might include development of new antiviral medications 
and modes of therapy, and novel dosing and administration regimens of currently registered antivirals 
to avert or overcome resistance. I analysed utility of oseltamivir by documenting a detailed timeline of 
circulating influenza strains since the release of oseltamivir in 1999, and the degree to which 
oseltamivir resistance had developed amongst them. I summarised in table format many published 
reports and case series from different countries and continents, representing different clusters. 
Oseltamivir resistance can be conferred by a single missense mutation at the gene coding for the 
oseltamivir-binding site.  Resistance arose and spread quickly in 2007–2008, resulting in a majority of 
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circulating seasonal influenza A/H1N1 strains being oseltamivir-resistant in 2008. I took a narrative 
approach, because the studies were heterologous. 
Strategies to reduce emergence of resistant strains, such as higher dose oseltamivir regimens, 
development of new antiviral classes, or even resurrection of historical treatment methods, warranted 
further examination. 
1.3.2 CHAPTER 2 – An Unblinded Randomised Controlled Trial of Standard versus Double Dose 
Oseltamivir 
My second paper explored one of these strategies: I conducted an unblinded controlled trial of 
differential oseltamivir dosing in healthy children and adults with influenza (15). I compared the 
current recommended doses to a regimen where the standard dose was doubled (16). Due to limits 
imposed by ethical considerations, the study was performed on healthy patients without serious 
comorbidities, in whom side effects would be better tolerated. The strategy of doubling the dose of 
oseltamivir has been employed in treating hospitalised immunocompromised patients, who shed virus 
for longer than immunocompetent people, and in those with severe influenza in an attempt to clear 
symptoms and stop viral shedding more quickly (17–19). Prolonged nasal shedding of the influenza 
virus can stretch hospital resources due to the requirement to isolate these patients. This strategy of 
doubling standard doses has been recommended by the WHO for immunosuppressed individuals 
with severe influenza, with acknowledgment that the evidence base is weak (20). Evidence is 
additionally lacking for the proposition that increasing the viral kill rate via higher antiviral doses 
reduces development of strains containing resistance-conferring mutations. However, oseltamivir has 
a narrow therapeutic index with frequent gastrointestinal side effects, which might limit higher doses 
(21). While a few studies have examined different dosing regimens of oseltamivir in hospitalised 
patients, where recognition of efficacy and side effects is enhanced by the ability for close clinical 
observation, most patients at increased risk of severe influenza are diagnosed and treated in the 
community, including those with obesity, diabetes, heart disease and asthma (22-25). Our study was 
unique in addressing patients with influenza in the mild to moderate (non-hospitalised) stages. We 
aimed to recruit from either a hospital emergency department with most cases discharged straight 
back into the community, or in a community general practice. The objectives of this study were to 
investigate the effectiveness of DD (150mg bid for adults or 10mg/kg for children) as compared with 
SD (75mg bid or 5mg/kg for children) oseltamivir in subjects ≥5 years old. I examined clinical disease, 
virological outcomes, adverse events and the frequency of detection of oseltamivir-resistant virus. If 
the results of this study demonstrated a clinical and virological advantage without increased 
gastrointestinal side effects, it could provide a case for extrapolating such a study to those with 
predisposing health conditions. The next chapter examined an alternative strategy for antiviral 
management in the context of oseltamivir resistance and novel strains, which, as I have discussed, 
place both the general population and those at risk of infection and disease severity at risk.  
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1.3.3 CHAPTER 3 – Heterologous Polyclonal Antibody Therapy for Influenza Management as a 
strategy for both Oseltamivir-Resistance and Avian Influenza 
My third paper explored another of the strategies for management of resistant influenza (and other 
infections) – heterologous polyclonal antibody therapy. I explored an 130-year-old strategy with 
modern applications – antibodies against various toxins and pathogens that have been raised in 
horses, sheep, and other animals, and are then extracted and purified before being applied to 
humans (42). I performed an extensive, original review. As my first paper demonstrated, currently 
circulating strains are largely sensitive to oseltamivir, but strains that predominated in previous 
seasons developed a high level of resistance, e.g. seasonal H1N1 during the 2007–2008 influenza 
season. Additionally, resistance can develop either de novo or during treatment. Such viruses can 
then circulate, and become responsible for clusters of oseltamivir-resistant influenza, such as the 29-
case cluster in 2011 of oseltamivir-resistant pandemic 2009 A (H1N1) viruses (‘swine flu’), from 
Hunter New England, New South Wales (Appendix 9.1). More worryingly, highly pathogenic avian 
viruses such as H5N1 and H7N9, which currently have limited human-to-human transmission ability 
and to which the population is by and large previously unexposed, may acquire virulence factors that 
would enable expedient human spread. This sets the scene for another global pandemic – one that 
may be far more devastating than the 2009 ‘swine flu’ pandemic, to which there was some pre-
existing population immunity in the elderly. These avian strains currently remain sensitive to 
oseltamivir. Were resistance to NAIs to become widespread, there would be no fallback treatment 
option, with potential to cause widespread morbidity and mortality. A relatively low number of cases of 
avian types, such as influenza A (H5N1) and influenza A (H7N9), have been reported; mainly in 
vulnerable groups such as the elderly and those with pre-existing chronic illnesses (26–31). Thus, 
vulnerable populations – the elderly, and those with underlying illnesses and compromised immune 
systems – are particularly at risk of avian influenza. There is serological evidence that the incidence of 
subclinical infection of H5N1 is much higher than clinical infection (32,33). These strains currently 
have low person-to-person transmissibility, but mutations that can confer this ability can set the scene 
for a global pandemic (27,34). There is no evidence of background serological immunity to H7N9 prior 
to 2012, and only of low background rate of immunity to H5N1, rendering the global population 
vulnerable to an avian influenza pandemic (32,35,36). The WHO and the United States-based 
Centers for Disease Control and Prevention both currently recommend early initiation of oseltamivir, 
based on limited data demonstrating a possible mortality benefit (37,38). However, several 
oseltamivir-resistant H7N9 and H5N1 clinical isolates have emerged (39–43). In the event of an 
epidemic or pandemic, secondary modes of effective treatment are warranted. Development of a 
reliable vaccine has been hampered by technical difficulties and poor immunogenicity on testing, 
requiring at this time a reliance on treatment modalities against avian influenza to address morbidity 
and mortality (44).  
Currently, heterologous polyclonal antibodies are used against snake venom toxin and rabies virus 
infection, with great success. Historically, however, they have had applications to a range of viruses 
and bacteria in the pre-antibiotic era, and may be called upon in the advancing era of multi-resistant 
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bacterial infections. (45,46). These therapies are being reexamined as treatment options for epidemic 
and pandemic strains of influenza, such as avian influenza (47). They were used in the 1918 ‘Spanish 
flu’ pandemic, and the WHO Blood Regulators Network has recognised their potential role against 
pandemic influenza in its ‘Position paper on collection and use of convalescent plasma or serum as 
an element in pandemic influenza planning; July 2009’ (48). Thus, there is a renewed focus on old 
technologies that predated the antibiotic era. This review aimed to examine the current utility of 
heterologous antibodies – their safety and efficacy, and modern ways of overcoming their past 
limitations, namely hypersensitivity reactions to animal proteins. I reported developments in their 
production for application to avian influenza, and the result of a phase I trial. This paper concluded my 
analysis of oseltamivir resistance as a condition that places the general population, particularly those 
at higher risk of influenza acquisition and severity, at risk of untreatable disease. I proceeded in the 
rest of my thesis to explore the impact of influenza and its management in various vulnerable sub-
populations. 
My last three papers focused on influenza in those individuals whose demographics confer 
vulnerability. 
1.3.4 CHAPTER 4 – A Protocol for a Randomised Controlled Trial of Oseltamivir for Management of 
Influenza Outbreaks in the Elderly Residing in Aged Care Facilities 
The first of these investigations of those whose demography predisposes them to influenza, was a 
study of strategies to prevent of influenza outbreaks amongst the elderly residing in aged care 
facilities (ACFs). Elderly people are at a heightened risk of acquiring influenza and dying from it. 
Moreover, communal living arrangements and sharing of both staff and amenities promote influenza 
outbreaks. Aged care facilities are also a potential source of community outbreaks. The 
Communicable Diseases Network of Australia guidelines on influenza outbreak management in 
residential care facilities were published in 2009 and were updated in 2017 (49,50). Both the previous 
and current guidelines advise ‘consideration’, only, of oseltamivir for treatment of cases plus treatment 
of contacts (prophylaxis) during outbreaks (as opposed to no prophylaxis). The lack of firm 
recommendations reflects the paucity of evidence.  
I generated a protocol for an extensive, unblinded, randomised controlled trial of influenza treatment 
of cases (arm 1) versus treatment of cases plus prophylaxis (arm 2) during influenza outbreaks, in up 
to 100 Western Sydney ACFs. Elderly residents of ACFs are particularly prone to influenza and its 
complications (51,52). Being frail, the institutionalised elderly person mounts a poorer immune 
response to the influenza vaccine than younger recipients (53–55). Elderly patients often have chronic 
illnesses and reduced mobility, both of which predispose them to complications of influenza, such as 
pneumonia (56,57). Aged care facilities are also a setting for influenza outbreaks amongst both 
residents and staff due to communal living arrangements; these outbreaks can potentially spread to 
the community via staff and visitors (51,52) 
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The role of oseltamivir itself has come under much scrutiny in the published literature, at meetings 
and conferences, and subsequently amongst health care professionals. A 2014 Cochrane review of 
randomised controlled trials concluded that oseltamivir treatment reduced symptoms of influenza by 
17 hours, and prophylaxis reduced development of influenza (58). Regarding development of 
complications or death, they reported either no reduction or a lack of firm conclusions.  They reported 
an increase in gastro-intestinal and neuropsychiatric side effects. Significantly, this review did not 
address institutional outbreaks. The review was criticised for excluding observational data, the main 
data type collected during the 2009 pandemic, and its findings were controversial. A 2014 review of all 
Roche-sponsored controlled trials by the United Kingdom-based Multiparty Group for Advice on 
Science came up with different findings: they showed symptom reduction by 25 hours, as well as a 
risk reduction in lower respiratory tract infections (pneumonia and bronchitis) of 44%, and a 63% risk 
reduction of hospital admission (59). They found only gastro-intestinal side effects, and no 
neuropsychiatric adverse events. Renowned Australian influenza epidemiologists Aeron Hurt and 
Heath Kelly recently called these secondary outcome findings into question, as hospital admissions 
were ‘all cause’ rather than specifically for influenza, and definitions of lower respiratory infection were 
not standardised. Various reviews of observational data of tens of thousands of hospitalised patients 
by the same Multiparty Group for Advice on Science demonstrated a reduction in mortality amongst 
those with laboratory-proven influenza in those who received oseltamivir within 48 hours (60,61). 
In 2016, Hurt and Kelly reviewed all these conflicting publications and concluded that oseltamivir 
reduces symptoms by up to 1 day, and possibly mortality in severely ill patients, when given early 
(within 48 hours) (62). 
Booy et al., in a study of 16 ACFs, showed oseltamivir significantly reduced acute influenza attack 
rates and outbreak duration when used for treatment of cases plus prophylaxis of contacts, compared 
to treatment of cases alone. It was underpowered to show differences in complications of severe 
influenza (63). In contrast, a recent study of 42 nursing homes over five seasons demonstrated 
oseltamivir prophylaxis was ineffective in preventing influenza or influenza-like illness, but this was 
also underpowered (64). A retrospective comparison of three different prophylaxis approaches in 
three individual ACFs during one influenza season showed that prophylaxis did not reduce attack rate 
but did reduce mortality, hospitalisation, and outbreak duration (65). These contrasting findings 
amongst underpowered studies of oseltamivir use in ACFs highlight the need for better data. An 
expanded study of 70–100 ACFs would provide the statistical power needed to accurately assess the 
benefits of antiviral prophylaxis.  
Therefore, this enlarged and expanded study protocol was developed with several additional 
measures proposed. This study introduces several elements not present in the smaller study. It 
includes information sessions conducted at ACFs to institute enhanced infection control before 
outbreaks, e.g., promoting vaccination, reinforcing hand hygiene, and instituting contact and droplet 
precautions. The protocol also introduces a computerised active surveillance system with clinical 
monitoring and early notification of cases of influenza-like illness, an intervention that could 
conceivably widened to other infectious outbreaks in ACFs. Influenza-like illness confirmed as 
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influenza with point-of-care tests for rapid detection of influenza – training and monitoring ACF staff 
performance of these tests would be a new challenge. Finally, the calculation of sample size and 
outcome measures required involvement of a statistician; I liaised with Professor Christopher Triggs, 
Head of Department of Statistics at University of Auckland. I supplied him data from Booy et al’s 
current study as well as other literature to enable sample size calculations, based on statistical 
modelling. 
I collaborated with a wide range of professionals with expertise in public health, geriatrics, infectious 
diseases and microbiology. This was required to encourage effective cooperation to enable 
implementation of an expanded study in terms of scope and size. 
In this study, we proposed a cluster-randomised, unblinded controlled trial of residents and staff of 
70–100 ACFs with partnership between various stakeholders: ACFs, clinical researchers, general 
practitioners, government public health bodies, and relevant industry partners. Over one influenza 
season, screening of symptoms to identify influenza-like illness would be followed up by rapid point-
of-care tests to diagnose influenza. Aged care facilities would be randomised to receive either 
oseltamivir treatment of cases or oseltamivir treatment of cases plus prophylaxis. We hoped to 
compare the attack rate of influenza in treatment vs. treatment and prophylaxis groups, and hospital 
admission incidence. Secondary outcome measures would be the rates of case fatality, lower 
respiratory tract infections, and adverse events as well as influenza outbreak duration. 
Hurt and Kelly commented that randomised controlled trials of oseltamivir are unlikely to be 
conducted on severe laboratory-confirmed influenza due to the ethical constraints (62). They 
recommended ongoing evaluation of prospectively collected observational data. We certainly found 
that we were subject to concerns about ethics in obtaining buy-in and consensus from prospective co-
authors and stakeholders to a randomised controlled trial of oseltamivir use in ACFs. Obtaining 
consent became the sticking point, as noted in my discussion. Ultimately, we were unsuccessful in 
obtaining consensus within the time frame for this PhD. However, there have been some positive 
discussions with prospective funding bodies for this study; the question will remain as to how the 
issue of consent will be resolved. Funding has been procured for an observational study of oseltamivir 
in management of outbreaks in ACFs with Professor Booy as lead.  
 
1.3.5 CHAPTER 5 – Pharmacokinetics Of Oseltamivir in Infants  
Extremes of age predispose individuals to influenza and its complications. This does not limit itself to 
the elderly, but also includes infants and neonates. I published an oseltamivir pharmacokinetic study 
in infants for my 5th chapter. Infants less than a year old are at greater risk of influenza infection than 
older children and adults (66,67). Vaccinating pregnant mothers is one strategy for protecting 
neonates and infants, via transplacental transfer of antibodies, but has not categorically confirmed a 
reduction in the risk of infant hospitalisation from influenza (5,68–70). When infants become very 
unwell with influenza, then treatment with oseltamivir is often attempted to reduce morbidity and 
mortality. In Australia, oseltamivir is registered for treatment from infancy and prevention from 1 year 
  
8 
of age (71). There is a paucity of pharmacokinetic data for oseltamivir use in infants under 1 year of 
age. The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices 
advise dosing regimens for those under the age of 1 year based on extrapolation of doses in older 
children and adults (72). This may or may not be appropriate, given differences in developmental 
physiology of infants affecting parameters such as absorption, volume of distribution and clearance 
(73).  
There is only published data from one series of infants examining serum/plasma oseltamivir levels at 
the recommended dosing regimens of 3-3.5 mg/kg/dose, and the results confirmed that the dosing 
recommendations reached target concentrations without excessive side effects (74). We conducted a 
case series of oseltamivir levels in infants receiving oseltamivir at doses decided by the treating 
teams (73). This study undertook to confirm these recommendations by analysing pharmacokinetic 
data from infants who received oseltamivir. We sampled blood at set time points post-oseltamivir 
administration, usually when blood was being collected for other purposes to reduce the frequency of 
sampling; additionally, an ethical restriction required babies be cannulated for another purpose for 
inclusion in the study. Recruitment of cases was complicated by the fact that, as oseltamivir is an oral 
agent, many babies didn't require cannulation. Another issue that arose was that some babies were 
cannulated for only a few hours, too short for our sampling time frame. One of the influenza seasons 
over which the study was conducted resulted in no suitable cases admitted to the paediatric infective 
care unit from which we were recruiting. On one occasion we were unable to obtain blood through the 
cannula. As a result, we were able to recruit 4 infants and sent the samples to a laboratory in the 
United States to measure oseltamivir serum levels.  
 
1.3.6 CHAPTER 6 – The Role of Chronic Diseases in Influenza Incidence and Severity Differential 
Between Indigenous Australians and Non-Indigenous Australian Populations During the 2009 
Influenza Pandemic in Australia  
My final paper is central to my thesis for a PhD in Sydney, Australia. No analysis of vulnerable 
Australians would be complete without attention to the responsibility health professionals have 
towards Indigenous Australians. The first people of this land, Aboriginal Australians, have been 
proven to be vulnerable to both communicable and non-communicable diseases introduced after 
colonisation (75). Chronic conditions, such as diabetes mellitus, cardiovascular disease, tobacco-
related respiratory conditions, malignancies, and alcohol-related diseases are often nominated as risk 
factors for severe influenza, and vaccination is subsidised for those who suffer from these (5). 
However, rarely is prevention of non-communicable diseases discussed as a central strategy in 
reducing propensity to severe influenza. It is theorised that Indigenous Australian peoples, like many 
hunter-gatherer populations, evolved physiological mechanisms, such as relative insulin resistance, to 
efficiently utilise food resources – the so called, albeit controversial, ‘thrifty phenotype’ phenomenon 
(76,77). Many Indigenous peoples have lost traditional dietary and activity patterns. Game, fibrous 
foods and roots, paired with high levels of activity to procure these, were the basis of the traditional 
pre-European lifestyle; this has been replaced with a processed, high-carbohydrate, high fat diet, and 
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poor access to modern economic systems, leading to inactivity (78). This has resulted in an epidemic 
of metabolic dysfunction with its sequelae of obesity, cardiovascular disease, and diabetes. Add the 
introduction of tobacco and alcohol, and psychosocial intergenerational trauma from being displaced 
and oppressed, and Aboriginal and Torres Strait Islander peoples have higher rates of modern health 
ailments than other Australians; diseases that they successfully avoided for tens of thousands of 
years. 
Severe influenza occurs more often in Aboriginal and Torres Strait Islander peoples – but so do non-
communicable, chronic diseases (79). We theorised that it is the disparity in the rates of these modern 
ailments that contribute to higher rates of severe influenza in Aboriginal and Torres Strait peoples, but 
a data analysis would help to confirm or refute our theory. If our theory is correct, it provides yet more 
impetus for focus on closing the gap in chronic conditions between Indigenous and non-Indigenous 
Australians (80). 
We conducted a data analysis of de-identified state and territory group aggregate data on Indigenous 
Australian and non-Indigenous Australian patients who developed influenza in 2009, who also had 
various background chronic illnesses. This is the first age-standardised analysis of Australian national 
data sets; this is in contrast to smaller local analyses, which were usually not age-standardised. We 
examined a national data set for notifications, hospitalisations, Intensive Care Unit admissions and 
deaths from influenza by Indigenous status and by presence of a one of five common background 
conditions, as coded by the International Classification of Diseases and Health Related Problems 
(ICD-11) (81). These were chronic lower respiratory conditions, renal disease, cardiac disease, 
diabetes mellitus, and obesity. We used data on influenza reported to the Communicable Diseases 
Network of Australia on Indigenous and non-Indigenous Australians, and information on background 
rates of chronic illness in these groups from national health surveys reported in both the National 
Aboriginal and Torres Strait Islander Health Survey, and in the National Health Survey. Population 
rates of chronic conditions were calculated using rates obtained from these surveys and population 
data from the 2011 Australian Bureau of Statistics census. Correlating this data allowed us to 
examine the impact differential background chronic disease rates between Indigenous and non-
Indigenous Australians had on the incidence and severity of influenza A (H1N1) in 2009. There were 
some data limitations: data was only available for adults; there was no separation of data into those 
with influenza who had none, one or multiple background chronic conditions. Therefore, the 
comparator was all reported cases of influenza, which comprised a combination of those with any and 
all chronic conditions. We theorised that, if higher rates of influenza infection in Indigenous versus 
non-Indigenous people are largely or solely due to the higher prevalence of chronic non-
communicable diseases, then this disparity would be largely or completely eliminated by comparing 
infection rates only amongst those with chronic conditions. Further, if chronic diseases predispose 
patients to more severe influenza disease, then the increasing disparity between Indigenous and non-
Indigenous people with increasing influenza severity would be largely or solely eliminated by 
comparing influenza disease rates only amongst those with chronic disease. Our results were 
interesting and highlighted a number of potential interpretations, as I will discuss. 
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1.4 Summary 
In summary, I examined influenza both in situations of vulnerability to the general population, and 
when demographics confer specific vulnerability to certain populations. I researched epidemiological 
patterns and management strategies, via literature reviews, data analyses, protocol generation and a 
randomised clinical trial. 
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2.1 CHAPTER 1: Preamble 
 
Emergence of Oseltamivir Resistance: Control and Management of Influenza before, during 
and after the Pandemic  
 
 
Only one class of antivirals are currently utilised for influenza due to resistance emerging to other 
antiviral classes: neuraminidase inhibitors (NAIs). Resistant strains of NAIs were introduced in 1999, 
and are the only specific anti-influenza antivirals currently registered in Australia. Oseltamivir 
resistance can be conferred by a single missense mutation at the gene coding for it’s binding site. 
Oseltamivir resistance renders those with suboptimal immunity due to chronic conditions, extremes of 
age or specific immune deficiencies at high-risk of severe influenza disease; many of these same risk 
groups have suboptimal vaccine responses. NAI-dependence is thus problematic for these vulnerable 
populations. The otherwise healthy population is also vulnerable in the case of antigenic shifted 
strains such as avian influenza in which vaccines are not yet registered, and in whom background 
population immunity is low, were they to acquire more efficient person-to-person transmission as well 
as mutations that confer oseltamivir resistance.  In this review, I analysed utility of oseltamivir by 
documenting a detailed timeline of circulating influenza strains since the release of oseltamivir in 
1999, and the degree to which oseltamivir resistance had developed amongst them. I did this to 
highlight the vulnerability of reliance on neuraminidase-inhibitors, alone, as treatment for influenza. I 
summarised in table format many published reports and case series from different countries and 
continents, representing different clusters. I took a narrative approach, because the studies were 
heterologous.  
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Abstract: Neuraminidase inhibitors (NAIs), such as oseltamivir and zanamivir, are the medicines of choice against influ-
enza A or B. Oseltamivir resistance can be conferred by a single point missense mutation from histidine to tyrosine at po-
sition 275 (H275Y) of the neuraminidase gene. Oseltamivir resistance in seasonal influenza A/H1N1 strains rose mark-
edly during the 2007-2008 season. Furthermore, oseltamivir resistant (OsR) strains of pandemic influenza A/H1N1 2009 
(influenza A(H1N1)pdm09) have been increasingly isolated, although the majority remain sensitive. These OsR strains re-
tain virulence, replicative fitness and transmissibility from person to person, with outbreaks reported. Treatment options in 
those at risk of severe or complicated disease are limited to zanamivir which is only licenced in those over the age of 5 
years; of further concern, strains demonstrating low level resistance to both oseltamivir and zanamivir have been reported. 
Strategies to reduce emergence of resistant strains, such as higher dose oseltamivir regimens, need further examination. 
Keywords: Influenza, neuraminidase inhibitors, oseltamivir, pandemic, resistance.  
1. INFLUENZA A RESISTANCE TO NEURAMINI-
DASE INHIBITORS 
Neuraminidase inhibitors (NAIs), such as oseltamivir and 
zanamivir, are the drugs of choice against seasonal influenza 
A or B. NAIs bind to the surface protein neuraminidase 
(NA) of influenza A and B viruses, interfering with the re-
lease of viral progeny from host cells thereby reducing 
spread of infection to adjacent cells [1]. As part of pandemic 
planning, many developed nations acquired large stockpiles 
of oseltamivir. It’s advantages over zanamivir include being 
licensed for use as early as the neonatal period [2]. Wide-
scale use of antiviral agents, such as during a pandemic, may 
promote drug resistance. 
NAI resistance most often results from substitution of the 
amino acid histidine to tyrosine at position 275 (H275Y) in 
the neuraminidase (NA) gene of H1N1 affecting the NA 
binding site [3]. Certain factors favour its selection, particu-
larly the pressure of using oseltamivir. There are increasing 
numbers of oseltamivir resistant (OsR) strains with mutations 
other than H275Y [4-9]. These amino-acid substitutions con-
fer variable degrees of reduced oseltamivir susceptibility. 
From the introduction of the new antivirals in 1999 until 
2007-08, the proportion of influenza viruses resistant to 
NAIs among circulating influenza viruses in children was 
lower than 6% in clinical trials
 
[10]. The detection of in-
creased oseltamivir resistance was quite often not linked to  
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increased oseltamivir use. For example, in Norway, where 
the reported frequency of OsR strains of pre-pandemic H1N1 
was highest, data indicated that prior to emergence of the 
OsR strain, between 2004-2007, oseltamivir usage was low 
(0.17–1.64 courses sold/1000 inhabitants)
 
[11]. In Japan, 
rates of OsR H1N1 strains increased from 1.5%–2.6% in 
the 2007-2008 season to almost 100% in the 2008-2009 
season. The influenza A/H1N1 Yamagata lineage Japanese 
strains of 2007-2008 were phylogenetically distinct from 
those found in Europe and low-level oseltamivir resistance 
emerged in the context of wide usage of oseltamivir in 
clinical settings. In contrast the OsR strains found during 
the 2008-2009 Japanese season appeared to have spread 
from Europe [12].  
2. OSELTAMIVIR RESISTANCE IN THE PRE-
PANDEMIC PERIOD 
During the 2007-2008 influenza season, OsR influenza 
A/H1N1 viruses, such as OsR A/Brisbane/59/07(H1N1) vi-
rus, were first detected in continental Europe (about 56% 
viruses being resistant by week 19 of 2008), particularly in 
Norway (67% of 272 viruses tested being resistant) [13, 14]. 
In the same season in the USA, 12.3% of influenza A/H1N1 
strains were resistant to oseltamivir [5]. A clinical trial 
showed emergence of oseltamivir resistant pre-pandemic 
influenza A (H1N1 & H3N2) virus in up to 27% of children 
in the UK [15].  
Spread to the southern hemisphere subsequently occur-
red, with OsR H1N1 increasing from <1% to >90% in less 
than 12 months in 2008 throughout South Africa, South East 
Asia and Oceania [16].  
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Global and local surveillance data from USA, Europe, 
South Africa, Japan, Hong Kong, and Taiwan demonstrated 
that oseltamivir resistance predominated in pre-pandemic 
influenza A H1N1 during the 2008-2009 season [17]. For 
instance, 2008-09 surveillance data from USA showed 
99.4% of influenza A H1N1 strains were resistant to osel-
tamivir [18]. No difference in clinical severity was noted 
between the OsR and oseltamivir sensitive (OsS) viruses 
[19]. Table 1 shows the most recent trial and surveillance 
data from different parts of the world on oseltamivir resistant 
influenza [8, 13-57]. 
3. OSELTAMIVIR RESISTANCE IN THE PANDEMIC 
PERIOD 
The pandemic influenza A /H1N1 virus was first detected 
in Mexico in March 2009 and in the USA in April 2009 
(influenza A(H1N1)pdm09) [58]. It spread rapidly around 
the world, with the WHO declaring a pandemic on 11 June 
2009 [58]. Oseltamivir was used liberally for both treatment 
and post-exposure prophylaxis [12]. In Australia, recorded 
oseltamivir prescribing increased from approximately 25,000 
units in 2008 to over 350,000 in 2009 [40]. This increased 
drug pressure heightened the potential for oseltamivir resist-
ance to develop in the influenza A(H1N1)pdm09 strain.  
3.1. Global Data 
Global data from WHO revealed 598 cases of OsR influ-
enza A(H1N1)pdm09 cases as of 21 September 2011 [59]. In 
the 78% from whom clinical information was available 
(468/598), 29% (133/468) of OsR strains were found in se-
verely immunocompromised patients and 71% (335/468) in 
non-immunocompromised patients. Amongst the immuno-
competent, 63% (211/335) were associated with oseltamivir, 
and/or peramivir, treatment or prophylaxis. All of these vi-
ruses demonstrated the same H275Y mutation that confers 
resistance to oseltamivir, but not to zanamivir. On the other 
hand, worldwide, more than 10,000 clinical specimens of the 
influenza A(H1N1)pdm09 virus were tested and found to be 
sensitive to oseltamivir [60].  
Data from the CDC in the USA demonstrated an OsR 
influenza A(H1N1)pdm09 rate of 1.1% in 2009-2010 [24]. 
In the 2009-2010 season, most (76%) of the people in whom 
OsR viruses were found were immunocompromised and 
89% of them had been treated with oseltamivir before the 
OsR viruses were detected; the latter figure may reflect, in 
part, collection of specimens in those who received osel-
tamivir who were clinically suspected to have developed 
resistance. In contrast, only 11% of those with OsS virus 
were immunocompromised and 14% had received osel-
tamivir treatment, with none having received oseltamivir 
prophylaxis [46]. In the USA 2010-11 season, influenza 
A(H3N2) predominated slightly over influenza A(H1N1)pdm09 
and influenza B, although early in the season influenza B 
peaked. Of almost 5800 strains, 41 (0.7%) from all subtypes 
were OsR; 39 were the 2009 pandemic influenza A strain 
and 2 influenza A/H3N2 [25]. Another source gave a rate of 
1% (35/3652) in 2010-2011, comparable to the rate for the 
2009-2010 influenza season [49]. In contrast to the 2009-
2010 season, in the 2010-2011 season only 26% of those 
with OsR virus had received oseltamivir, and only 24% were 
immunocompromised [49].  
Multi-drug resistant strains of influenza A(H1N1)pdm09 
have been reported in association with I223R (isoleucine to 
arginine) mutation in the NA protein, mainly with immuno-
compromised patients, but also from case reports of immu-
nocompetent patients from North America [5-7, 61]. The 
clinical and public health significance of this mutation is 
undetermined as the IC50 (the concentration of drug required 
to inhibit 50% of NA activity) for each of oseltamivir and 
zanamivir remain below serum levels achieved by standard 
dosing regimens.  
Influenza B infection rates have been higher in recent 
seasons and some oseltamivir resistance has been reported. 
Sleeman et al. reported a cluster of 59 influenza B viruses 
isolated from patients in North Carolina that displayed osel-
tamivir resistance as a result of an isoleucine to valine substi-
tution at position 221 (I221V) [50]. This mutation is at an 
analogous site to the S247N mutation (substitution of serine 
with asparagine at position 247) found in influenza A virus. 
As the IC50 for oseltamivir of influenza B viruses is already 
far greater than that of influenza A viruses, the I221V muta-
tion may tip the viruses into clinically significant oseltamivir 
resistance. The IC50 for zanamivir for influenza B viruses is 
low; accordingly no zanamivir resistant isolates have been 
identified [62]. One OsR resistant influenza B case has also 
been isolated in the UK, as well as one in the Philippines and 
two in New Zealand. Influenza B does not generally cause 
epidemics and usually is a milder illness, however it can 
cause significant myositis, paediatric encephalomyelitis and 
more severe disease as well as complications in the debili-
tated and immunocompromised [63, 64]. 
3.2. Australian Clusters 
Co-circulation of different influenza strains, primarily 
influenza A(H1N1)pdm09 strain, influenza B and influenza 
A/H3N2 characterised the influenza seasons of the northern 
and southern hemispheres for 2010/2011, 2011, 2011/2012 
and 2012. Within Australia, the majority of influenza virus 
detections in 2011 were influenza A(H1N1)pdm09 with 
some co-circulation of influenza B [56]. At the start of the 
2011 season, high levels of influenza A/H3N2 were seen. 
More than 6% of positive influenza samples for the 2011 
season in Australia were sent to the World Health Organisa-
tion Collaborating Centre (WHO CC) in Melbourne. The 
WHO detected an influenza A(H1N1)pdm09 virus isolate 
that was resistant to oseltamivir, harbouring the H275Y mu-
tation. Initially two resistant viruses were detected in Austra-
lia, in January 2011 and March 2011 respectively, prior to a 
cluster of 25 OsR influenza A(H1N1)pdm09 cases identified 
from the Newcastle region in New South Wales between 
May and August 2011,
 
none of whom had received oseltami-
vir [54]. A further two OsR influenza A(H1N1)pdm09 vi-
ruses which were virologically related to the Newcastle clus-
ter, but geographically further afield, were detected in un-
treated children in July and August: one was from Sydney 
(160 kilometres from Newcastle) and the other was from 
Orange (380 kilometres away). This Newcastle cluster repre-
sents, globally, the largest cluster of oseltamivir resistant 
viruses reported by the WHO to date [65]. However, spread 
of oseltamivir resistant influenza A(H1N1)pdm09 strains to 
Sydney was limited, with only 2/143 (1.2%) of pre-treatment
19
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Table 1. Recent data on oseltamivir resistance across the world. 
Reference Nature of
Study 
Site Duration Subtype Percentage of resistant 
viruses % (resistant 
cases/tested samples) 
Neuramini-
dase muta-
tions 
Susceptibility to 
zanamivir (R/S) 
Comment 
Stephenson 
et al. [15]*  
Clinical 
trial 
United  
Kingdom 
2005-07 Pre-pandemic 
seasonal H1N1 
H3N2 
B 
Pre-pandemic seasonal 
H1N1:  
27.3% (3/11) 
H3N2:  
2.9% (1/34) 
B:  
0% (0/19) 
H275Y 
(H1N1) 
R292K 
(H3N2) 
R292K  
(H3N2): 10 fold 
reduction in 
susceptibility 
H275Y  
(H1N1): S 
Dharan et al. 
[19]  
Surveil-
lance 
USA Sep 07-
May 08 
Sep 08-
Feb 09 
Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1 
07-08: 
12.3% (142/1155)  
Pre-pandemic seasonal 
H1N1 
08-09: 
98.5% (264/268) 
H275Y S 
Besselaar et 
al. [20] 
Surveil-
lance 
South Africa 2007-08 Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 
100% (68/68) 
H275Y Not specified A/Brisbane/59/
2007 
Tamura et al. 
[21] 
Surveil-
lance 
Japan 2007-08 Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 
1.5% (3/202) 
H275Y Not specified A/Yokohama/
UTZS-48/08 
A/Yokohama/
UTKEI-62/08 
A/Tottori/UT-
52/08 
Hauge et al. 
[14]  
Surveil-
lance 
Norway 2007-08 Pre-pandemic 
seasonal H1N1  
Pre-pandemic seasonal 
H1N1: 
67.3% (183/272) 
H275Y S 
Meijer et al. 
[13]  
Surveil-
lance 
EU 2007-08 Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 
24% (712/2949) 
H275Y S A/Solomon 
Islands/3/2006  
A/Brisbane/59/
2007 
Cheng et al. 
[22] 
Surveil-
lance 
Hong Kong Jan 08-Jun
08 
Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 
12.5% (87/697) 
H275Y Not specified A/Brisbane/59/
2007  
A/Hong Kong 
/2652/2006 
Dia et al. 
[23] 
Surveil-
lance 
Senegal Jul 08-
Sept 08 
Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 
100% (86/86) 
H275Y Not specified 
Hurt et al. 
[16] 
Surveil-
lance 
South Africa, 
Oceania and 
south-east 
Asia 
2008 Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 
63.6% (168/264) 
H275Y S 
2009-10 A(H1N1)pdm09 A(H1N1)pdm09: 
1.1% (53/4811) 
Not specified S 
2010-11 A(H1N1)pdm09 
H3N2 
B 
Overall: 0.7% (41/5758) 
A(H1N1)pdm09: 0.9% 
(39/4229) 
H3N2: 0.2%(2/806) 
B: 0% (0/723) 
Not specified S 
2011-12 A(H1N1)pdm09 
H3N2 
B  
Overall: 0.6% (16/2756) 
A(H1N1)pdm09:  
1.4% (16/1164) 
H3N2: 0% (0/1275) 
B: 0% (0/317) 
Not specified S 
CDC,  
2009-2013 
[18,24-27] 
Surveil-
lance 
USA 
2012-13 A(H1N1)pdm09 
H3N2 
B 
Overall: 0.1% (4/2768) 
A(H1N1)pdm09: 0.5% 
(2/427) 
H3N2: 0.1% (2/1692) 
B: 0% (0/649) 
H275Y S No resistance 
amongst B or 
H3N2 strains 
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(Table 1) contd…. 
Reference Nature of
Study 
Site Duration Subtype  Percentage of resistant 
viruses % (resistant 
cases/tested samples) 
Neuramini-
dase muta-
tions 
Susceptibility to 
zanamivir (R/S) 
Comment 
2007-08 Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 0% (0/44) 
H275Y Not specified  
2008-09 Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1: 
100% (32/32) 
H275Y Not specified 
Kawai et al. 
[28] 
Surveil-
lance 
Japan 
2009-10 A(H1N1)pdm09 A(H1N1)pdm09:  
2.4% (2/82) 
H275Y Not specified The resistance 
developed post
oseltamivir 
therapy 
May 09- 
Apr 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.8% (45/5587) 
H275Y S 
2010-11 
influenza 
season 
A(H1N1)pdm09 A(H1N1)pdm09: 3.1% 
(56/1781) 
H275Y S 
2011-12 
influenza 
season 
A(H1N1)pdm09 
H3N2 
B  
Overall: 0% (0/177) 
A(H1N1)pdm09: 0% (0/6)
H3N2: 0% (0/164) 
B: 0% (0/7) 
H275Y S 
HPA [29]  Surveil-
lance 
United King-
dom 
2012-13 
influenza 
season 
A(H1N1)pdm09 
H3N2 
 2 resistant 
A(H1N1)pdm09 isolates 
1 resistant B isolate 
A: Not speci-
fied 
B: I221T 
A: S 
B I221T: S 
Several hun-
dred viruses 
tested (exact 
data not given)
2009-10 A(H1N1)pdm09 A(H1N1)pdm09:  
2.0% (40/1974) 
Not specified S 
2010-11 A(H1N1)pdm09 
H3N2 
B 
Overall: 2.7% (109/4076)
A(H1N1)pdm09:  
3.1% (109/3526) 
H3N2: 0% (0/90) 
B: 0% (0/460) 
H275Y S 
2011-12 A(H1N1)pdm09 
H3N2 
B 
Overall: 0% (0/297) H275Y S Numbers of 
each subtype 
tested not 
specified 
EuroFlu [30] Surveil-
lance 
Europe 
2012-13 A(H1N1)pdm09 
H3N2 
B 
Overall: 0.8% (6/730) 
A(H1N1)pdm09:  
1.7% (5/302) 
H3N2: 0% (0/194) 
B: 0.4% (1/234) 
A: H275Y 
B: Not speci-
fied 
A H275Y: not 
specified 
B: S 
Zhou et al. 
[31] 
Surveil-
lance 
China Jan 08-
Aug 09 
Pre-pandemic 
seasonal H1N1 
A(H1N1)pdm09 
H3N2 
2009 Influenza B
Pre-pandemic seasonal 
H1N1: 47.8% (107/224) 
A(H1N1)pdm09:  
0% (0/221) H3N2: not 
tested for susceptibility 
2009 Influenza B: Not 
tested for susceptibility 
H275Y S 2008: 
A/Brisbane/59/
2007 
Alfaresi et al.
[32] 
Surveil-
lance 
United Arab 
Emirates 
July 09- 
Nov 09 
A(H1N1)pdm09 A(H1N1)pdm09:  
1% (1/96) 
H275Y Not specified  
Harvala et al. 
[33] 
Surveil-
lance 
England and 
Scotland 
Nov 09- 
Dec 09 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.6% (10/1608) 
H275Y Not specified  
Suppiah  
et al. [34] 
Surveil-
lance 
Malaysia 2009 A(H1N1)pdm09 A(H1N1)pdm09:  
0 % (0/67) 
H275Y Not specified  
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(Table 1) contd…. 
Reference Nature of
Study 
Site Duration Subtype Percentage of resistant 
viruses % (resistant 
cases/tested samples) 
Neuramini-
dase muta-
tions 
Susceptibility to 
zanamivir (R/S) 
Comment 
Burrel et al. 
[35] 
Surveil-
lance 
South-western
France 
2007-09 Pre-pandemic 
seasonal H1N1 
A(H1N1)pdm09 
H3N2 
07-08 Pre-pandemic 
seasonal H1N1: 
47.6% (10/21) 
08-09 Pre-pandemic 
seasonal H1N1: 
100% (5/5) 
08-09: A(H1N1)pdm09: 
0% (0/129) 
08-09 H3N2: 
0% (0/92) 
H275Y S 
Souza et al. 
[36] 
Surveil-
lance  
Brazil Apr 09-
Dec 09; 
sporadic 
cases 
2010 
A(H1N1)pdm09 A(H1N1)pdm09:  
<10% quoted (exact data 
not given) 
H275Y Not specified 
Shin et al. 
[37] 
Surveil-
lance 
South Korea May 09-
Jan 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
16% (11/67) 
H275Y 
I117M (1/67, 
low level OR) 
Not specified All those tested
were suspected
OR (e.g. Im-
munosuppres-
sion, young 
age) 
Yang et al. 
[17] 
Surveil-
lance 
Taiwan May 09- 
Jan 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.7% (8/1187) 
H275Y S 
Sheu et al. 
[38] 
Surveil-
lance 
Global Oct 08- 
Sept 09 
Oct 09- 
Jan 10 
Pre-pandemic 
seasonal H1N1 
Pre-pandemic seasonal 
H1N1 
08-09: 
92.7%(1328/1432) 
Pre-pandemic seasonal 
H1N1 
09-10: 
4% (1/25) 
H275Y S 
Ujike et al. 
[39] 
Surveil-
lance 
Japan May 09-
Feb 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
1.4% (61/4307) 
H275Y 3/482 just outside
reference range 
Hurt et al. 
[21] 
Surveil-
lance 
Oceania, Asia
and Africa: 
World Health 
Organization 
Collaborating
Centre for 
Reference and
Research on 
Influenza 
(WHO CC), 
Melbourne, 
Australia 
Mar 09-
Mar 10 
A(H1N1)pdm09 A(H1N1)pdm09  
All countries:  
1.1% (16/1488) 
A(H1N1)pdm09  
Australia:  
1.3% (12/961) 
H275Y S 9/16 immuno-
compromised 
Longtin et al. 
[41] 
Surveil-
lance 
Ontario, 
Canada 
Jun 09-
Mar 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.6% (5/804) 
H275Y S 
Ramirez-
Gonzalez  
et al. [42]  
Surveil-
lance 
Mexico May 09-
April 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.1% (1/692)  
H275Y S 8 month old 
girl with recur-
rent respiratory
tract infections,
had received 
oseltamivir 
Calatayud  
et al. [43] 
Surveil-
lance 
England and 
Scotland 
April 09- 
April 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.6% (36/6379) 
A(H1N1)pdm09  
amongst hospitalised 
patients: 
1.0% (36/3515) 
H275Y S Immunosuppre
ssion risk 
factor for OR 
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(Table 1) contd…. 
Reference Nature of
Study 
Site Duration Subtype  Percentage of resistant 
viruses % (resistant 
cases/tested samples) 
Neuramini-
dase muta-
tions 
Susceptibility to 
zanamivir (R/S) 
Comment 
Meijer et al. 
[44] 
Surveil-
lance 
Netherlands April 09-
May10 
A(H1N1)pdm09 A(H1N1)pdm09:  
Maximum 5.7% 
(63/>1100)  
H275Y R >1100 viruses 
tested (exact 
data not given)
One OR case 
(H275Y) 
developed 
zanamivir 
resistance post
zanamivir 
treatment 
Ledesma  
et al. [45]  
Surveil-
lance 
Spain April 09-
May 10  
A(H1N1)pdm09 A(H1N1)pdm09:  
0.7% (8/1229).  
H275Y Not specified All OR cases 
inpatients, nil 
in community 
Graitcer  
et al. [46] 
Surveil-
lance 
USA April 09-
June 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.5% (37/6740) 
H275Y S 
Payungporn 
et al. [47] 
Surveil-
lance 
Thailand Apr 09-
Oct 10 
A(H1N1)pdm09 A(H1N1)pdm09:  
0.31% (4/1288) 
H275Y Not specified  
Hurt et al. 
[8] 
Surveil-
lance 
Asia-Pacific 
region 
Apr 09-
Dec 10 
H1N1 not other-
wise specified 
A(H1N1)pdm09: Maxi-
mum 1.6% (45/>2900 ) 
H275Y 
S247N 
H275Y: Not 
specified 
S247N: R 
>2900 viruses 
tested (exact 
data not given)
S247N confers
low level OR 
and ZR. 
S247 accounted
for 22 cases of
OR. 
Kourti et al. 
[48] 
Hospital 
Surveil-
lance 
Greece 2010-11 
influenza 
season 
A(H1N1)pdm09 A(H1N1)pdm09:  
1% (2/50) 
H275Y S All subjects 
pretreated with
oseltamivir 
prior to hospi-
talisation 
Storms et al.
[49] 
Surveil-
lance 
USA 2010-11 
influenza 
season 
A(H1N1)pdm09 A(H1N1)pdm09:  
1.0% (35/3652) 
H275Y S 
Sleeman  
et al. [50] 
Surveil-
lance 
USA 2010-11 
influenza 
season 
B B: 12.3% (59/478) I221V S B/North  
Caro-
lina/11/2010 
Miller H.  
et al. [51] 
Surveil-
lance 
Hawaii and 
US-affiliated 
Pacific islands
Jun 09- 
Jul 11 
A(H1N1)pdm09 A(H1N1)pdm09:  
 0% (0/263) 
H275Y S 
Hurt et al. 
[52] 
Surveil-
lance 
Australia May 11-
Aug 11 
A(H1N1)pdm09 A(H1N1)pdm09:  
15.9% (29/182)  
H275Y S 
Wang et al. 
[53] 
Surveil-
lance 
Australia Jun 11- 
Aug 11 
A(H1N1)pdm09 A(H1N1)pdm09  
Untreated cases: 1.4% 
(2/143) 
A(H1N1)pdm09  
Treated cases: 
13.0% (3/23) 
H275Y Not specified 
Hurt et al. 
[54] 
Surveil-
lance 
Hunter New 
England, 
Australia 
May 11- 
Sept 11 
A(H1N1)pdm09 A(H1N1)pdm09:  
15.2% (29/191) 
H275Y S 
Leang et al. 
[55] 
Surveil-
lance 
Asia-Pacific 2011 A(H1N1)pdm09 
H3N2 
B Victoria 
B Yamagata 
A(H1N1)pdm09:  
2.9% (42/1435) 
H3N2:  
0% (0/795) 
B Victoria: 
0.3% (3/1073) 
B Yamagata: 
0% (0/52) 
H275Y 1/3355 resistant, 
?lab artefact. 
Novel OR 
influenza B 
detected. Not 
isolated in 
previous sea-
sons 
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Reference Nature of
Study 
Site Duration Subtype  Percentage of resistant 
viruses % (resistant 
cases/tested samples) 
Neuramini-
dase muta-
tions 
Susceptibility to 
zanamivir (R/S) 
Comment 
DoHA [56] Surveil-
lance 
Australia 2012 H3N2 
B 
Overall: 0.1% (1/1314) H275Y Not specified Numbers of 
each subtype 
not specified. 
The resistant 
case was a 
A(H1N1)pdm0
9 strain virus. 
WHO [57] Surveil-
lance 
Europe 2012-13 
influenza 
season 
A(H1N1)pdm09 
H3N2 
B 
A(H1N1)pdm09: 
1.0% (1/100) 
H3N2: 0% (0/95) 
B: 0% (0/67) 
H275Y Not specified 
* This study (Stephenson et al. [15]) dealt with children aged 1-12 years, all other studies dealt with ‘all age groups’. 
strains surveyed exhibiting the H275Y mutation [53]. All of 
the resistant viruses were similar antigenically to the H1N1 
strain contained in that season’s trivalent seasonal influenza 
vaccine, indicating that vaccination would provide protec-
tion. Overall, the vast majority of the influenza 
A(H1N1)pdm09 viruses received by Australia’s WHO CC 
by August 2011 were sensitive to oseltamivir. The other two 
circulating influenza viruses (H3N2 and B) were also sensi-
tive to oseltamivir.  
In 2010 an influenza A(H1N1)pdm09 strain was de-
tected, which demonstrated low-level resistance to both osel-
tamivir (6 fold higher IC50) and zanamivir (3 fold higher 
IC50), in 10% of community samples from Singapore and in 
30% of community samples from Darwin, Northern Austra-
lia [8]. Such strains have also been found at lower levels in 
Western Australia, Brunei and rarely in the United States, 
Europe and Asia since 2009. This is due to a S247N 
neuraminidase mutation (substitution of serine with aspara-
gine at position 247). The maximum drug levels achieved via 
the recommended dose are much greater than the IC50 
values of the S247N mutant, so the variant is unlikely to be 
clinically resistant [8]. Dual H275Y/S247N strains have been 
detected. An immuncocompromised patient from Perth, 
Western Australia, was diagnosed with a strain containing 
both H275Y and S247N mutations, which conferred a 7000-
fold increase in IC50 to oseltamivir but only a fivefold in-
crease in IC50 to zanamivir, which would therefore remain 
effective.  
3.3. At-risk Patients and OsR Influenza  
The propensity to development of oseltamivir resistance 
whilst on treatment has been repeatedly demonstrated for 
both immunosuppressed patients and those with underlying 
chronic medical conditions [39, 46, 66-69]. Whilst annual 
influenza vaccinations are recommended, generation of an 
immune response can be suboptimal in these populations 
[70, 71]. Vaccination of close contacts such as family and 
health care workers, who are the usual sources of transmis-
sion, is an alternative strategy. From March 2009 to March 
2010 the Australian WHO CC isolated 16 oseltamivir resist-
ant influenza A(H1N1)pdm09 strains from the Asia-Pacific 
region [40]. Nine of these 16 cases were from immunocom-
promised subjects receiving oseltamivir. Some strains dem-
onstrated prolonged viral shedding of up to nine weeks, and 
received multiple courses of both single and double-dose 
oseltamivir. A case-control study from the United Kingdom 
revealed that those infected with oseltamivir resistant influ-
enza A(H1N1)pdm09 virus were more likely to have one or 
more underlying medical conditions than those that were 
infected with an OsS strain (93.3% vs. 58.9%). Those with 
OsR strains were more often immunosuppressed than those 
infected with OsS strains (75% vs. 6.9%). This difference 
was attributed to selective drug pressure amongst 
immunocompromised patients [43]. Viral shedding for up to 
18 months in immunosuppressed patients has been reported 
[72]. 
Prolonged viral shedding and thus increased viral replica-
tion provide conditions that promote emergence of drug re-
sistance [68]. Immunosuppressed patients with prolonged 
viral shedding may serve as a reservoir for NAI resistant 
H1N1 virus in the community [66, 73, 74]. Given the H275Y 
mutation is of the oseltamivir-binding site, a higher dose will 
not overcome the resistance. However, whether either a 
higher dose and/or longer duration of oseltamivir treatment 
would reduce the emergence of resistance is unresolved. It 
has been suggested that zanamavir be considered first line 
therapy in patients who are immunocompromised in certain 
populations with known oseltamivir resistance [39, 75-77].  
4. OSELTAMIVIR RESISTANCE IN THE POST-
PANDEMIC PERIOD 
The predominating strains for the southern hemisphere 
influenza season 2012 and northern hemisphere 2012 – 13 
influenza season have been influenza A(H3N2) and influ-
enza B.  
4.1. Global data 
In the USA 2011-12 season, 86% of almost 20,000 sur-
veyed strains were influenza A viruses of which 74% were 
influenza A (H3N2) and 26% were influenza A(H1N1)pdm09 
[26]. OsR strains were 0.6% of a selection of almost 2800 
strains from all subtypes sampled, all were influenza 
A(H1N1)pdm09 viruses.  
Influenza B (e.g. 73.5% in week 12) predominated in the 
USA 2012-2013 season, followed by influenza A/H3N2 
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(8.7% of isolates tested in week 12). Of the remaining posi-
tive isolates in week 12, only 1.5% were influenza 
A(H1N1)pdm09, with 16% being untyped influenza A. This 
low level of the 2009 pandemic strain is reflected in only 
four cases of OsR influenza isolated on surveillance up to the 
week ending 23 March 2013 (0.1% of almost 2700 strains 
tested: 2/1693 (0.1%) influenza A/H3N2 and 2/427 (0.5%) 
influenza A(H1N1)pdm09, nil influenza B) [27]. 
In Europe during 2012-2013, reasonably equal rates for 
co-circulation of all three strains were reported, with influ-
enza A(H1N1)pdm09 representing 31% of surveyed strains, 
as opposed to the 2011-2012 season when influenza A 
(H3N2) predominated [30]. In the 2012-13 season, resistance 
to oseltamivir in Europe remained low with only 2 cases of 
OsR isolates reported to surveillance agencies, both influ-
enza A(H1N1)pdm09; there were no OsR cases reported in 
the 2011-12 season, reflecting the low numbers of 2009 pan-
demic influenza A circulating during that season [30].  
4.2. Australian Data 
During 2012 in Australia, influenza A/H3N2 and influ-
enza B were the predominant circulating strains, with a low 
level of influenza A(H1N1)pdm09 detected on surveillance 
[56]. During this season no strains of influenza H3N2 tested 
by the WHO CC were resistant to oseltamivir. The single 
OsR strain detected of 1,314 tested was an influenza 
A(H1N1)pdm09. Compared to 2011, this low-level osel-
tamivir resistance detected in 2012 likely reflects the overall 
lower circulation of influenza A(H1N1)pdm09. 
5. PUBLIC HEALTH SIGNIFICANCE OF RESISTANT 
STRAINS 
Selection and subsequent spread of an NAI-resistant 
strain are dependent upon the transmission fitness of that 
strain [78]. Before the 2007-2008 influenza seasons, detec-
tion of oseltamivir-resistant viruses in humans had typically 
been reported only among persons treated with oseltamivir 
and human-to-human transmission of an NAI-resistant virus 
had never been documented [79-81]. From 2007 until March 
2008, 1182 of 7530 pre-pandemic influenza A/H1N1 viruses 
(16%) tested and reported to the WHO were resistant to osel-
tamivir [82]. By 2009 virtually all pre-pandemic influenza 
A/H1N1 viruses globally were oseltamivir-resistant [38]. 
This suggests the mutant virus retains transmission fitness 
[83].  
Studies of the transmissibility of the OsR influenza 
A(H1N1)pdm09 yield mixed results. A study of infected 
ferrets revealed fitness, transmissibility and pathogenicity 
were not compromised [84]. However, some studies do 
demonstrate loss of replicative fitness in OsR strains in vitro
and in vivo [85, 86]. The authors of one such study con-
cluded that the OsR virus would require further modifica-
tions, such as antigenic drift, additional mutations or intense 
selection pressure to spread and predominate. Whether any 
additional genetic polymorphisms have been acquired to 
compensate for any conferred loss of replicative fitness in 
OsR strains is presently unclear. Permissive mutations in the 
neuraminidase gene, V234M (replacement of valine by me-
thionine) and R222Q (replacement of arginine by glutamine) 
appeared to have enabled pre-pandemic influenza A strains 
with the H275Y mutation to retain viral fitness [87]. Neither 
of these compensatory mutations has yet been detected in 
any influenza A(H1N1)pdm09 virus. One possible mecha-
nism for retention of viral fitness may be inherent to the 
H275Y substitution. An earlier mutation of the NA protein 
that increased its receptor affinity may have actually com-
promised the “fitness” of the influenza strain by disrupting 
the functional balance between its haemagglutinin and 
neuraminidase proteins. The H275Y mutation, which re-
duces neuraminidase substrate affinity, may have restored 
this balance, and also enhanced the NA cleaving function 
[83, 88]. Hayden et al. suggested that such mutations may 
not require drug pressure in order to be selected and may 
explain those cases and clusters of untreated OsR influenza 
A [88]. 
Human-to-human transmission has recently been identi-
fied around the world. Reports emerged initially in 2009, 
with the CDC reporting acquisition of OsR influenza 
A(H1N1)pdm09 amongst two adolescents who received 
oseltamivir during a mass chemoprophylaxis drive during an 
outbreak of influenza-like illness at a summer camp; whether 
the mutations developed de-novo or whether the strain 
spread from one to the other was unclear [89]. Ujike et al.
reported that 2/61 cases of laboratory-confirmed OsR influ-
enza A(H1N1)pdm09 were suspected to be due to human to 
human transmission between close contacts [39]. However, 
there was no evidence of sustained spread of OsR influenza 
A(H1N1)pdm09 in Japan. Person to person transmission of 
OsR strains have also been reported from Wales and Viet-
nam; similarly, transmission was not sustained [40]. Moore 
et al. report person-to-person spread of OsR influenza 
A(H1N1)pdm09 in a haematology unit in the United King-
dom [90]. Of seven cases of OsR influenza in immunocom-
petent patients from the Oceania WHO surveillance, four had 
not received oseltamivir and additionally they developed 
influenza after the peak of the pandemic period, suggesting 
possible establishment of OsR viruses [40]. The largest re-
port involves the Newcastle, New South Wales, cluster de-
scribed above and suggested a wide region of spread but 
limited establishment of the OsR influenza A(H1N1)pdm09 
[53, 91].
 
That a greater proportion of OsR influenza A(H1N1)pdm09 
cases in the USA received pre-treatment with oseltamivir in 
the 2009-2010 (89%) season versus the 2010-2011 season 
(26%) suggests establishment of a low level of community 
transmission of oseltamivir-resistant influenza A(H1N1) 
pdm09 [24, 49].  
6. CLINICAL SIGNIFICANCE OF RESISTANT 
STRAINS 
Norwegian surveillance data reveal that overall, the ob-
served clinical manifestations associated with OsR pre-
pandemic influenza viruses A (H1N1) were as expected for 
pre-pandemic influenza [14]. No differences were noted for 
virus shedding, primary symptoms, complications or hospi-
talisation rates amongst those infected with either OsS or 
OsR viruses. Likewise, neither USA nor UK surveillance 
data reported any prolongation or increase of symptoms in 
those with OsR versus OsS pre-pandemic influenza viruses 
[15, 19]. The OsR influenza A(H1N1)pdm09 strain has also 
25
42    Infectious Disorders – Drug Targets, 2013, Vol. 13, No. 1 Dixit et al. 
been reported to be no more virulent than the sensitive strain 
[92]. Due to pre-existing immunity (perhaps from exposure 
to a similar strain in those aged over 65 years) [93], influ-
enza A(H1N1)pdm09 caused more morbidity and mortality 
in younger adults and children, in contrast to the usual pat-
tern for seasonal influenza which disproportionately affects 
the elderly [94]. However, OsR influenza A(H1N1)pdm09 
strains were associated with a significantly higher risk for 
complications, particularly respiratory, in the 2009-2010 UK 
influenza season, even after adjusting for chronic illness and 
immunosuppression [43]. 
  Management of OsR influenza viruses is unclear. The 
influenza A(H1N1)pdm09 strain retains sensitivity to 
zanamivir whilst being resistant to oseltamivir and peramivir
 
[95]. As noted, inhaled or intravenous zanamivir in high risk 
patients may be considered first line therapy [39, 75-77]. 
Zanamivir is licensed only for those over 5 years of age. 
However, there are isolated reports of use of zanamivir in 
those under the age of 5 years. Dulek et al. report the use of 
intravenous zanamivir in a profoundly neutropenic 18 month 
old girl with a haematological malignancy who had a lower 
respiratory tract infection with influenza A(H1N1)pdm09 re-
peatedly isolated from her respiratory tract in the context of 
clinical deterioration [77]. A twenty day course of intrave-
nous zanamivir was utilised with reduction in viral load from 
endotracheal aspirates. The regimen was well tolerated. 
Nonetheless respiratory deterioration progressed and the 
patient died. 
7. CONCLUSIONS 
In conclusion, in the 2 years before the 2009 pandemic 
due to H1N1 influenza A, the circulating pre-pandemic 
H1N1strains had largely become resistant to oseltamivir; 
resistance is now emerging in the influenza A(H1N1)pdm09 
strain, which remains prevalent and at times the predominant 
community strain of influenza A. Dual low level resistance 
to oseltamivir and zanamivir has been detected in various 
strains, which sets the scene for further new mutations induc-
ing clinical resistance to both of these agents. Ongoing, care-
ful surveillance is important to monitor the incidence of re-
sistant virus and inform recommendations for changes to 
first-line therapy in the event that resistant strains begin to 
predominate. There are limited treatment options in high risk 
patients.  
Whether a higher dose and/or longer duration of osel-
tamivir treatment, for example doubling the dose of the stan-
dard oseltamivir regimen, reduces the emergence of resist-
ance is unresolved. This question is being addressed in a 
randomised controlled trial conducted by this authorship 
team and the results may help inform the current ad-hoc use 
of such regimens in certain settings. 
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2.3 CHAPTER 1: Synopsis 
Emergence of Oseltamivir Resistance: Control and Management of Influenza before, 
during and after the Pandemic - Synopsis 
 
Over 2007 – 2008, influenza strains became predominantly oseltamivir resistant, and these 
strains was both arising independently and locally, and spreading globally, amongst pre-
pandemic influenza A (H1N1). The potential detrimental effects of limitation of treatment 
options can be compounded failures in preventative strategies, such as reduced vaccine 
effectiveness. During the 2017 season, influenza vaccine effectiveness only 33%, with 
resultant larger national influenza epidemics [Sullivan SG, Chilver MB, Carville KS, Deng Y-
M, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 
24 September 2017. Eurosurveillance [Internet]. 2017 Oct 26;22(43)]. 
Acquisition of additional mutations that conferred a selective advantage over wild-type strains 
enabled oseltamivir-resistant strain of influenza to dominate in the 2007-8 season, despite the 
mutation compromising replicative fitness. Intense selection pressure from widespread 
oseltamivir use, e.g. during a future pandemic, may result in predominance of oseltamivir 
resistance in current circulating strains.   
Strategies to reduce emergence of resistant strains, such as higher dose oseltamivir 
regimens, development of new antiviral classes, or even resurrection of historical treatment 
methods, need further examination. Two of these strategies are explored: in a clinical trial of 
double dose oseltamivir in chapter 2, and through a review of the application of an old 
treatment modality and it’s modern reworking – heterologous polyclonal antibody therapy, 
chapter 3. 
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3.1 CHAPTER 2: Preamble  
A Randomized Study of Standard versus Double Dose Oseltamivir for Treating Influenza in the 
Community  
 
Neuraminidase inhibitors (NAIs, e.g., oseltamivir, zanamivir) are the treatment of choice against 
seasonal influenza. Given the paucity of other specific anti-influenza agents, higher dose regimens 
have been tried to maximise clinical resolution and reduce development of antiviral resistance via 
more rapid virological clearance. Whilst influenza is usually self-limiting, it is important to have a 
treatment modality when it is severe, or to curb outbreaks. As noted elsewhere, antiviral resistance 
confers vulnerability to the general population in the context of a novel strain circulating, and to those 
in whom, due to a variety of clinical conditions, vaccine effectiveness is reduced or vaccines are 
contra-indicated.  
Double-dose (DD) regimens of oseltamivir have been used in both immunocompromised and 
artificially ventilated patients, without a strong evidence base. Our study was unique in addressing 
patients with influenza in the mild to moderate (non-hospitalised) stages. The objectives of this study 
were to investigate the effectiveness of DD (150mg bid for adults or 10mg/kg for children) compared 
with SD (75mg bid or 5mg/kg for children) oseltamivir in subjects ≥5 years old. I examined clinical 
disease, virological outcomes, adverse events and the frequency of detection of oseltamivir-resistant 
virus.  
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Background: The neuraminidase inhibitors are the 
treatment of choice for influenza virus infection. 
Oseltamivir-resistant (OsR) strains of influenza 
A(H1N1)pdm09 are described, but the effect of higher 
dose oseltamivir on efficacy, safety and emergence of 
resistance has not been addressed in the developed 
setting in outpatients. The objectives of the study were 
to compare standard dose (SD) versus double dose (DD) 
oseltamivir regimens for frequency of detecting OsR 
influenza virus, clinical disease resolution, virological 
clearance and adverse events.
Methods: This was an unblinded randomized controlled 
trial of community-based patients with confirmed influ-
enza. Participants were randomized to a 5-day regimen of 
either SD or DD oseltamivir.
Results: Of 52 participants (aged 4.8–54.8 years), 25 
received SD and 27 DD oseltamivir. Clinical resolution did 
not differ by dosing regimen (P=0.43); neither did viro-
logical clearance differ for either influenza A (P=0.20) or 
B (P=0.70). Adverse events, predominantly gastrointes-
tinal, were greater with DD than SD (P=0.04). One OsR 
strain was detected prior to treatment and two individu-
als developed OsR strains during treatment, one each on 
SD and DD. Those with OsR strains did not appear to have 
a different clinical course.
Conclusions: DD oseltamivir did not appear to provide a 
clinical or virological advantage, nor reduce the emer-
gence of oseltamivir resistance, but our study was under-
powered. Adverse events occurred more frequently on DD 
compared to SD oseltamivir.
Neuraminidase inhibitors (NAIs; for example, 
oseltamivir and zanamivir) are the treatment of choice 
against seasonal influenza. Since NAIs were intro-
duced in 1999 and until 2007, ≤1% of viruses tested 
had mutations conferring oseltamivir resistance [1,2]. 
Oseltamivir-resistant (OsR) influenza A/H1N1 was 
first detected in Europe during the northern hemi-
sphere winter of 2007–2008 and spread globally, 
such that by the 2008–2009 northern hemisphere 
winter, most strains of seasonal influenza A/H1N1 
were OsR [3–6]. No difference in clinical severity 
was noted between the OsR and oseltamivir-sensitive 
(OsS) viruses [7]. Influenza A(H1N1)pdm09 was first 
detected in Mexico in March 2009, with the World 
Health Organization (WHO) declaring a pandemic 
on 11 June 2009 [8]. Surveillance has detected an 
increasing minority of influenza A(H1N1)pdm09 
viruses to be OsR, almost all bearing the H275Y 
mutation in the neuraminidase (NA) gene. Between 
2009–2011 approximately 600 of >30,000 influenza 
A(H1N1)pdm09 viruses were reported by the WHO 
as OsR [9–11]. Both the circulating influenza A/H3N2 
and influenza B strains have generally remained OsS.
In preparation for an influenza pandemic many 
nations stockpiled oseltamivir, preferring it to zanami-
vir for its oral administration, systemic bioavailability 
and licensure for use from ≥1 year of age, as opposed 
to ≥5 years with zanamivir. Filled oseltamivir pre-
scriptions in Australia increased from approximately 
25,000 in 2008 to more than 350,000 in 2009, a pro-
cess that may potentially promote the emergence of 
OsR viruses [6].
NAIs bind to the surface protein NA of the influenza 
virus, preventing release of viral progeny from host 
cells. Oseltamivir may select drug-resistant strains of 
influenza, especially in the immunocompromised, in 
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whom there is reduced viral clearance and prolonged 
viral replication [12–15]. The most common resistance 
mutation for oseltamivir is an amino acid tyrosine sub-
stituting histidine (H275Y) in the NA gene, altering the 
NAI binding site. This results in high-level resistance to 
oseltamivir but not zanamivir [16,17]. In clinical trials, 
OsR pre-pandemic influenza virus strains developed 
more frequently in children (5–27%) than in adults 
(1–2%) [18–23].
Higher doses of oseltamivir may more rapidly 
reduce viral load, averting the selection of resist-
ant strains, but evidence of this is lacking. Double 
dose (DD) regimens of oseltamivir have been used in 
both immunocompromised and artificially ventilated 
patients [6,24,25]. This study aimed to investigate 
whether this would be an effective strategy to reduce 
oseltamivir resistance, particularly amongst children 
(≤15 years), recruited from both the children’s hospi-
tal and a general practice.
The objectives of this study were to investigate the 
effectiveness of DD (150 mg twice daily for adults 
or 10 mg/kg for children) compared with standard 
dose (SD; 75 mg twice daily or 5 mg/kg for children) 
oseltamivir in subjects ≥5 years old on the frequency 
of detection of OsR virus, clinical disease and adverse 
events (AEs).
Methods
Trial design
This was an unblinded, randomized, parallel 1:1 study.
Participants
Participants were those aged ≥5 years old, presenting 
within 48 h with fever ≥37.8°C, with at least one respira-
tory symptom and a positive QuickVue point-of-care test 
(POCT; Quidel, San Diego, CA, USA), for influenza A or 
B presenting to either a family practice or a children’s 
hospital emergency department in West Sydney [26,27]. 
Given the higher false-negative rate of rapid POCT in 
older children and adults compared to younger children, 
a rapid nucleic acid test (NAT) using PCR was imple-
mented for POCT-negative cases: the GenXpert FLU 
assay (Cepheid, Sunnyvale, CA, USA), with results avail-
able within 4 h [28–30]. Those positive for either test 
were offered inclusion in the study.
Those excluded were patients with a secondary bac-
terial infection, a poorly controlled underlying medical 
condition as determined by the treating doctor, immu-
nosuppression (for example, malignancy, transplant 
or immunosuppressive agents), pregnant or lactating 
females, known oseltamivir allergy, participation in 
another clinical trial with an investigational drug or 
device, or insufficient English language skills to give 
informed consent.
Interventions
Participants were randomized in equal numbers to 
either SD or DD of oseltamivir for 5 days. The study did 
not prescribe clinical management beyond oseltamivir.
Doses were as follows, and standard dosing adhered 
to international guidelines for children (≤15 years; 
Table 1) [31]. Adult SD (>15 years) was 75 mg twice 
daily and DD 150 mg twice daily.
Outcomes
The end points of this study were the difference in the 
percentage of OsR influenza viruses in patients treated 
with SD versus DD oseltamivir at day 5 of follow-
up, rates of clinical resolution and of the shedding of 
influenza virus at day 5 ±1 and adverse event profiles 
between dosing regimens. Clinical resolution was deter-
mined by patient or caregiver nominating date of cessa-
tion of all originally reported symptoms.
Adverse events
AEs were defined as symptoms developing during 
therapy that were not present at baseline or a symp-
tom as reported on the subject daily record as present 
at baseline which resolved for one or more days but 
subsequently reappeared during therapy.
Sample size
Allowing for a 20% drop-out rate, the original target 
was 125 patients, yielding 100 completed subjects, con-
ferring an 80% probability of detecting a difference in 
the frequency of OsR virus emergence from 25% to 5% 
under a single-tailed test with a=0.05, based on a 2009 
study of OsR emergence in 27% of children treated 
with oseltamivir for influenza A H1N1 [23].
Randomization and sequence generation
We used block randomization to allocate interventions. 
A colleague not involved in the trial used the Excel 
random number generator to generate the allocation 
sequence consisting of randomly permuted blocks of 
four. Randomization was unblinded to patients and cli-
nicians but blinded to laboratory researchers.
Implementation
The study was carried out at The Children’s Hospital at 
Westmead and at a nearby general practice, during the 
Southern hemisphere winter 2011.
First visit (day 1)
The procedures at the first visit (the initial clinical 
presentation) included collecting nose and throat speci-
mens using a flocked cotton swab, with performance of 
a rapid POCT and a rapid NAT if POCT was negative 
(instituted 12 July 2011, one-third of the way through 
recruitment to increase sensitivity) and dispensing 
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oseltamivir. Study personnel completed a Baseline 
Clinical Symptoms Questionnaire for each subject, 
eliciting either presence or absence of temperature 
≥37.8°C, sore throat, runny nose, shortness of breath, 
conjunctivitis, wheezing, diarrhoea, nausea, vomiting, 
myalgia, joint pain, headache, seizures, insomnia and 
dizziness. A urine pregnancy test was performed for 
females aged ≥9 years.
Second visit (day 5 ±1)
At follow-up, repeat swabs were collected. A day 5 
Clinical Symptoms and Adverse Events questionnaire 
was completed.
Laboratory methods
All swabs were cultured on Madin–Darby canine 
kidney (MDCK) cells using shell vials and confirmed 
by immunofluorescence (influenza A and B DFA rea-
gents; Diagnostic Hybrids, Athens, OH, USA). An in-
house reverse transcriptase (RT)-PCR for influenza 
A matrix (M) gene and B nucleoprotein (NP) gene 
was also performed on the swabs. A rolling-circle 
amplification method confirmed the presence of the 
H275Y resistance mutation [32]. All isolates were 
sent to the WHO Collaborating Centre for Reference 
and Research on Influenza (WHOCC) in Melbourne, 
Victoria, Australia for ascertainment of influenza A 
subtype, resistance phenotype and genotype.
Statistical methods
Data were analysed according to a pre-specified plan, 
by intention-to-treat, using SPSS version 20 (2011, 
IBM, New York, NY, USA) for statistical analysis. Com-
parisons between treatment groups, and recruitment 
sites, for a significant difference (P<0.05) in baseline 
demographics, virological outcomes and AEs were per-
formed by a two-sample t-test for continuous data with 
normal distribution, Wilcoxon’s rank sum test for con-
tinuous variables with non-normal distribution and a 
two-sample c2 test for binomial data. A Kaplan–Meier 
analysis was used to estimate ‘mean time to recovery’ 
(in days) and its corresponding 95% CI, for selected 
subgroups of the cohort. The Mantel Cox ‘log rank’ test 
was used to compare ‘mean times to recovery’ for dif-
ferent cohort sub-groups at the level of P<0.05.
Ethics
The Sydney Children’s Hospitals Network Human 
Research Ethics Committee approved the study. All 
patients or caregivers (for subjects aged <18 years) 
signed informed consent forms.
Results
Recruitment
A total of 52 participants were recruited over the 2011 
influenza season April to August 2011 (Figure 1). Two 
patients, both in the standard dose group, had short 
hospital admissions; the rest were outpatients.
Baseline data
Neither age nor gender differed between the two treat-
ment groups, with 62% of recruits being children (≤15 
years). The general practice site recruited 20 adults (13 
female) and 15 children (6 male); the Children’s Hos-
pital recruited 17 children (4 female; Table 2). Almost 
all participants were healthy amongst the SD group, 
one child had uncomplicated, stable sickle cell anaemia 
and one adult had well-controlled epilepsy. In the DD 
group, one child had a treated Wolff–Parkinson–White 
syndrome, one child had a stable neurological condition 
with an unspecified myopathy and autism, one child 
had episodes of syncope that were under investigation 
but, inter-episodically, was neurologically normal.
Of the 50 cases for which an influenza type was 
determined by POCT or NAT, 21 (42%) had influenza 
A and 29 (58%) influenza B. Of the influenza A cases, 4 
(19%, all adults) had A/H3N2 subtype (Table 3).
Outcomes
Clinical resolution
Outcomes for all 52 patients were analysed by intention-
to-treat. There was no significant difference in time to 
clinical resolution between the two dosing regimens 
(Figures 2 and 3). A total of 8 of 25 (32%) on SD and 
6 of 27 (22%) on DD oseltamivir had residual symp-
toms by treatment day 5 (P=0.43). Children recovered 
an average of one day faster than persons aged >15 
years; this difference was significant comparing within 
the SD regimen, the DD regimen and across both regi-
mens (Figure 2). A 5-year-old boy with influenza B, who 
received the DD regimen, was given only 3 days of treat-
ment due to nausea and was later admitted to hospital 
10 days post last dose of oseltamivir with pneumonia 
Standard dose oseltamivir
<15 kg 60 mg per day divided into 2 doses
15–23 kg 90 mg per day divided into 2 doses
24–40 kg 120 mg per day divided into 2 doses
>40 kg 150 mg per day divided into 2 doses
Double dose oseltamivir 
<15 kg 120 mg per day divided into 2 doses
15–23 kg 180 mg per day divided into 2 doses
24–40 kg 240 mg per day divided into 2 doses
>40 kg 300 mg per day divided into 2 doses
Table 1. Paediatric dosing regimens
Doses are shown and standard dosing adhered to international guidelines for 
children (≤15 years). Adult standard (>15 years) dose 75 mg twice daily and 
double dose 150 mg twice daily. 
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requiring intravenous antibiotics. His viral culture and 
NAT for influenza were negative at 5 days after first dose 
of oseltamivir; thus it is unlikely that incomplete viral 
treatment led to the development of pneumonia.
Virological outcome
Of the 48 cases that were NAT-positive on visit 1, the 
dosing regimen did not significantly affect virological 
clearance as determined by NAT-negative swabs by visit 
2 (SD 11/23, 47.8% versus DD 17/25, 68%; P=0.16). 
Of those recruited, 44 were culture-positive on visit one 
(SD 21/25, 84% versus DD 23/27, 85.2%; P=0.91). 
There was no difference by dose in virological clear-
ance as determined by culture-negative swabs by visit 2 
(SD 20/21, 95.2% versus DD 21/23, 91.3%; P=0.61). 
Clearance was not lower in the SD than the DD group 
for either by influenza A by NAT (SD 3/11, 27.3% ver-
sus DD 6/10, 60.0%; P=0.20) or by culture (SD 9/10, 
90% versus DD 7/8, 87.5%; P=0.87), nor for influenza 
B by NAT (SD 8/12, 66.7% versus DD 11/15, 73.3%; 
P=0.70) or by culture (SD11/11, 100% versus DD 
14/15, 93.3%; P=0.76). Influenza subtype was not sig-
nificantly associated with virological clearance by NAT 
(influenza A 9/21, 42.9% versus influenza B 19/27, 
70.4%; P=0.08) or culture (influenza A 16/18, 88.9% 
versus influenza B 25/26, 96.2%; P=0.35). There was 
Standard
dose 
(n=25)
Compliance
Yes =22No =3
Patient 1. Sickle
cell anaemia,
pallor. Hb 90 mg/l
pre and post
therapy.
Patient 2. Forgot
to complete; no
side effects noted.
Reasons
Patient 3. Did
not complete; no
further information.
Double
dose 
(n=27)
Compliance
Yes =25No =2
Patient 1. Ceased 
as nausea and
vomiting on Day 3.
Patient 2. Ceased 
as nausea and
vomiting on Day 4.
Reasons
Figure 1. Compliance between dosing regimens
Hb, haemoglobin.
Standard dose Double dose P-value
Median age, years (range) 13.7 (4.8–51.9) 9.0 (5.0–54.8) 0.20
Male gender, n (%) 15 (60.0) 11 (40.7) 0.27
Female gender, n (%) 10 (40.0) 16 (59.2) 
Table 2. Participant characteristics by dose regimen
Neither age nor gender differed between the two treatment groups, with 62% 
of recruits being children (≤15 years). The general practice site recruited 20 
adults (13 female) and 15 children (6 male); The Children’s Hospital recruited 17 
children (4 female). 
Standard dose Double dose 
Influenza type and subtype (n=25) (n=27) P-value
Influenza A and 9 (36) 8 (29.6) 0.77
influenza A(H1N1)pdm09
Influenza A H3N2 2 (8) 2 (7.4) 1.00
Influenza B 13 (52) 16 (59.2) 0.78
No strain documented 1 (4) 1 (3.7) 1.00
Table 3. Virological result by dosing regimen (POCT, NAT or 
isolation) at recruitment
Data are n (%) unless otherwise indicated. Of the 50 cases for which an 
influenza type was determined by point-of-care test (POCT) or nucleic acid test 
(NAT), 21 (42%) had influenza A and 29 (58%) influenza B. Of the influenza A 
cases, 4 (19%, all adults) had A/H3N2 subtype.
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no significant difference in mean time between swabs 
1 and 2 for SD cases (4.65 days; 95% CI 4.17, 5.13) 
versus DD (4.92 days; 95% CI 4.44, 5.40) nor for those 
with influenza A (4.86 days; 95% CI 4.36, 5.36) ver-
sus influenza B (4.72 days; 95% CI 4.22, 5.22), thus 
the lack of difference in virological clearance was not 
confounded by length of time between collection of the 
two swabs.
Three influenza A(H1N1)pdm09 viruses were OsR, 
one pre-treatment and two post-treatment (Table 4), 
all carrying the H275Y mutation. OsR was detected by 
NAT post-treatment in one case in each of the SD and 
DD groups (SD 1/23, 4.3% SD versus DD 1/25, 4.0%; 
P=0.95). A mixture of oseltamivir sensitive and resist-
ant viruses was detected in the case receiving the SD 
regimen, whereas in the case receiving DD only resist-
ant virus was detected. The case that was OsR at enrol-
ment was genotypically related to a cluster of 31 OsR 
influenza cases, all carrying the H275Y mutation, from 
the Newcastle region in New South Wales, Australia 
between May and August 2011 [10,33,34]. No cases 
reported recent contact with Newcastle.
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Figure 3. Proportion of participants who reported recovery by 
day of treatment
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Adverse events
There was a difference in frequency of AEs reported 
between the two dose regimen groups (SD 4/25, 25% 
versus DD 13/27, 48%; P=0.02); gastrointestinal (GI) 
AEs occurred in 16 patients (nausea, vomiting or diar-
rhoea), with one case of insomnia (DD). The differ-
ence remained when solely GI events were analysed 
(P=0.04). More adults than children reported AEs 
(P=0.01). Amongst the children from whom AEs were 
reported, all were ≤6 years of age. Two children older 
than 6 years were recruited (both 14 years old) and nei-
ther reported AEs. This age-based difference was signif-
icant for influenza A but not influenza B (Table 5), and 
for both DD and SD (Table 6). This was in the context 
of no significant relationship between influenza strain 
and patient age. AEs were not significantly different by 
recruitment site (general practice 13/35, 37.1% versus 
The Children’s Hospital 4/17, 23.5%).
Other results
Overall, there were no significant differences in the 
distribution of influenza strains between either treat-
ment groups, the site of recruitment or age band (data 
available on request). In total, 49 cases were initially 
recruited based on positive POCT and 3 by positive 
rapid NAT; all had a subsequent ‘in-house’ real-time 
(RT)-PCR performed. Four cases, two in the DD group 
and two in the SD group, were POCT positive, but 
both RT-PCR and cell culture negative. Of these, two 
were influenza B positive by POCT, but the influenza 
type was not recorded for the other two. Influenza A 
peaked earlier than influenza B (Figure 4).
Discussion
This study examined the impact of SD versus DD 
oseltamivir on the selection of OsR virus, safety and 
effectiveness of therapy. Oseltamivir treatment was 
associated with a significant increase in overall AEs, 
particularly GI. The study did not support the hypoth-
esis that DD reduced oseltamivir-resistance, however, it 
was underpowered. DD oseltamivir was not shown to 
be more clinically or virologically efficacious. Of those 
with influenza A, more adults than children reported 
AE; age-related differences in AE were not shown for 
influenza B. Thus, influenza type may influence mani-
festation of GI symptoms. Whilst more adults than chil-
dren reported AE, there was no statistically significant 
difference in median age between the two dosing regi-
mens, thus age did not confound the influence of dosing 
on AEs. The age differential may reflect children’s AEs 
being recorded by parent/guardian while persons aged 
≥15 years recorded their own AEs; however, neither of 
the two 14-year-old children reported AEs, although 
numbers are too small to draw conclusions. In contrast 
to our study, a study of 273 pupils and 53 staff at a jun-
ior school reported a high frequency of minor AEs to 
oseltamivir, but did not find a difference in rate of AEs 
between staff and pupils [35].
The large number of cases of influenza A(H1N1)
pdm09 and the lack of A/H3N2 patients recruited 
amongst the Children’s Hospital recruits reflected 
national Australian surveillance data for the 2011 influ-
enza season, where most hospitalized cases were pre-
dominantly influenza A(H1N1)pdm09 with far fewer 
influenza A/H3N2 infections [36]. Analysis by age and 
site of recruitment revealed no statistical difference in 
distribution of influenza types.
All three cases with OsR influenza A(H1N1)pdm09 
experienced an illness with similar severity to other 
subjects, however the study was underpowered to draw 
conclusions about the effect of resistance on illness 
severity. All resistant viruses were similar antigenically 
to that contained in the 2011 influenza vaccine, high-
lighting the importance of immunization as a measure 
to reduce circulating OsR influenza.
Case 1 Case 2 Case 3
Gender/age M/5 years M/5 years M/11 years
NAT visit 1 pH1N109 pH1N109 pH1N109
Viral culture (visit 1) Influenza A Influenza A Influenza A
Oseltamivir sensitivity (visit 1) Sensitive Sensitive Resistant (H275Y)
Dose D S S
NAT visit 2 A(H1N1)pdm09 A(H1N1)pdm09 A(H1N1)pdm09
Viral culture (visit 2) Negative Influenza A Negative
Oseltamivir sensitivity (visit 2) Resistant (H275Y) Mix of sensitive and resistant (H275Y) Resistant (H275Y)
Comorbidities Nil Nil Nil
Compliance Yes Yes Yes
Table 4. Cases with oseltamivir-resistant influenza A(H1N1)pdm09 virus
Three influenza A(H1N1)pdm09 viruses were oseltamivir-resistant, one pre-treatment and two post-treatment, all carrying the H275Y mutation. D, double; M, male; 
NAT, nucleic acid test; S, standard. 
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Co-circulation of different influenza strains/types 
has characterized the recent 2010, 2010/2011, 2011, 
2011/2012 influenza seasons in Northern and Southern 
hemispheres [37–43]. The reported low prevalence of 
OsR in currently circulating influenza viruses is consist-
ent with our result of 1/51 cases with pre-treatment OsR 
(2%) [9–11]. However 2/52 (4%) of the cases developed 
OsR on treatment, both influenza A(H1N1)pdm09. In 
Stephenson et al.’s study [23] OsR development occurred 
in 27% (3/11) post-treatment of pre-pandemic influenza 
A (H1N1) virus amongst children. In contrast, two large 
studies with 106 cases with influenza A(H1N1)pdm09, 
one of which recruited predominantly children, did not 
yield any OsR-influenza A(H1N1)pdm09 strains post-
treatment [44,45]. An increasing number of neuramini-
dase-resistant influenza strains demonstrate mutations 
associated with reduced susceptibility other than due 
to H275Y [46–51]. The WHO recommends continued 
monitoring of OsR prevalence [10,52].
Globally, the WHO has reported that of those from 
whom OsR influenza was isolated, of the immunocom-
petent subgroup, 37% had not received prior oseltamivir, 
Influenza A Influenza B Both strains
Adults (n=20) 8/11 (72.7) 3/9 (33.3) 11/20 (55)
Children (n=30a) 0/10 (0) 6/20 (30) 6/30 (20)
P-value <0.001 1.01 0.01
Table 5. Adverse events by age and influenza type
Data are n/total n (%) unless otherwise indicated. This age-based difference was 
significant for influenza A but not influenza B. aInfluenza type was unknown for 
two children. Neither reported adverse events.
Age group SD DD Both SD and DD
Adults ≥15 years (n=19) 4/11 (36.3) 6/8 (75) 10/19 (53.6)
Children <15 years 0/14 (0) 6/18 (33.3) 6/32 (18.8)
(n=32)
P-value 0.01 0.05a 0.01
Table 6. Adverse events by age and dose regimen
Data are n/total n (%) unless otherwise indicated. aP=0.049. DD, double dose; 
SD, standard dose. 
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Influenza A peaked earlier than influenza B. 
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demonstrating community OsR virus circulation [9]. 
Our case of pre-treatment OsR-influenza A(H1N1)
pdm09 was included in the ‘Newcastle cluster’, to date 
the largest reported community cluster of OsR-influ-
enza A(H1N1)pdm09 infection [10,41]. Whilst this was 
one of two cases in the cluster found up to 380 km from 
Newcastle, it appears significant spread of this virus 
has not developed [32,53]. A review reported several 
clusters and cases of OsR influenza A(H1N1)pdm09, 
including untreated cases, and a cluster of six cases of 
community-acquired OsR influenza A(H1N1)pdm09 
was reported from Japan, recently [43,54]. A smaller 
proportion of OsR influenza A(H1N1)pdm09 cases in 
the USA received pre-treatment with oseltamivir in the 
2010–2011 season (26%) compared to the 2009–2010 
(89%) season, suggesting community transmission of 
the resistant strain [55,56].
A recent randomized controlled trial by Farrar 
et al. [44] of over 300 hospitalized South East Asian 
patients with influenza, mostly children, demonstrated 
that there were no improvements in virological or 
clinical outcomes with DD over SD oseltamivir. Inter-
estingly, there was also no difference in the AE rate 
between the two arms of the study (approximately 
16% in each arm), a finding which differed from our 
own; this difference may be partially because our study 
recruited a lower proportion of children (61% <15 
years in our study versus 75% <13.5 years by Farrar 
et al. [44]), and, in our study, adults experienced more 
AEs for DD, SD and overall. Farrar et al. [44] did not 
analyse AE by age. There was no significant difference 
in mean age between the two dosing regimens in our 
study, so age did not confound AE incidence between 
doses. No OsR developed in the 72 patients with influ-
enza A(H1N1)pdm09, half of whom received DD. 
The study was conducted in hospitalized cases in Asia, 
conferring potential case severity, ethnic and other dif-
ferences. Our study is unique in addressing developed 
world patients with mild (non-hospitalized) influenza 
and finding significant differences in AEs based on age 
and dose regimen.
Another recent study from Hong Kong comparing 
SD versus DD oseltamivir also focused on hospitalized 
patients, again demonstrating no difference in clini-
cal outcomes or virological clearance, but did not find 
emergence of OsR. A greater incidence of GI AEs was 
reported in the DD group when analysed by dose regi-
men, but no significant difference in AE was reported 
when intention-to-treat arms were compared [45]. 
Interestingly, subgroup analysis demonstrated a trend 
towards increased rate of viral NAT clearance for influ-
enza B with DD oseltamivir, whereas in both our study 
and Farrar’s et al.’s study [44], there was no difference 
in clearance of influenza B by day 5. Unlike our study, 
the Hong Kong study included neither children nor 
community cases; the average patient was aged in their 
60s and no OsR emerged post-treatment.
Two older studies demonstrated that higher dose 
oseltamivir did not reduce influenza viral load more 
than lower dose oseltamivir [57,58]. Treanor et al. [57] 
revealed no difference in symptom resolution between 
doses but Hayden et al. [58] did not compare between 
dose regimens. Neither study compared safety out-
comes between doses [57,58]. Another study by 
Hayden et al. [59] reported a greater frequency of GI 
AEs in higher dose oseltamivir compared with lower 
dose but a significance level was not reported. No sig-
nificant difference in viral clearance was elicited and 
clinical comparisons were not made [59].
Limitations of our study include the small sample 
size and the exclusion of both those aged <5 years and 
immunocompromised patients. Despite our best efforts, 
we were unable to fulfil our aim of recruiting 125 cases 
in an attempt to demonstrate a significant difference 
in rates of development of oseltamivir resistance. In 
conclusion, this study demonstrated no difference in 
development of antiviral resistance and no difference in 
efficacy of different oseltamivir doses, but increased GI 
adverse effects were elicited with DD oseltamivir.
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3.3 CHAPTER 2: Synopsis 
 
A Randomized Study of Standard versus Double Dose Oseltamivir for Treating 
Influenza in the Community  
 
Our study did not support any clinical advantage to doubling the dose of oseltamivir in at least 
the healthy population, and adds to the literature examining such a strategy amongst different 
population groups. There was not enough power in the study to demonstrate a difference in 
emergence of oseltamivir resistance on treatment. However, there was a trend towards more 
rapid virological clearance, particularly in those with influenza A, in the double dose group (p 
= 0.16), suggesting that conditions for oseltamivir resistance, prolonged viral shedding, may 
be mitigated by double dose regimens.  
 
Recent studies on high dose influenza vaccine showed, promisingly, that immunogenicity 
improved in cardiac patients, cancer sufferers and elderly recipients. However, other specific 
antivirals have not yet been developed. Could there be a place for resurrecting old strategies, 
such as polyclonal antibodies, currently used in, for example, rabies infection and arachnid 
venom toxicity? This is the focus of my next paper. 
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4.1 CHAPTER 3: Preamble  
Benefits of Using Heterologous Polyclonal Antibodies and Potential Applications to 
New and Undertreated Infectious Pathogens  
 
Neuraminidase inhibitors (NAI) are the only anti-influenza antivirals currently registered in 
Australia, leaving the general population vulnerable to epidemics and pandemics were 
antiviral resistance to develop. This risk of untreatable infection is potentiated in those most at 
risk of influenza, in whom vaccine efficacy is reduced, such as those with immune deficits, 
chronic diseases and those at extremes of age. Additionally, the global population is at risk 
from novel strains of influenza such as ‘avian flu’, arising from antigenic shift, to which there is 
low background immunity and no effective vaccine. Were they to develop the ability to 
efficiently transmit between humans, a pandemic could ensue. Epidemiological data indicate 
that the elderly and those with chronic conditions are most at risk of clinical avian influenza, 
as well as poorer poultry farmers in Asian countries. Here, I present an extensive review of an 
alternative strategy for management of resistant influenza, avian influenza (and other 
infections) – heterologous polyclonal antibody therapy. Currently, heterologous polyclonal 
antibodies are used against snake venom toxin and rabies virus infection. However, they 
have had historical applications to a range of viruses and bacteria in the pre-antibiotic era, 
and the World Health Organisation recognise their potential in the fight against pandemic 
influenza in its ‘Position paper on collection and use of convalescent plasma or serum as an 
element in pandemic influenza planning; July 2009’. I examine their past use, how safety 
limitations in their applicability have been overcome, and what current studies have 
demonstrated about their effectiveness against avian influenza. 
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Background: Passive immunotherapy using polyclonal antibodies (immunoglobulins) has been used for
over a century in the treatment and post-exposure prophylaxis of various infections and toxins. Heterol-
ogous polyclonal antibodies are obtained from animals hyperimmunised with a pathogen or toxin.
Aims: The aims of this review are to examine the history of animal polyclonal antibody therapy use, their
development into safe and effective products and the potential application to humans for emerging and
neglected infectious diseases.
Methods: A literature search of OVID Medline and OVID Embase databases was undertaken to identify
articles on the safety, efficacy and ongoing development of polyclonal antibodies. The search contained
database-specific MeSH and EMTREE terms in combination with pertinent text-words: polyclonal anti-
bodies and rare/neglected diseases, antivenins, immunoglobulins, serum sickness, anaphylaxis, drug
safety, post marketing surveillance, rabies, human influenza, Dengue, West Nile, Nipah, Hendra, Mar-
burg, MERS, Hemorrhagic Fever Virus, and Crimean-Congo. No language limits were applied. The final
search was completed on 20.06.2015. Of 1960 articles, title searches excluded many irrelevant articles,
yielding 303 articles read in full. Of these, 179 are referenced in this study.
Results: Serum therapy was first used in the 1890s against diphtheria. Early preparation techniques
yielded products contaminated with reactogenic animal proteins. The introduction of enzymatic diges-
tion, and purification techniques substantially improved their safety profile. The removal of the Fc
fragment of antibodies further reduces hypersensitivity reactions. Clinical studies have demonstrated
the efficacy of polyclonal antibodies against various infections, toxins and venoms. Products are being
developed against infections for which prophylactic and therapeutic options are currently limited, such
as avian influenza, Ebola and other zoonotic viruses.
Conclusions: Polyclonal antibodies have been successfully applied to rabies, envenomation and intoxi-
cation. Polyclonal production provides an exciting opportunity to revolutionise the prognosis of both
longstanding neglected tropical diseases as well as emerging infectious threats to humans.
Crown Copyright © 2016 Published by Elsevier Ltd. All rights reserved.
1. Introduction and methods
The aims of this review are to examine the history of animal
polyclonal antibody therapy use, its development into a safe and
effective product and its potential future application to humans for
emerging viruses and neglected tropical diseases.
A literature search was undertaken by an experienced medi-
cal librarian to identify articles on both the safety of polyclonal
∗ Corresponding author at: 8 Weaver St, Lismore, NSW 2480, Australia.
Tel.: +61 448886199.
E-mail address: rushmi7@gmail.com (R. Dixit).
antibodies and the use for the treatment of rare or neglected
diseases. The databases searched included OVID Medline and
OVID Embase. The searches contained database-specific MeSH
and EMTREE terms in combination with pertinent text-words:
polyclonal antibodies and rare/neglected diseases, antivenins,
immunoglobulins, serum sickness, anaphylaxis, drug safety, post
marketing surveillance, rabies, human influenza, Dengue, West
Nile, Nipah, Hendra, Marburg, MERS, Hemorrhagic Fever Virus, and
Crimean-Congo. Tominimise bias, no language limitswere applied.
Thefinal searchwas completed on20.06.15. These searches yielded
1960 articles. Title searches excluded many irrelevant articles,
yielding 303 thatwere then read in full. Of these, 179 are referenced
in this study.
http://dx.doi.org/10.1016/j.vaccine.2016.01.016
0264-410X/Crown Copyright © 2016 Published by Elsevier Ltd. All rights reserved.
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In 1890, von Behring and Kitasato discovered that sera from
rabbits immunised against diphtheria or tetanus were able to pro-
tect exposed mice [1]. By 1894, animal derived anti-diphtheria
serum was used in humans during a European epidemic [2]; con-
currently, Phisalex and Bertrand demonstrated that the blood
of horses immunised with Viper aspis (the European viper) had
antivenin properties [3]. Sera from both humans and animals were
subsequently used for management of illness caused by viruses
such as measles, varicella and the pandemic Spanish influenza
of 1918 [4,5]. Anti-rabies polyclonal antibody preparations from
hyper-immunised horseswere developed in the early 20th century
[6]. In thispre-antibiotic era, serumtherapywasalsoapplied tobac-
terial infections such as pneumococcal pneumonia, meningococcal
meningitis and streptococcal scarlet fever [7,8].
The early, crudepreparations of serumwereoften contaminated
with animal proteins; as a result, serum sickness and anaphy-
laxis limited their safe application. Antibiotics against bacterial
infections largely superseded serum therapy in the late 1930s and
1940s [7]. During the 1960s, however, therewere improvements in
enzymatic digestion and purification of equine immunoglobulins,
enabling safer polyclonal antibody therapies to be developed for
envenomation, rabies exposure and viral infections such as hepati-
tis A and B, varicella–zoster virus and respiratory syncytial virus
(RSV) [8].
The development ofmonoclonal antibodies (mAbs) in the 1970s
enabled large quantities of specific antibody to beproduced [8]. The
humanisationofmAbs allowed their use in the treatment of chronic
disease by repeated administration. However, polyclonal antibod-
ies still proved more effective than monoclonal antibodies in the
treatment of many infectious diseases. To date, most monoclonal
antibody therapies are produced for either autoimmune condi-
tions (such as systemic lupus erythematosus or Crohns disease)
or neoplastic conditions. The only licenced monoclonal antibody
to an infectious target is palivizumab, for RSV [9]. In contrast to
monoclonal antibodies, polyclonal therapy, by targeting multiple
epitopes, can protect against epitope mutation [4]. Additionally,
moremaybeneededof a lowaviditymonoclonal antibodyprepara-
tion, compared with a polyclonal preparation, to neutralise a given
amount of toxin or pathogen, as is generally the case for antitoxins
to snake envenomation [10].
Animal derived polyclonal antibody therapy has been suc-
cessfully and safely applied to (i) medication overdoses such as
colchicine and digoxin, (ii) poisoning by snake, arachnid, marine
and plant toxins, and (iii) post-exposure prophylaxis against the
rabies virus [11–15]. Polyclonal antibody products can be made
in large quantities and cost-effectively to respond to the great
endemic demands in Asia and Africa as well as potential pandemic
situations, globally.
2. Modern processing dramatically reduces adverse
reactions
Adverse reactions in humans to animal-derived polyclonal
antibodies are usually due to the presence of highly immuno-
genic animal proteins. Type 1 hypersensitivity reactions, including
anaphylaxis, begin within minutes. Type 3 hypersensitivity, or
serum-sickness, results from deposition of immune complexes on
small vessels of the skin, joints and kidneys; this can develop
at any point over the three weeks it takes to clear the injected
antibodies [3]. Antibodies consist of the antigen binding (Fab) frac-
tions, linked by disulphide bonds as F(ab′)2, and the crystallisable
fraction (Fc). The reactogenic Fc fragment can induce complement-
mediated urticaria, angioedema, lymphadenopathy, arthralgia, and
nephropathy [3]. Fc removal with retention of the immunogenic
F(ab)/F(ab′)2 components was first applied to digoxin antiserum
in 1976 [16]. The F(ab)/F(ab′)2 fragments were isolated initially
through salt precipitation and subsequently, since the mid-1990s,
via chromatographic purification [17]. Complementmediated any-
phylactoid reactions, fever and hypersensitivity have been reduced
by careful elimination from the final product of bacterial endo-
toxins (pyrogens) as well as protein and cell aggregates, through
pasteurisation, ultrafiltration and additional chromatography [18].
With this combination of purity and safety advancements, serious
adverse events are now rare, even very rare. With equine rabies
immunoglobulin (ERIG), anaphylactic shock is reported in less than
1/45, 000 treatments, serumsickness in<0.5%andall-gradeadverse
events in <5% [3,15].
Ammonium sulphate precipitation of the F(ab′)2 was the main
method of purification until the mid-1990s when chromatography
was introduced [19]. Examples of current production techniques
are for that of the rabies equine immunoglobulin produced by
QMSI (Queen Saovabha Memorial Institute, Bangkok) and Favirab
(Sanofi-Pasteur) as well as equine snake antivenins [19,20]. Briefly,
the techniques involve hyper-immunisation of the source animal
daily for several days and collection of sera 2–4 weeks after the
last injection, which enables antibody affinity maturation, result-
ing in a highly avid, concentrated product, which reduces the
co-administered load of contaminant animal proteins [21].
The purification process often starts with an anion-exchange
chromatography step which isolates the immunogenic horse IgG
subclass, and removes other immunoglobulins, proteins, cell aggre-
gates and contaminants [19]. Enzymatic cleavage or digestion by
low pH pepsin of IgG to Fc and active F(ab′) or F(ab′)2 regions
reduces adverse reactions [17]. A second anion-exchange chro-
matography excludes the Fc fragments, protein and cell aggregates
which result from low pH pepsin digestion, as well as bacterial
pyrogens [22]. European guidelines require animal immunosera
that are test-negative for pyrogens [23]. A final pasteurisation step
involves heat-treatment for 10h at 60 ◦C, which destroys viruses,
and thermocoagulates excess proteins [20]. High performance liq-
uid chromatography is used to control purity of the final product;
usually 90% of the content is covalent F(ab′)2, 5% F(ab) fragments,
and <0.5% are polymers/aggregates [18]. Importantly, immunore-
activity remains intact after these steps [19]. The final antiviral
antibody titre is determined for example by ELISA or seroneu-
tralisation assays for antiviral immunoglobulins. Variations in the
production process include application of potassium sulphate for
F(ab′)2-Fc separation, and precipitation of non-immunoglobulin
proteins, caprylic acid precipitation to purify whole IgG (resulting
in near total exclusion of albumin, less activation of complement
as well as lower total protein/protein aggregates compared to
ammoniumsulphateprecipitation), andcentrifugation toeliminate
cellular elements and proteins [3,24–27]. Preservatives are added
to the final products to prevent bacterial and fungal contamina-
tion [28]. Refrigeration and avoidance of prolonged storage avoids
protein/cell reaggregation and precipitation [28].
Apart from pasteurisation, steps that neutralise pathogens
include low-pH pepsin hydrolysis and high-temperature caprylic
acid precipitation, both of which lipolyse enveloped viruses such
as Herpes, Sindbis and West Nile viruses; and ultra/nano filtra-
tion e.g. using 0.22mmgauge filters, for virus and bacterial removal
[4,29,30]. Subculturing can confirmbacterial sterility [4]. TheWHO,
in recognition of some inconsistency in antivenin production qual-
ity, has released the ‘WHO Guidelines for the Production, Control
and Regulation of Snake Antivenom’ [31].
Large relative molecular mass (Mr) bivalent antibodies (IgG
and F(ab′)2 fragments) have a smaller volume of distribution
and a longer half-life in the human body than the lower Mr
F(ab′) fragments [32]. Both IgG and F(ab′)2 fragment elimina-
tion occurs mainly by formation and elimination of immune
complexes (catabolism), whereas F(ab′) is cleared renally [33].
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The longer half-life means that antivenins made from IgG and
F(ab′)2 persist, which reduces rebound symptoms of enveno-
mation associated with F(ab′) antitoxins [34]. Additionally, the
preservation of large Mr antivenins in the vascular compart-
ment draws venin out of tissues into the bloodstream to form
antivenin-venom complexes, promoting venom clearance [35].
However, recenthumanpharmacokinetic data suggests that F(ab′)2
also extravasates into tissues [36,37]. This tissue penetration may
assist with neutralizing viruses infecting various organs.
Cleaving of the Fc fragment, whilst reducing adverse events,
possibly reduces it’s potentiating effect on generation of natu-
ral immunity towards a pathogen or toxin. Fc interaction with
antigen-presenting may stimulate and promote development of
active immunity towards the exposure [38,39].
These features may have implications for the selection of
molecule type in the production of polyclonal immunotherapy,
particularly for post-exposure prophylaxis against viruses such as
Mers-CoV and Ebola. Dosing intervals are longer and therefore dos-
ing regimensmore pragmaticwith IgG and F(ab′)2 and IgG alsomay
promote development of host immunity. However, this needs to
be balanced against the increased risk of hypersensitivity reactions
from the Fc molecule.
Half-time of elimination (t1/2) of the product in the plasma
compartment was analyzed after intravenous (IV) administration
of F(ab′)2 against avian influenza A H5N1 in 3 healthy volunteers
receiving 1 dose and in 10 healthy volunteers receiving 5 doses
[40]. The plasmatic elimination of F(ab′)2 after one IV infusion had
a mean t1/2 of 16.77 h and after 5 infusions 24 h  apart, a mean of
10.89h. These results indicated the persistence of equine F(ab′)2
in the plasma for the duration of the therapeutic protocol with
evidence of a slight accumulation between day 1 and day 5. After
the fifth infusion, equine F(ab′)2 remained detectable by ELISA in
plasma, (above>1mg/mL) for between 3 to 14 days. These results
were consistent with another human study of intravenous equine
F(ab′)2, with a plasma t1/2 of 14.2h and a later catabolismof F(ab′)2
with a t1/2 of around 7 days[37]. Thus, the protection inducedmay
continue several days after the end of the treatment protocol, up
until the patient’s immunity generates host antibodies.
3. Management of rare secondary effects
A meta-analysis of seven studies and a  Cochrane review each
concluded that adrenaline premedication, but not other agents, sig-
nificantly reduced early adverse reactions [41]. Additionally, early
use of adrenaline for anaphylactic reactions post antivenin is effec-
tive [42].
Ovine (sheep-derived) products may be somewhat less reac-
togenic than equine products, but the latter are more economical
to produce given the larger amounts of sera available, and have a
longer half-life, reducing requirement of re-administration [43,44].
Equine antivenin may also have superior antitoxin effects com-
pared to ovine[45].
There are no recorded cases of viral or prion transmission
from equine-derived antitoxins and current processes aim to pre-
serve this safety record [29]. Both initial measures (e.g. donor
selection, epidemiological exclusion, quarantine, health status
of the animal) and processing of final product reduce the risk
of a contaminating virus. Animals are contained within closed
flocks or maintained in areas free of insect vectors of certain
arboviruses. For example, rattlesnake, viper and digoxin antitox-
ins are manufactured in South Australia, a region free of prions
and many viral pathogens [46]. Source animals may also be vac-
cinated against local pathogens such as rabies, anthrax and viral
equine encephalitides [31]. Molecular diagnostic screening of ani-
mals for viruses may be performed [29,31]. Record-keeping and
regular stock inspections contribute to quality control [4]. The
rigor of the application of such processes varies by resource avail-
ability e.g. in resource-challenged countries where much of the
world’s antivenin/antitoxin is both required and produced, not
all safety measures may be employed [15,47]. Polyvalent (source
animal immunised with more than one venin) polyclonal
antivenins have higher rates of adverse reactions thanmonovalent
(source animal immunised to just one venin) polyclonal antivenins,
e.g. 24% vs. 9% for Australian produced CSL snake antivenins, due
in part to the larger volumes required to be administered for
treatment with the polyvalent rather than monovalent polyclonal
antibodies [48].
4. Efficacy and safety of modern polyclonal
immunoglobulin products
Clinical studies have demonstrated the safety and efficacy of
equine immunoglobulin. These therapies can even be given to
pregnant women as no passage of F(ab′)2 across the placenta is
expected and thus no teratogenicity anticipated[49].
Of 7660Filipino recipients of F(ab′)2 equine rabies immunoglob-
ulin (ERIG), (Favirab, Sanofi Pasteur, Lyon, France) only two
developed rabies; neither had received post-exposure prophylaxis
(PEP) strictly as per theWHOguidelines [50,51]. Of the151 subjects
in this cohortwho sustained bites from laboratory-confirmed rabid
animals, therewere no reported cases of rabies. Of 193 persons bit-
ten by rabid dogs in the Philippines, therewas just a single recorded
PEP failure; due to location of the bite (on the lip) local ERIG infiltra-
tion was difficult, and, against official protocol, she received a mix
of intradermal and intramuscular rabies vaccine [52]. These results
emphasise the importance of adherence to WHO rabies guidelines
in administering PEP.
The safety of current ERIG products has also been demonstrated
in clinical trials and post marketing surveillance. Of over 12,000
ERIG recipients in the Philippines, Thailand and India, 0.3 and 1%
of recipients developed local reactions and 0.03–3% had systemic
reactions [15,52–54]. Some of these reactions may have been due
to co-administered tetanus toxoid.
A retrospective review of over 70,000 patients in Thailand who
received either human rabies immunoglobulin (HRIG) (59.6%) or
ERIG (40.4%) demonstrated that 1.83% of ERIG recipients had an
adverse events, versus 0.09% ofHRIG recipients; however the broad
date ranges includedERIGproducedbothbefore andafter the intro-
duction of modern purification techniques [55]. Serum sickness
was reported in 0.72% of ERIG recipients vs. 0.007% of HRIG recipi-
ents, and no deaths were reported.
Antivenins are also effective. While there are few randomised
prospective controlled human studies, mice studies, retrospective
human studies and human case reports provide evidence for effec-
tive and safe treatment of life-threatening envenomations and
coagulopathy [56,57].
Several human reports confirm efficacy of various snake
antivenins (Tables 1 and 2) [33,58–62].
Efficacy of rattlesnake antivenin has been studied, particularly
in the USA, where rattlesnakes predominate; introduction of rat-
tlesnake whole IgG polyvalent crotalid antivenin (ACP) reduced
mortality from up to 25% to <0.5% when delivered in a health
care facility in the United States[63]. A 10-year retrospective chart
review revealed the fractionated Crotalidae polyvalent immune
F(ab′) (CroFab®) to be more effective at avoiding fasciotomies
than the whole IgG product ACP[64]. A 12 year review of CroFab®
revealed a response rate of 77% amongst 24 cases of severe enven-
omation, including neurotoxicity, whilst in another series of 28
severe envenomations, all responded to CroFab® [65,66]. A liter-
ature review of controlled and observational studies confirmed the
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Table 1
Efficacy of various snake antivenins.
Study Efficacy Mild reactions (%) Serum sickness Anaphylaxis
Otero et al.
Bothrops whole IgG [48]
67/67 treated: coagulopathy reversed 48H 15–24 nil nil
Thomas et al.
BothropsF(ab′) [49]
45 cases treated vs. 27 no treatment
Treatment favoured:
•  mortality  (nil  vs. 22%)
• neurological  complications (nil vs. 3%)
•   shorter hospitalisation
•  fasciotomy  requirement  unchanged
4.4% 2.2%
Thomas et al.
Bothrops F(ab′) [50]
68 treated vs. 64 untreated
Treatment favoured:
•  Mortality  (nil  vs. 12.5%)
• Reduced  coagulopathy  (nil vs. 17.5%),
• Reduced  thrombosis (nil  vs.  28.1%)
•  Shorter  hospital  stay  (5 days  vs. 12
5.9 1.5% 1.5%
Ha et al.
Bungarusmulticinctus F(ab′) [51]
27 treated vs. 54 untreated
Treatment favoured (in days):
• Duration  of  limb paralysis (2.2  vs. 7.5)
• Diaphragm  palsy (1.6 vs. 7.0)
• Duration  of  ptosis (3.5  vs.  6.3)
• Duration  of  ventilation  (2.3  vs.  8.6)
•  ICU  stay  (6.1  vs. 11.6)
7.4 nil nil
Chippaux et al.
Polyvalent F(ab)2IPSER AFRICA (Pasteur
Merieux Connaught, Lyon, France) [52]
223 patients
Cure rate 96.3%
Fatality rate 1.3%
6.3 0.4% 0.4%
Chippaux et al.
Polyvalent F(ab)2 FAV-Africa (Pasteur Merieux
Connaught, Lyon, France)[53]
46 patients
All survived
4 nil nil
Chippaux et al.
Polyvalent F(ab′)2 AfricanAntivipmyn
(Laboratorios Silanes, Mexico City, Mexico)
[54]
289 patients
Survival rate 99.3%
Fatality rate 0.7%
19 nil nil
Table 2
Safety estimates from meta-analysis of non-crotalidae antivenin observational and controlled trials.
95% CI Mild Reactions
A vs. B
95% CI Serum Sickness
A  vs. B
95% CI Anaphylaxis A vs. B
Pre-1995 all antivenin [A: 111 cases] vs. post
1995 all antivenin [B: 2873 cases]
25.2–33.2% 2.7–4.2% −1.5–2.5% (no significant difference)
Whole IgG [A: 899 cases] vs.F(ab′)/F(ab′)2 [B:
2085 cases]
12.8–16.2% 1.3–2.0% 7.2–8.6%
Post 1995: Whole IgG [A: 874] vs.
F(ab′)/F(ab′)2 [B: 1999]
14.9–18.0% 1.9–2.5% 7.7–9.2%
efficacy and safety of CroFab® [67]. Crofab® has also been demon-
strated to be effective in paediatric patients [68,69]. However, a
South American study demonstrated a locally produced whole IgG
antivenin was more effective than two F(ab′)2 preparations but
with more anaphylactoid reactions [70]. Amongst the fractionated
products, a comparison of F(ab′) and F(ab′)2 rattlesnake antivenin
demonstrated a significant reduction in late coagulopathy in those
who received F(ab′)2 compared to F(ab′) (29.7% vs. 10.3%) due to
the longer half-life of the divalent over the monovalent product
[34]. This advantage of F(ab′)2 over F(ab′) has been demonstrated
for other antivenins [71,72].
Epidemiological data from Europe demonstrates that the intro-
duction of antivenin has resulted in a several-fold decrease in
snakebite mortality [73]. Australian snake antivenins have been
considered more effective at neutralising the neurotoxic effects
than the pro-coagulant effects, and plasma transfusions are recom-
mended along with antivenin [46,74,75]. This limitation of current
Australian antivenins has been disputed, however [76].
Safety of snake antivenins has improved with antibody frac-
tionation andmodern processing. Whole IgG rattlesnake antivenin
(e.g. Antivenin Crotalidae Polyvalent ACP) was associated with a
18–50% frequency of immediate and delayed reactions [77–83].
Thiswasmore than halved after the removal of Fc and implantation
ofmodern purificationmethods (e.g. Crofab®) [63,67,84–93,65,94].
A meta-analysis of CroFab® revealed an immediate hypersensi-
tivity rate of 8% and serum sickness of 13%[95], with even lower
rates reported in a subsequent study of 340 cases: <2% immediate
hypersensitivity reactions and 5% serum sickness [96]. Likewise,
the adverse event rate of bothrops antivenin improved from 25 to
82% for ammonium sulphate precipitated whole IgG preparations
to 11–28% for caprylic acid precipitated whole IgG and 12–36% for
F(ab′)2 antivenin [26,28].
A meta-analysis was conducted by us, the authors, of 30 observa-
tional and controlled studies of various snake antivenins, excluding
rattlesnake antivenin for which a meta-analysis has been reported
above [27,33,43,48,59,60,62,70–72,97–116] (Table 2). A simple lin-
ear weighting by the sample size of each study was applied.
The weighted mean and standard deviation for each set of stud-
ies were compared using a formula to isolate the effect of the
independent variable (the anti-venin) given to an otherwise sim-
ilar population distribution. We determined an estimate of the
percentage difference with z=1.96 to give 95% confidence inter-
vals, which are reported below. This analysis demonstrates that
F(ab′) and F(ab′)2 are safer than whole IgG and that there was
a reduction in adverse events after introduction of purification
techniques in the mid-1990s, with the exception of no reduc-
tion in anaphylaxis pre and post 1995 for all types of antivenins,
combined.
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There are approximately 1.5 million scorpion envenomations
annually resulting in about 2600 deaths, from autonomic over-
stimulation and/or an overwhelming inflammatory response. A
randomised controlled trial (RCT) of anti-scorpion F(ab′)2 in Ari-
zona revealed a significant difference in the following: rapid
symptom resolution, midazolam requirement and plasma venom
levels, compared to placebo [117]. A meta-analysis of 4 RCTs and
5 observational studies demonstrated effectiveness in new world
(American) scorpion envenomations but not in the old world[118].
Adverse events were higher in non-randomised trials, e.g. serum
sickness occurred in 57% of those treated in one study, but lasted
only 3 days, and antivenin was highly effective, reducing symptom
duration from 22h to 31min [119]. Adverse events were infre-
quent in the RCTs (0–2%). However, this meta-analysis included
a 2011 Indian (‘old world’) controlled trial where scorpion F(ab′)2
antivenin reversed clinical envenomation more effectively than no
antivenin [120]. Three other old-world studies not included in the
meta-analysis have demonstrated efficacy. An uncontrolled Indian
study of scorpion F(ab′)2 antiveninwhere 41/48 (85.4%) responded,
with onemild reaction[121]; a prospective case-control series from
India of 62 patients under the age of 18 years which demonstrated
that dopamine and dobutamine requirement was reduced and
recoverywas faster in thosewho received scorpion antivenin [122]
and a controlled trial from Saudi Arabia that reported a reduction
in mortality from 4–8% to <0.05%, with mild reactions only (13.9%)
[123]. In a review of 10 studies, only this Indian uncontrolled trial
of scorpion F(ab′)2 antivenin revealed efficacy, as opposed towhole
IgG in all the other trials [124]. However, withdrawal of IgG scor-
pion antisera in the USA in 2002 with no alternative substituted,
resulted ina5-fold increase in ICUadmissions for stings [125]. Saudi
Arabian data demonstrated a reduction in deaths from 1.7% to nil,
in pulmonary oedema from11.1% to 1.2% and in cardiac arrest from
7.4% to 0.4% after introduction of scorpion antivenin in 1991 [126].
Spider antivenin is also effective and safe. A review ofwhole IgG
funnel-web spider antivenin use in Australia reported a complete
response in 97% of 75 recipients, with only one local reaction, one
caseof anaphylaxis andonecaseof serumsickness [127].Whole IgG
black widow spider (lactodectrus) antivenin reduced durations of
symptom and hospitalisation inmoderate to severe envenomation
in a US review [128,129]. Intravenous (as compared to intramuscu-
lar) administration was associated with high rates of anaphylaxis
(e.g. 9% in 1989) and serum sickness (33%) prior to reducing the
speedof administration,which reduced the total adverse event rate
to less than3% [130]. EquinederivedF(ab′)2 blackwidowantivenins
have been developed and are being tested [131]. An Australian
study of 95 cases of redback spider antivenin F(ab′)2 yielded 4 cases
of anaphylaxis (4.2%) and a serum sickness rate of 9.3% [132]. Over-
all, polyclonal antibodies used as antidotes are also reportedly safe.
A study of 717 patients who received anti-digoxin F(ab′) revealed
an allergy rate of 0.8% [133].
5. Polyclonal antibodies for emerging and neglected viral
diseases
Polyclonal serum therapy is emerging as potentially applicable
to a rangeof viruses forwhich there are limited therapeutic options.
Highly pathogenic avian influenza (HPAI) viruses such as H5N1
and H7N9 are new targets for polyclonal F(ab′)2 immunoglobulin
therapy. Stockpiles of effective product for prophylaxis and treat-
ment are required in anticipation of epidemics. The neuraminidase
inhibitor oseltamivir remains the mainstay of treatment with an
overall reduction ofmortality risk reported of 49% [134]. Reports of
oseltamivir resistance in HPAI H5N1 as well as in seasonal human
influenza strains suggests complementary treatment options are
necessary [135,136].
TheWorld Health Organisation (WHO) recognises the potential
role of serum therapy for influenza pandemic planning, given its
historical success in infectious outbreaks [137]. Use of convales-
cent plasma during the 1918 Spanish influenza epidemic of 1918
apparently reducedmortality by 50% [5,138]. Convalescent plasma
has been used in two cases of HPAI H5N1, both of whom survived
[139,140]. Since the first human case of HPAI H5N1 in 1997, the
WHO has recorded 718 human infections with 413 deaths as of 26
January 2015, a case fatality rate of 57.5% [141]. All cases have been
in Africa, Asia or theMiddle East, or travellers returning [142]. Sur-
vivors produce demonstrable neutralising antibodies [143]. Whilst
there is currently only limitedperson-to-person transmission, anti-
genic shift (via reassortmentwith circulating human viruses) could
confer this, setting the stage for a devastating pandemic [144].
In vivo proof-of-concept studies of equine polyclonal F(ab′)2 to
HPAI H5N1 have been conducted in mice [145]. The product was
able to prevent infection after an intranasal HPAI H5N1 challenge.
Sero-neutralising assays and haemagglutination inhibition tests
confirmed the potent neutralising abilities of equine polyclonal
anti-HPAI H5N1 F(ab′)2 preparations in mice[145]. In another
study, four H5N1 avian influenza equine F(ab′)2 preparations
demonstrated cytopathic effect against cultured Madin–Darby
canine kidney (MDCK) cells infected with H5N1 and protected
mice against lethal challenge, both given prior (prophylaxis) or
post (therapeutic) exposure [146]. These studies concurwithearlier
mice studies of polyclonal antibodies to seasonal influenzaA. In one
such study,micewere immunisedwith theM2 antigen of influenza
A, anti-influenza IgG was obtained and intravenously injected into
other exposed mice leading to 100% survival with high dose (320
micrograms) IgG [147].
A phase 1 study in 16 healthy young human males aged 21–40
years who received intramuscular polyclonal F(ab′)2 to HPAI H5N1
yielded no serious adverse events, no changes in blood or uri-
nary parameters, and only one febrile reaction, likely related to the
product; there was also evidence of clinical benefit as assessed by
seroneutralising and haemagglutination inhibition testing of the
subjects’ plasma samples [40]. As ethically no placebo-controlled
efficacy studies in humans can be performed, further effectiveness
data will have to be gathered from compassionate case-based use.
Other fatal avian influenza viruses are emerging in people; in
March 2013 the H7N9 avian influenza virus emerged in China
and spread to Hong Kong, Taiwan and Malaysia; 718 cases and
413 deaths have been reported to date [148]. Both HPAI H5N1
and H7N9, have demonstrated rare person-to-person transmis-
sion [148–151]. In May 2013, the first case of avian influenza A
H6N1was reported in Taiwan [152]. Three human caseswith avian
influenza H10N8 were reported in China between December 2013
and February 2014 [153–165]. Both of these are low pathogenic
strains currently, but the potential remains for acquisition of
mutations that may increase pathogenicity. Several studies have
suggested the potential role of respiratory tract administration of
polyclonals to prevent and treat seasonal influenza infection, sug-
gesting a potential for these to be applied to avian influenza strains
[156–158].
As well as the threat of new avian influenza viruses, the Mid-
dle Eastern respiratory syndrome coronavirus (MERS-CoV) that
emerged in 2012 has pandemic potential. MERS-CoV causes severe
respiratory illness and, sometimes, renal injury [133,159]. Whilst
most cases have occurred in several Middle Eastern countries,
particularly Saudi Arabia, cases have been reported from Korea,
Europe and North Africa [160,161] Of the 1368 reported cases of
Mers-CoV to WHO by 7 July 2015, 487 have died (35.6%); but a
large proportion of cases may go undiagnosed [162]. There appear
to be a mix of zoonotic (bat and/or camel) and human sources
for transmission; person-to-person transmission has been par-
ticularly documented in health-care settings [162–164]. There is
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neither a specific treatment nor a licenced vaccine. In a recent
study, serumof Egyptian dromedary camelswhowere seropositive
for Mers-CoV was administered to mice infected with Mers-CoV,
with Australian camel sero-negative sera serving as a control
[165]. Mers-CoV seropositive camel serum given both pre- and
post-exposure protected infected mice from weight loss, dimin-
ished lung histological changes and accelerated virus clearance.
Polyclonal antibodies could provide post-exposure prophylaxis for
close contacts as well as a therapeutic strategy for those severely
affected by MERS-CoV. One potential setting for the development
of an epidemic of either H5N1 or MERS-CoV is the annual HAJJ pil-
grimage in Saudi Arabia, where preparations for a potential MERS
outbreak are being refined [166].
Equine polyclonal antibody therapies could also be developed
for other widespread and severe neglected tropical diseases e.g.
the viral haemorrhagic fevers Crimean-CongoHaemorrhagic Fever,
Dengue, Ebola andMarburg; bat-transmitted viruses such as Nipah
and Hendra, as well as Lassa virus, West Nile Virus (WNV) and
severe acute respiratory syndrome-associated coronavirus (SARS).
The WHO has reported 27,705 cases of Ebola with over 11,269
reported deaths in the 2014–2015 West African epidemic [167].1
A stockpile of polyclonal antibodies may form part of epidemic
preparation.
Animal studies exist demonstrating efficacy of polyclonal
antibody therapy for various neglected tropical viral diseases.
Unimmunisedhamsters that receivedWNV-immunehamster anti-
seraonehourbefore and24hafter aWNVchallengewereprotected
from lethal WNV infection [168]. Duck egg polyclonal F(ab′)2 neu-
tralised Andes virus (the primary agent for pulmonary hantavirus
syndrome in South America) in vitro; hamsters given the poly-
clonal F(ab′)2 post-exposure had improved survival compared to
controls [169]. Polyclonal antibodies against theMarburg andEbola
filoviruses were acquired from non-human primates (NHPs) that
survived filovirus challenge and, when given post-exposure, pre-
vented disease and death in virus-challenged NHPs compared
to controls [170]. Similar results were obtained from injecting
Ebola infected mice with polyclonal sera from E. bola immu-
nised mice [171]. Other studies of mice, monkeys and guinea pigs
have demonstrated purified equine whole IgG has prolonged sur-
vival against Ebola [172–176]. Equine F(ab’)2 has been verified to
protect both mice and hamsters from development of infection
with SARS-CoV infection when given prophylactically and reduced
lung viral titres when given therapeutically, compared to controls
[177–179].
6. Conclusions
In summary, clinical studies have demonstrated the efficacy
of animal-derived polyclonal antibody therapies against various
infections, toxins and venoms. The safety of current products has
been demonstrated in clinical trials and post marketing surveil-
lance. When WHO guidelines are followed in administering rabies
equine polyclonal antibodies, post-exposure prophylaxis is highly
effective in averting rabies. Antivenins are also safe andeffective for
snake and arachnid bites, with available data suggesting a positive
effect against scorpion bites. Antidotes are also reportedly safe and
effective. Polyclonal antibodies are being developed against viruses
with epidemic and pandemic potential for which prophylactic and
therapeutic options are currently limited, such as avian influenza
and other zoonotic viruses. Preclinical studies as well as phase 1
safety studies against avian H5N1 influenza, are promising and
the technology exists to rapidly apply the methods of polyclonal
production against a wide range of pathogenic antigens, provid-
ing an exciting opportunity to revolutionise the prognosis of both
longstanding neglected tropical diseases as well as emerging viral
threats to humans.
Conflict of interest statement
The authors have no conflict to declare.
Acknowledgements
CécileHerbreteau-Delale (Fab’entench).
References
[1] Von Behring E, Kitasato S. Ueber das zustandekommen der diphtherie-
immunität und der tetanus-immunität bei thieren. Deutsche Medicininis-
che Wochenschrift 1890;49(Dec):1113–4, http://dx.doi.org/10.1016/0161-
5890(91)90033-G.
[2] Strohl WR, Knight DM. Discovery and development of biopharmaceu-
ticals: current issues. Curr Opin Biotechnol 2009;20(Dec (6)):668–72,
http://dx.doi.org/10.1016/j.copbio.2009.10.009.
[3] Chippaux J-P, GoyffonM. Venoms, antivenoms and immunotherapy. Toxicon
1998;36(6):823–46, http://dx.doi.org/10.1016/S0041-0101(97)00160-8.
[4] Newcombe C, Newcombe AR. Antibody production: polyclonal derived bio-
therapeutics. J Chromatogr R Analyt Technol Biomed Life Sci 2007;848(Mar
(1)):2–7, http://dx.doi.org/10.1016/j.jchromb.2006.07.004.
[5] Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent
blood products for Spanish influenza pneumonia: a future H5N1 treatment?
Ann Intern Med 2006;145(Oct (8)):599–609, http://dx.doi.org/10.7326/
0003-4819-145-8-200610170-00139.
[6] Association for Prevention & Control of Rabies in India. Manual on
rabies immunoglobulin (RIG) administration [pamphlet]. Bangalore: Asso-
ciation for Prevention & Control of Rabies in India; 2009. Available
from: 〈http://rabies.org.in/rabies/wp-content/uploads/2009/11/Manual-on-
Rabies-Immunoglobulin-Administration.pdf〉.
[7] Berry JD, Gaudet RG. Antibodies in infectious diseases: polyclonals, mono-
clonals and niche biotechnology. N Biotechnol 2011;28(Sep (5)):489–501,
http://dx.doi.org/10.1016/j.nbt.2011.03.018.
[8] Casadevall A, Dadachova E, Pirofski LA. Passive antibody ther-
apy for infectious diseases. Nat Rev Microbiol 2004;2(9):695–703,
http://dx.doi.org/10.1038/nrmicro974.
[9] TerMeulen J. Monoclonal antibodies in infectious diseases: clinical
pipeline in 2011. Infect Dis Clin North Am 2011;25(Dec (4)):789–802,
http://dx.doi.org/10.1016/j.idc.2011.07.006.
[10] Theakston RDG, Warrell DA, Griffiths E. Report of a WHO work-
shop on the standardization and control of antivenoms. Toxicon.41
(5) (pp 541-557), 2003. Date of Publication: 01 May 2003. Stan-
dardization and control of antivenoms. Toxicon 2003;419(5):541–57,
http://dx.doi.org/10.1016/S0041-0101(02)00393-8.
[11] Baud FJ, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C,
et al. Brief report: treatment of severe colchicine overdose with
colchicine-specific Fab fragments. N Engl J Med 1995;332(Mar (10)):642–5,
http://dx.doi.org/10.1056/NEJM199503093321004.
[12] Antman EM, Wenger TL, Butler Jr VP, Haber E, Smith TW. Treatment of
150 cases of life-threatening digitalis intoxication with digoxin-specific
Fab antibody fragments. Final report of a multicenter study. Circulation
1990;81(6):1744–52, http://dx.doi.org/10.1161/01.CIR.81.6.1744.
[13] Eddleston M, Persson H. Acute plant poisoning and antitoxin antibod-
ies. J Toxicol Clin Toxicol 2003;41(3):309–15, http://dx.doi.org/10.1081/
CLT-120021116.
[14] Pépin-Covatta S, LutschC,GrandgeorgeM, Lang J, Scherrmann JM. Immunore-
activity andpharmacokinetics of horse anti-scorpion venomF(ab′)2-scorpion
venom interactions. Toxicol Appl Pharmacol 1996;141(Nov (1)):272–7,
http://dx.doi.org/10.1016/S0041-008X(96)80033-0.
[15] Wilde H, Chomchey P, Punyaratabandhu P, Phanupak P, Chutivongse S. Puri-
fied equine rabies immune globulin: a safe and affordable alternative to
human rabies immune globulin. Bull World Health Organ 1989;67(6):731–6.
[16] Smith TW, Haber E, Yeatman L, Butler Jr VP. Reversal of advanced
digoxin intoxication with Fab fragments of digoxin-specific antibodies.
N  Engl J Med  1976  8;294(Apr (15)):797–800,  http://dx.doi.org/10.1067/
mem.2002.123134.
[17] Leoı´n G, Monge M, Rojas E, Lomonte B, Gutierrez JM. Comparison between
IgG and F(ab′)2 polyvalent antivenoms: neutralization of systemic effects
induced by Bothropsasper venom inmice, extravasation ofmuscle tissue, and
potential for induction of adverse reactions. Toxicon 2001;39(6):793–801.
[18] Grandgeorge M, Véron JL, Lutsch C, Makula MF, Riffard P, Pépin S, Scher-
rmenn JM. Preparation of improved F(ab′)2 antivenoms. An example:
new polyvalent anti-European vipers (equine). Toxicon 1996;34(2):148,
http://dx.doi.org/10.1016/0041-0101(96)83667-1.
49
1158 R. Dixit et al. / Vaccine 34 (2016) 1152–1161
[19] Pépin-Covatta S, LutschC, GrandgeorgeM, Scherrmann JM. Immunoreactivity
of a new generation of horse F(ab′)2 preparations against European viper
venoms and the tetanus toxin. Toxicon 1997;35(3):411–22, http://dx.doi.org/
10.1016/S0041-0101(96)00144-4.
[20] Luekrajang T, Wangsai J, Phanuphak P. Production of antirabies serum of
equine origin; 2015. Available from: 〈http://www.who.int/rabies/vaccines/
en/Laboratory techniques in rabies chapter44.pdf?ua=1〉 [updated 2015;
´
˜
cited 2015 Mar 17].
[21] Burnet FM. A modification of Jerne’s theory of antibody production using
the concept of clonal selection. CA 1976;26(2):119–21, http://dx.doi.org/
10.3322/canjclin.26.2.119. A Cancer Journal for Clinicians.
[22] Lovrecek D, Tomic SA. century of antivenom. Coll Antropol
2011;35(1):249–58.
[23] Council of Europe. Immunosera for human use, animal [monograph on inter-
net]. In: European pharmacopeoia. 5th ed. Strasbourg: Council of Europe;
2004. p. 573–5. Available from: 〈http://lib.njutcm.edu.cn/yaodian/ep/
EP501E/06 general monographs/immunosera for human use animal/0084e.
pdf〉 [cited 2015 October 12].
[24] Gutiérreza JM, León G, Burnouf T. Antivenoms for the treatment of snakebite
envenomings: the road ahead. Biologicals 2011;39(May (3)):129–42,
http://dx.doi.org/10.1016/j.biologicals.2011.02.005.
[25] Guidlolin RG, Marcelino RM, Gondo HH, Morais JF, Ferreira RA, Silva CL,
et al. Polyvalent horse F(Ab′)2 snake antivenom: development of pro-
cess to produce polyvalent horse F(Ab′)2 antibodies anti-African snake
venom. Afr J Biotechnol 2010;9(Apr (16)):2446–55, http://dx.doi.org/
10.5897/AJB2010.000-3056.
[26] Otero-Patino R. Epidemiological, clinical and therapeutic aspects of Bothrop-
sasper bites. Toxicon 2009;54(7):998–1011.
[27] Otero R, Gutiérrez JM, Rojas G, Núnez V, Díaz A, Miranda E, et al.
A  randomized  blinded  clinical  trial  of  two  antivenoms, prepared  by
caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops
and Porthidium snake bites in Colombia: correlation between safety and
biochemical characteristics of antivenoms. Toxicon 1999;37(6):895–908,
http://dx.doi.org/10.1016/S0041-0101(98)00220-7.
[28] GarcíaM,MongeM, LeónG, Lizano S, Segura E, SolanoG, et al. Effect of preser-
vatives on IgG aggregation, complement-activating effect and hypotensive
activity of horse polyvalent antivenom used in snakebite envenomation. Bio-
logicals 2002;30(Jun (2)):143–51, http://dx.doi.org/10.1006/biol.2002.0329.
[29] Burnouf T, Griffiths E, Padilla A, Seddik S, Stephano MA, Gutiérrez JM.
Assessment of the viral safety of antivenoms fractionated from equine
plasma. Biologicals 2004;32(Sep (3)):115–28, http://dx.doi.org/10.1016/
j.biologicals.2004.07.001.
[30] Solano S, Segura Á, León G, Gutiérrez JM, Burnouf T. Low pH formu-
lation of whole IgGantivenom: impact on quality, safety, neutralizing
potency and viral inactivation. Biologicals 2012;40(Mar (2)):129–33,
http://dx.doi.org/10.1016/j.biologicals.2011.11.006.
[31] WHO. WHO guidelines for the production, control and regulation of snake
anitvenom immunoglobulins; 2010. Available from: 〈http://www.who.int/
bloodproducts/snake antivenins/snakeantiveninguideline.pdf〉 [cited 2014
Feb 20].
[32] Gutiérrez JM, León G, Lomonte B. Pharmacokinetic-pharmacodynamic
relationships of immunoglobulin therapy for envenomation. Clin Pharm
2003;42:721–41.
[33] Chippaux JP, Lang J, Eddine SA, Fagot P, RageV, Peyrieux JC, et al. Clinical safety
of a polyvalent F(ab′)2 equine antivenom in 223 African snake envenoma-
tions: a field trial in Cameroon. VAO (Venin Afrique de l’Ouest) Investigators.
Trans R Soc Trop Med Hyg 1998;92:657–62. NOTE CROSS REFERENCE.
[34] Bush SP, Ruha AM, Seifert SA, Morgan DL, Lewis BJ, Arnold TC, et al.
Comparison of F(ab′)2 versus Fab antivenom for pit viper envenomation:
a  prospective, blinded,  multicenter,  randomized  clinical  trial.  Clin  Toxicol
(Phila) 2015;53(1):37–45, doi:.
[35] Rivière G, et al. Effect of antivenom on venom pharmacokinetics in experi-
mentally envenomed rabbits: toward an optimization of antivenom therapy.
J  Pharm Exp  Ther 1997;281:1–8.
[36] Sevcik C, D’Suze G, Diaz P, Salazar V, Hidalgo C, Azpurua H, et al. Modelling
Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active
immunoglobulin G’s F(ab′)2 extrusionmechanism fromblood to tissues. Tox-
icon 2004;44:731–41.
[37] VazquezH, Chavez-Haro A, Garcia-UbbelohdeW,Mancilla-Nava R, Paniagua-
Solis J, Alagon A, et al. Pharmacokinetics of a F(ab′)2 scorpion antivenom in
healthy human volunteers. Toxicon 2005;46:797–805.
[38] Chippaux JP, Boyer LV, Alagón A. Post-exposure treatment of Ebola
virus using passive immunotherapy: proposal for a new strategy. Lancet
2015;15(3):285–92.
[39] Hu CC, Yin J, Chau D, Cherwonogrodzky JW, Hu WG. Active immunity
induced by passive IgG post-exposure protection against ricin. Toxins (Basel)
2014;6(1):380–93, http://dx.doi.org/10.3390/toxins6010380.
[40] Bal C, Herbreteau CH, Buchy P, Rith S, ZaidM, KristantoW, et al. Safety, poten-
tial efficacy, and pharmacokinetics of specific polyclonal immunoglobulin
F(ab′)(2) fragments against avian influenza A (H5N1) in healthy volunteers: a
single-centre, randomised, double-blind, placebo-controlled, phase 1 study.
Lancet Infect Dis 2015;15:285–92.
[41] Nuchpraryoon I, Garner P. Interventions for preventing reactions to
snake antivenom. Cochrane Database Syst Rev 2000;2:CD002153,
http://dx.doi.org/10.1002/14651858.CD002153.
[42] Isbister GK, Brown SG, MacDonald E, White J, Currie BJ. Australian Snakebite
Project Investigators. Current use of Australian snake antivenoms and fre-
quency of immediate-type hypersensitivity reactions and anaphylaxis. Med
J  Aust 2008;188(8):473–6.
[43] Karlson-Stiber C, Persson H, Heath A, Smith D, Al-Abdulla IH, Sjöström L.
First clinical experiences with specific sheep Fab fragments in snake bite.
Report of a multicentre study of Viperaberusenvenoming. J Intern Med
1997;241(1):53–8, http://dx.doi.org/10.1046/j.1365-2796.1997.80896000.x.
[44] Sjöström L, al-Abdulla IH, Rawat S, Smith DC, Landon J. A com-
parison of ovine and equine antivenoms. Toxicon 1994;32(4):427–33,
http://dx.doi.org/10.1016/0041-0101(94)90294-1.
[45] Meyer WP, Habib AG, Onayade AA, Yakubu A, Smith DC, Nasidi A, et al. First
clinical experienceswithanewovineFabEchisocellatus snakebiteantivenom
inNigeria: randomized comparative trialwith Institute Pasteur Serum (Ipser)
Africa antivenom. Am J Trop Med Hyg 1997;56(3):291–300.
[46] Winkel KD, Mirtschin P, Pearn J. Twentieth century toxinology and
antivenom development in Australia. Toxicon 2006;48(Dec (7)):738–54,
http://dx.doi.org/10.1016/j.toxicon.2006.08.001.
[47] Gutiérrez JM, Williams D, Fan HW, Warrell DA. Snakebite envenoming from
a  global perspective:  towards  an  integrated approach.  Toxicon 2010;56(Dec
(7)):1223–35, http://dx.doi.org/10.1016/j.toxicon.2009.11.020.
[48] Williams DJ, Jensen SD, Nimorakiotakis B, Müller R, Winkel KD. Antiven-
omuse, premedication and early adverse reactions in the management of
snake bites in rural Papua New Guinea. Toxicon 2007;49(May (6)):780–92,
http://dx.doi.org/10.1016/j.toxicon.2006.11.026.
[49] Radulescu L, Antohe F, Jinga V, Ghetie V, SimionescuM. Neonatal Fc receptors
discriminatesandmonitors thepathwayofnativeandmodified immunoglob-
ulin G in placental endothelial cells. Hum Immunol 2004;65(6):578–85.
[50] Quiambao BP, DyTioco HZ, Dizon RM, Crisostomo ME, Laot TM, Teuwen
DE. Rabies post-exposure prophylaxis in the Philippines: health sta-
tus of patients having received purified equine F(ab′)2 fragment
fabies immunoglobulin (Favirab). PLoS Negl Trop Dis 2008;2(5):e243,
http://dx.doi.org/10.1371/journal.pntd.0000243.
[51] WHO. WHO guide for rabies pre and post exposure prophylaxis
in humans; 2013. Available from: 〈http://www.who.int/rabies/
WHO Guide Rabies Pre Post Exposure Prophylaxis Humans 2013.pdf?ua=1〉
[updated 2013; cited 2014 Feb 4].
[52] Quiambao BP, Dy-Tioco HZ, Dizon RM, Crisostomo ME, Teuwen DE. Rabies
post-exposure prophylaxis with purified equine rabies immunoglobulin:
one-year follow-up of patients with laboratory-confirmed category III
rabies exposure in the Philippines. Vaccine 2009;27(Nov (51)):7162–6,
http://dx.doi.org/10.1016/j.vaccine.2009.09.036.
[53] Behera TR, Satapathy DM, Pratap AK, Tripathy RM. Post-exposure prophy-
laxis for rabies with ERIG and IDRV in children. J Commun Dis 2011;43(Mar
(1)):31–7.
[54] Wilde H, Chomchey P, Prakongsri S, Punyaratabandhu P. Safety of
equine rabies immune globulin. Lancet 1987;330(Nov (8570)):1275,
http://dx.doi.org/10.1016/S0140-6736(87)91885-X.
[55] Suwansrinon K, Jaijareonsup W, Wilde H, Benjavongkulchai M, Sriaroon
C, Sitprija V. Sex- and age-related differences in rabies immunoglob-
ulin hypersensitivity. Trans R Soc Trop Med Hyg 2007;101(2):206–8,
http://dx.doi.org/10.1016/j.trstmh.2006.04.009.
[56] Otten EJ. Antivenin therapy in the emergency department. Am J Emerg Med
1983;1(Jul (1)):83–93, http://dx.doi.org/10.1016/0735-6757(83)90040-2.
[57] Smith MS, Ownby CL. Ability of polyvalent (Crotalidae) antivenin to
neutralize myonecrosis, hemorrhage and lethality induced by timber rat-
tlesnake (Crotalus horridus horridus) venom. Toxicon 1985;23(3):409–25,
http://dx.doi.org/10.1016/0041-0101(85)90025-X.
[58] Otero R, León G, Gutiérrez JM, Rojas G, Toro MF, Barona J, et al. Effi-
cacy and safety of two whole IgG polyvalent antivenoms, refined by
caprylic acid fractionation with or without beta-propiolactone, in the treat-
ment of Bothropsasper bites in Colombia. Trans R Soc Trop Med Hyg
2006;100(12):1173–82, http://dx.doi.org/10.1016/j.trstmh.2006.01.006.
[59] Thomas L, TyburnB, Lang J, Ketterle J. Early infusion of a purifiedmonospecific
F(ab′)2 antivenom serum for Bothrops Ianceolatus bites inMartinique. Lancet
1996;347(Feb (8998)):406.
[60] Thomas L, Tyburn B, Lang J, Ketterle J, Biao T, Moravie V, et al.
Snake (Bothrops lanceolatus) F(ab′)2 antivenom (equine) use in Mar-
tinique: safety and efficacy. Reanimation Urgences 1998;7(Jul (4)):381–7,
http://dx.doi.org/10.1016/S1164-6756(98)80004-2.
[61] Ha TH, Höjer J, Trinh XK, Nguyen TD. A controlled clinical trial of a novel-
antivenom in patients envenomed by Bungarus multicinctus. J Med Toxicol
2010;6(Dec (4)):393–7, http://dx.doi.org/10.1007/s13181-010-0051-4.
[62] Chippaux JP, Massougbodji A, Stock RP, Alagon A. Investigators of African
Antivipmyn in Benin. Clinical trial of an F(ab′)2 polyvalent equine antivenom
for African snake bites in Benin. Am J TropMedHyg 2007;77(Sep (3)):538–46.
[63] Gold BS, Barish RA, Dart RC. North American snake envenomation: diagno-
sis, treatment, and management. Emerg Med Clin North Am 2004;22(May
(2)):423–43.
50
R. Dixit et al. / Vaccine 34 (2016) 1152–1161 1159
[64] Corneille MG, Larson S, Stewart RM, Dent D, Myers JG, Lopez PP,
et al. A large single-center experience with treatment of patients with
crotalid envenomations: outcomes with and evolution of antivenin ther-
apy. Am J Surg 2006;192(Dec (6)):848–52, http://dx.doi.org/10.1016/
j.amjsurg.2006.08.056.
[65] Lavonas EJ, Schaeffer TH, Kokko J, Mlynarchek SL, Bogdan GM. Crotaline Fab
antivenom appears to be effective in cases of severe North American pit
viper envenomation: an integrative review. BMC Emerg Med 2009;9(13),
http://dx.doi.org/10.1186/1471-227X-9-13.
[66] Lavonas EJ, Kokko J, Schaeffer TH, Mlynarchek SL, Bogdan GM, Dart RC.
Short-term outcomes after Fab antivenom therapy for severe crotaline
snakebite. AnnEmergMed2011;57(2):128–37.e3, http://dx.doi.org/10.1016/
j.annemergmed.2010.06.550.
[67] Keating GM. Crotalidae polyvalent immune Fab: in patients with North
American crotaline envenomation. BioDrugs 2011;25(Apr (2)):69–76,
http://dx.doi.org/10.2165/11207250-000000000-00000.
[68] Pizon AF, Riley BD, LoVecchio F, Gill R. Safety and efficacy of crotalidae poly-
valent immune Fab in pediatric crotaline envenomations. Acad Emerg Med
2007;14(4):373–6, http://dx.doi.org/10.1197/j.aem.2006.10.095.
[69] Johnson PN, McGoodwin L, Banner Jr W. Utilisation of crotalidae polyvalent
immune fab (ovine) for Viperidae envenomations in children. Emerg Med J
2008;25(12):793–8, http://dx.doi.org/10.1136/emj.2007.054916.
[70] Smalligan R, Cole J, Brito N, Laing GD, Mertz BL, Manock S, et al. Crotaline
snake bite in the Ecuadorian Amazon: randomised double blind comparative
trial of three South American polyspecific antivenoms. BMJ 2004;329(Nov
(7475)):1129, http://dx.doi.org/10.1136/bmj.329.7475.1129.
[71] Ariaratnam CA, Sjostrom L, Raziek Z, Kularatne SA, Arachchi RW, Sheriff MH,
et al. An open, randomized comparative trial of two antivenoms for the treat-
ment of envenoming by Sri Lankan Russell’s viper (Daboia russelii russelii).
Trans Roy Soc Trop Med Hyg 2001;95:74–80.
[72] Meyer WP, Habib AG, Onayade AA, Yakubu A, Smith DC, Nasidi A, et al. First
clinical experienceswithanewovineFabEchisocellatus snakebiteantivenom
in Nigeria: a randomized comparative trial with Institute Pasteur Serum
(IPSER) Africa antivenom. Am J Trop Med Hyg 1997;56:291–300.
[73] Chippaux JP. Epidemiology of snakebites in Europe: a systematic
review of the literature. Toxicon 2012;59(1):86–99, http://dx.doi.org/
10.1016/j.toxicon.2011.10.008.
[74] Isbister GK, Duffull SB, Brown SG, ASP Investigators. Failure of antivenom
to improve recovery in Australian snakebite coagulopathy. QJM
2009;102(8):563–8, http://dx.doi.org/10.1093/qjmed/hcp081.
[75] Brown SG, Caruso N, Borland ML, McCoubrie DL, Celenza A, Isbister
GK. Clotting factor replacement and recovery from snake venom-
induced consumptive coagulopathy. Intensive CareMed 2009;35(9):1532–8,
http://dx.doi.org/10.1007/s00134-009-1556-7.
[76] Isbister GK, O’Leary MA, Schneider JJ, Brown SG, Currie BJ, ASP Investiga-
tors. Efficacy of antivenom against the procoagulant effect of Australian
brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies. Toxicon
2007;49(1):57–67, http://dx.doi.org/10.1016/j.toxicon.2006.09.007.
[77] Burgess JL, Dart RC. Snake venom coagulopathy: use and abuse of blood
products in the treatment of pit viper envenomation. Ann Emerg Med
1991;20(7):795–801, http://dx.doi.org/10.1016/S0196-0644(05)80845-5.
[78] WhiteRR,WeberRA. Poisonous snakebite in central Texas:possible indicators
for antivenin treatment. Ann Surg 1991;213(5):466–72.
[79] Murrant T, Bihari D. Anaphylaxsis and anaphylactoid reactions. Int J Clin Pract
2000;54(Jun (5)):322–8.
[80] Tanen D, Ruha A, Graeme K, Curry S. Epidemiology and hospital course of
rattlesnake envenomations cared for at a tertiary referral center in Cen-
tral Arizona. Acad Emerg Med 2001;8(2):177–82, http://dx.doi.org/10.1111/
j.1553-2712.2001.tb01284.x.
[81] Jurkovich GJ, Luterman A, McCullar K, Ramenofsky ML, Curreri PW. Com-
plications of crotalidae antivenin therapy. J Trauma 1988;28(7):1032–7,
http://dx.doi.org/10.1097/00005373-198807000-00020.
[82] LoVecchio F, Klemens J, Roundy EB, Klemens A. Serum sickness following
administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed
rattlesnake envenomation. Wilderness Environ Med 2003;14(4):220–1.
[83] Offerman SR, Smith TS, Derlet RW. Does the aggressive use of polyvalent
antivenin for rattlesnake bites result in serious acute side effects?West JMed
2001;175(2):88–91.
[84] Campbell BT, Corsi JM, Boneti C, Jackson RJ, Smith SD, Kokoska ER.
Pediatric snakebites: lessons learned from 114 cases. J Pediatr Surg
2008;43(7):1338–41, http://dx.doi.org/10.1016/j.jpedsurg.2007.11.011.
[85] Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the
United States. Ann EmergMed 2001;37(2):181–8, http://dx.doi.org/10.1067/
mem.2001.113372.
[86] Jamieson R, Pearn J. An epidemiological and clinical study of snake-bites in
childhood. Med J Aust 1989;150(Jun (12)):698–702.
[87] DartRC, Seifert SA,Boyer LV, et al. A randomizedmulticenter trial ofCrotalinae
polyvalent immune Fab (ovine) antivenom for the treatment for Crotaline
snakebite in the United States. Arch Intern Med 2001;161:2030–6.
[88] Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic
reactions toCrotalidaepolyvalent immuneFab (ovine) antivenom.AnnEmerg
Med 2002;39(6):671–6.
˜
[89] RuhaAM,Curry SC, BeuhlerM,KatzK, BrooksDE,GraemeKA, et al. Initial post-
marketing experience with crotalidae polyvalent immune Fab for treatment
of rattlesnake envenomation. Ann Emerg Med 2002;39(6):609–15.
[90] Weant KA, Bowers RC, Reed J, Braun KA, Dodd DM, Baker SN.
Safety and cost-effectiveness of a clinical protocol implemented to
standardize the use of Crotalidae polyvalent immune Fab antivenom
at an academic medical centre. Pharmacotherapy 2012;32(5):433–40,
http://dx.doi.org/10.1002/j.1875-9114.2012.01026.x.
[91] Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate
hypersensitivity reaction and serumsickness following administrationof cro-
talidae polyvalent immune Fab antivenom: ameta-analysis. Acad EmergMed
2012;19(2):121–31.
[92] Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, et al. A randomized
multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for
the treatment for crotaline snakebite in the United States. Arch Intern Med
2001;161(Sep (16)):2030–6.
[93] Dart RC, Seifert SA, Carroll L, et al. Affinity-purified, mixed monospecific cro-
talid antivenomovine Fab for the treatment of crotalid venompoisoning. Ann
Emerg Med 1997;30:33–9.
[94] Pizon AF, Riley BD, LoVecchio F, et al. Safety and efficacy of crotalidae poly-
valent immune Fab in pediatric crotaline envenomations. Acad Emerg Med
2007;14(Apr (4)):373–6.
[95] Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate
hypersensitivity reaction and serumsickness following administrationof cro-
talidae polyvalent immune Fab antivenom: ameta-analysis. Acad EmergMed
2012;19(2):121–31, http://dx.doi.org/10.1111/j.1553-2712.2011.01276.x.
[96] Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions asso-
ciated with administration of crotalidae polyvalent immune Fab
antivenom. Ann Emerg Med 2008;51(4):407–11, http://dx.doi.org/10.1016/
j.annemergmed.2007.09.036.
[97] Malasit P, Warrell DA, Chanthavanich P, Viravan C, Mongkolsapaya J,
Singhthong B, et al. Prediction, prevention, and mechanism of early (ana-
phylactic) antivenom reactions in victims of snake bites. Br Med J (Clin Res
Ed) 1986;292(Jan (6512)):17–20.
[98] Bentur Y, Raikhlin-Eisenkraft B, Galperin M. Evaluation of antivenom
therapy in Vipera palaestinae bites. Toxicon 2004;44(Jul (1)):53–7,
http://dx.doi.org/10.1016/j.toxicon.2004.04.006.
[99] Abubakar IS, Abubakar SB, Habib AG, Nasidi A, Durfa N, Yusuf PO, et al.,
Nigeria-UK EchiTab Study Group. Randomised controlled double-blind
non-inferiority trial of two antivenoms for saw-scaled or carpet viper
(Echisocellatus) envenoming in Nigeria. PLoS Negl Trop Dis 2010;4(7):e767,
http://dx.doi.org/10.1371/journal.pntd.0000767.
[100] Isbister GK, White J, Currie BJ, O’Leary MA, Brown SG, ASP Investigators.
Clinical effects and treatment of envenoming by Hoplocephalus spp. snakes
in Australia: Australian Snakebite Project (ASP-12). Toxicon 2011;58(Dec
(8)):634–40, http://dx.doi.org/10.1016/j.toxicon.2011.09.013.
[101] Isbister GK, Buckley NA, Brown SGA. Tiger snake (Notechisspp) envenom-
ing: Australian Snakebite Project (ASP-13). Med J Aust 2013;198(4):194–5,
http://dx.doi.org/10.5694/mja12.11690.
[102] Otero-Patino R, Segura A, Herrera M, Angulo Y, León G, Gutiérrez JM,
et al. Comparative study of the efficacy and safety of two polyvalent,
caprylic acid fractionated [IgG and F(ab′)2] antivenoms, in Bothrop-
sasper bites in Colombia. Toxicon 2012;59(2):344–55, http://dx.doi.org/
10.1016/j.toxicon.2011.11.017.
[103] Isbister GK, Shahmy S, Mohamed F, Abeysinghe C, Karunathilake H, Ari-
aratnam A. A randomised controlled trial of two infusion rates to decrease
reactions to antivenom. PLoS ONE 2012;7(6):e38739, http://dx.doi.org/
10.1371/journal.pone.0038739.
[104] Grönlund J, Vuori A, Nieminen S. Adder bites. A report of 68 cases. Scand J
Surg 2003;92(2):171–4, http://dx.doi.org/10.1177/145749690309200211.
[105] Campbell CH. Clinical aspects of snake bite in the Pacific area. Toxicon
1969;7(Jun (1)):25–8, http://dx.doi.org/10.1016/0041-0101(69)90158-5.
[106] Bucarethi F, Douglas JL, FonsecaMRCC, Zambrone FAD,VieiraRJ. Snake enven-
omation in children: early reactions frequency at antivenom in patients
pretreatedwith histamine antagonists HI andH2 and hydrocortisone. Revista
do Instituto de Medicina Tropical de São Paulo 1994;36(5):451–7.
[107] Harry P, de Haro L, Asfar P, David JM. Evaluation of intravenous immunother-
apy with purified F(ab′)2 fragments (Viperfav). Presse Med 1999;28(Nov
(35)):1929–34.
[108] Thiansookon A, Rojnuckarin P. Low incidence of early reactions to
horse-derived F(ab′)(2) antivenom for snakebites in Thailand. Acta Trop
2008;105(2):203–5, http://dx.doi.org/10.1016/j.actatropica.2007.09.007.
[109] Scop J, Little M, Jelinek GA, Daly FF. Sixteen years of severe Tiger snake
(Notechis) envenoming in Perth, Western Australia. Anaesth Intensive Care
2009;37(Jul (4)):613–8.
[110] Wood D, Webb C, DeMeyer J. Severe snakebites in northern KwaZulu-Natal:
treatment modalities and outcomes. S Afr Med J 2009;99(11):814–8.
[111] Churchman A, O’Leary MA, Buckley NA, Page CB, Tankel A, Gavaghan C, et al.
Clinical effects of red-bellied black snake (Pseudechis porphyriacus) envenom-
ing and correlation with venom concentrations: Australian Snakebite Project
(ASP-11). Med J Aust 2010;193(11):696–700.
[112] Baldé MC, Chippaux JP, Boiro MY, Stock R, Massougbodji A. clinical study
of tolerance and effectiveness of a F(ab′)(2) polyvalent antienom for African
51
1160 R. Dixit et al. / Vaccine 34 (2016) 1152–1161
snake bites in Kindia, Guinea. Bull Soc Pathol Exot 2012;105(Aug (3)):157–61,
http://dx.doi.org/10.1007/s13149-012-0223-3.
[113] Boels D, Hamel JF, BretaudeauDeguigne M, Harry P. European viper
envenomings: assessment of ViperfavTM and other symptomatic treat-
ments. Clin Toxicol (Phila) 2012;50(3):189–96, http://dx.doi.org/10.3109/
15563650.2012.660695.
[114] Hung HT, Höjer J, Kiem TX, Nguyen TTD. A controlled clinical trial of a novel
antivenom in patients envenomed by Bungarus multicinctus. J Med Toxicol
2010;6(12 (4)):393–7.
[115] Chippaux JP, Lang J, Amadi-Eddine S, Fagot P, Le Mener V. Short report: treat-
ment of snake envenomations by a new polyvalent antivenom composed of
highly purified F(ab)2: results of a clinical trial in northern Cameroon. Am J
Trop Med Hyg 1999;61(Dec (6)):1017–8.
[116] Isbister GK, Tankel AS, White J, Little M, Brown SG, Spain DJ, et al. High rate
of immediate systemic hypersensitivity reactions to tiger snake antivenom.
Med J Aust 2006;184(Apr (8)):419–20.
[117] Boyer LV, Theodorou AA, Berg RA, Mallie J, Chávez-Méndez A,
García-Ubbelohde W, et al. Antivenom for critically ill children with
neurotoxicity from scorpion stings. N Engl J Med 2009;360:2090–8,
http://dx.doi.org/10.1056/NEJMoa0808455.
[118] Abroug F, Ouanes-Besbes L, Ouanes I, Dachraoui F, Hassen MF, Haguiga
H, et al. Meta-analysis of controlled studies on immunotherapy in
severe scorpion envenomation. Emerg Med J 2011;28(11):963–9,
http://dx.doi.org/10.1136/emj.2010.104158.
[119] LoVecchio F, McBride C. Scorpion envenomations in young children in cen-
tral Arizona. J Toxicol Clin Toxicol 2003;41(7):937–40, http://dx.doi.org/
10.1081/CLT-120026514.
[120] Bawaskar HS, Bawaskar PH. Efficacy and safety of scorpion antivenom
plus prazosin compared with prazosin alone for venomous scorpion
(Mesobuthus tamulus) sting: randomised open label clinical trial. BMJ
2011;342(Jan):c7136, http://dx.doi.org/10.1136/bmj.c7136.
[121] Natu VS, Murthy RK, Deodhar KP. Efficacy of species specific anti-scorpion
venom serum (AScVS) against severe, serious scorpion stings (Mesobuthus
tamulus concanesisPocock)—an experience from rural hospital in western
Maharashtra. J Assoc Phys India 2006;54(Apr):283–7.
[122] PandurangKS, Singh J, Bijesh S, SinghHP. Effectiveness of anti scorpionvenom
for red scorpion envenomation. Indian Pediatr 2014;51(2):131–3. Epub 2013
Sep 5.
[123] Ismail M. Treatment of the scorpion envenoming syndrome: 12-years
experience with serotherapy. Int J Antimicrob Agents 2003;21(2):170–4,
http://dx.doi.org/10.1016/S0924-8579(02)00289-3.
[124] Khattabi A, Achour S, SoulaymaniBencheikh R. Yes or no for serotherapy
in the treatment of scorpion stings and envenomations: a system-
atic review. Clin Toxicol 2012;50:273–366, http://dx.doi.org/10.3109/
15563650.2012.669957.
[125] Riley BD, LoVecchio F, Pizon AF. Lack of scorpion antivenom leads to
increased pediatric ICU admissions. Ann Emerg Med 2006;47(4):398–9,
http://dx.doi.org/10.1016/j.annemergmed.2005.11.042.
[126] Soomro RM, Andy JJ, Sulaiman KA. clinical evaluation of the effective-
ness of antivenom in scorpion envenomation. Med Forum Mon 2001;12(7):
9–11.
[127] Isbister GK, Gray MR, Balit CR, Raven RJ, Stokes BJ, Porges K, et al. Funnel-
web spider bite: a systematic review of recorded clinical cases. Med J Aust
2005;182(Apr (8)):407–11.
[128] Clark RF, Wethern-Kestner S, Vance MV, Gerkin R. Clinical presenta-
tion and treatment of black widow spider envenomation: a review of
163 cases. Ann Emerg Med 1992;21(7):782–7, http://dx.doi.org/10.1016/
S0196-0644(05)81021-2.
[129] Monte AA, Bucher-Bartelson B, Heard KJ. A US perspective of symp-
tomatic Latrodectus spp. envenomation and treatment: a National
Poison Data System review. Ann Pharmacother 2011;45(12):1491–8,
http://dx.doi.org/10.1345/aph.1Q424.
[130] Nordt SP, Clark RF, Lee A, Berk K, Lee Cantrell F. Examination of adverse
events followingblackwidowantivenomuse inCalifornia. Clin Toxicol (Phila)
2012;50(1):70–3, http://dx.doi.org/10.3109/15563650.2011.639714.
[131] Dart RC, Bogdan G, Heard K, Bucher Bartelson B, Garcia-Ubbelohde W, Bush
S, et al. A randomized, double-blind, placebo-controlled trial of a highly puri-
fied equine F(ab)2 antibody black widow spider antivenom. Ann Emerg Med
2013;61(4):458–67, http://dx.doi.org/10.1016/j.annemergmed.2012.10.008.
[132] Isbister GK. Safety of i.v. administration of redback spider antivenom.
Intern Med J 2007;37(12):820–2, http://dx.doi.org/10.1111/j.1445-
5994.2007.01513.x.
[133] Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg
CD, et al. Digoxin immune Fab therapy in the management of digitalis
intoxication: safety and efficacy results of an observational surveil-
lance study. J Am Coll Cardiol 1991;17(3):590–8, http://dx.doi.org/
10.1016/S0735-1097(10)80170-6.
[134] Adisasmito W, Chan PK, Lee N, Oner AF, Gasimov V, Aghayev F, et al.
Effectiveness of antiviral treatment in human influenza A(H5N1) infections:
analysis of a Global Patient Registry. J Infect Dis 2010;202(Oct (8)):1154–60,
http://dx.doi.org/10.1086/656316.
[135] WHO. Clinical management of human infection with avian influenza
A (H5N1) virus;  Aug 2007.  Available  from:  
´
〈http://www.who.int/
influenza/resources/documents/ClinicalManagement07.pdf?ua=1〉 [cited
2015 Mar 17].
[136] Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R. Emergence of oseltamivir
resistance: control and management of influenza before, during and
after the pandemic. Infect Disord Drug Targets 2013;13(Feb (1)):34–45,
http://dx.doi.org/10.2174/18715265112129990006.
[137] WHO Blood Regulators Network (BRN). Position paper on collection
and use of convalescent plasma or serum as an element in pandemic
influenza planning; July 2009. Available from: 〈http://www.who.int/
bloodproducts/brn/BRNPosition-ConvPlasma10July09.pdf〉 [cited 2014
February 20].
[138] Wu JT, LeeCK, CowlingBJ, YuenKY. Logistical feasibility andpotential benefits
of a population-wide passive immunotherapy program during an influenza
pandemic. Influenza Other Respi Viruses 2011;5(May (Suppl 1)):226–9,
http://dx.doi.org/10.1111/j.1750-2659.2011.00209.x.
[139] Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for
Influenza A (H5N1) infection. N Engl J Med 2007;357(October):1450–1,
http://dx.doi.org/10.1056/NEJMc070359.
[140] Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent
plasma. Hong Kong Med J 2006;12(Dec (6)):489.
[141] WHO. Cumulative number of confirmed human cases of avian
influenza A(H5N1) reported to WHO; Mar 2015. Available from:
〈http://www.who.int/influenza/human animal interface/EN GIP 20150126
CumulativeNumberH5N1cases.pdf〉 [cited 2015 Mar 7].
[142] WHO. Human infection with avian influenza A(H5N1) virus—update; Jan
2014. Available from: 〈http://www.who.int/csr/don/2014 01 09 h5n1/en/〉
[cited 2015 Mar 17].
[143] de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN,
et al. Fatal outcome of human influenza A (H5N1) is associated with
high viral load and hypercytokinaemia. Nat Med 2006;12(10):1203–7,
http://dx.doi.org/10.1038/nm1477.
[144] Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau
NV, et al. Prophylactic and therapeutic efficacy of human mono-
clonal antibodies against H5N1 influenza. PLoS Med 2007;4(5):e178,
http://dx.doi.org/10.1371/journal.pmed.0040178.
[145] Herbreteau CH, Jacquot F, Rith S, Vacher L, Nguyen L, Carbonnelle C, et al.
Specific polyclonal F(ab′)2 neutralize a large panel of highly pathogenic avian
influenza A viruses (H5N1) and control infection in mice. Immunotherapy
2014;6(6):699–708, http://dx.doi.org/10.2217/imt.14.40.
[146] Zhao Z, Yan F, Chen Z, et al. Cross clade prophylactic and therapeutic efficacy
of polyvalent equine immunoglobulin F(ab’)2 against highly pathogenic avian
influenza H5N1 in mice. Int Immunopharmacol 2011;11:2000–6.
[147] Király J, Varecˇková E, Mucha V, Kostolansky F. Evaluation of anti-influenza
efficiency of polyclonal IgG antibodies specific to the ectodomain of M2
protein of influenza A virus by passive immunization of mice. Acta Virol
2011;55(3):261–5, http://dx.doi.org/10.4149/av 2011 03 261.
[148] WHO. Influenza at the human-animal interface; Mar 2015. Available
from: 〈http://www.who.int/influenza/human animal interface/Influenza
Summary IRA HA interface 3  March  2015.pdf〉 [cited  2015 Mar 21].
[149] Qi X, Qian YH, Bao CJ, Guo XL, Cui LB, Tang FY, et al. Probable per-
son to person transmission of novel avian influenza A (H7N9) virus in
Eastern China, 2013: epidemiological investigation. BMJ 2013;347:f4752,
http://dx.doi.org/10.1136/bmj.f4752.
[150] Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Putha-
vathana P, et al. Probable person-to-person transmission of avian
influenza A (H5N1). N Engl J Med 2005;352(4):333–40, http://dx.doi.org/
10.1056/NEJMoa044021.
[151] Wang H, Feng Z, Shu Y, Yu H, Zhou L, Zu R, et al. Probable limited person-
to-person transmission of highly pathogenic avian influenza A (H5N1)
virus in China. Lancet 2008;371(Apr (9622)):1427–34, http://dx.doi.org/
10.1016/S0140-6736(08)60493-6.
[152] Wei SH, Yang JR, Wu HS, Chang MC, Lin JS, Lin CY, et al. Human
infection with avian influenza A H6N1 virus: an epidemiological anal-
ysis. Lancet Respir Med 2013;1(Dec (10)):771–8, http://dx.doi.org/
10.1016/S2213-2600(13)70221-2.
[153] To KK, Tsang AK, Chan JF, Cheng VC, Chen H, Yuen KY. Emergence in China of
human disease due to avian influenza A(H10N8)—cause for concern? J Infect
2014;68(3):205–15, http://dx.doi.org/10.1016/j.jinf.2013.12.014.
[154] WHO. Avian influenza A (H10N8). Factsheet; 2014. Available from:
〈http://www.wpro.who.int/china/mediacentre/factsheets/h10n8/en/〉
[updated 2014 Jan 30; cited 2015 Mar 21].
[155] The Malaysian Insider. China records new H10N8 bird flu death; Feb 2014.
Available from: 〈http://www.themalaysianinsider.com/world/article/china-
records-new-h10n8-bird-flu-death-bernama〉 [cited 2015 Mar 17].
[156] Ng WC, Wong V, Muller B, Rawlin G, Brown LE. Prevention and treat-
ment of influenza with hyperimmune bovine colostrum antibody. PLoS ONE
2010;5(10):e13622, http://dx.doi.org/10.1371/journal.pone.0013622.
[157] Hernandez E, Ramisse F, Lhonneux A, Noury J, Bazin H, Cavallo JD. Compared
protective effect of nasal immunoprophylaxis using a new human mono-
clonal IgM antibody, human polyclonal antibodies, F(ab′)2, amantadine, and
52
R. Dixit et al. / Vaccine 34 (2016) 1152–1161 1161
zanamivir for prophylaxis of influenza A virus pneumonia in mice. Mil Med
2003;168(3):246–51.
[158] Rinaldi C, Penhale WJ, Stumbles PA, Tay G, Berry CM. Modula-
tion of innate immune responses by influenza-specific ovine poly-
clonal antibodies used for prophylaxis. PLoS ONE 2014;9(2):e89674,
http://dx.doi.org/10.1371/journal.pone.0089674.
[159] Guery B, Poissy J, el Mansouf L, Séjourné C, Ettahar N, Lemaire X,
et al. Clinical features and viral diagnosis of two cases of infection
with Middle East Respiratory Syndrome coronavirus: a report of noso-
comial transmission. Lancet 2013;381(9885):2265–72, http://dx.doi.org/
10.1016/S0140-6736(13)60982-4.
[160] Centers forDiseaseControl andPrevention (CDC).Updated informationon the
epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV)
infection and guidance for the public, clinicians, andpublic health authorities,
2012–2013.MMWRMorbMortalWkly Rep 2013;62(Sep (38)):793. Available
from: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6238a4.htm〉
[cited 2015 Mar 17].
[161] Disease Outbreak News. Middle East respiratory syndrome coronavirus
(MERS-CoV)—Republic of Korea. Disease Outbreak News 19 June 2015.
〈http://www.who.int/csr/don/19-june-2015-mers-korea/en/〉 (accessed 25
July 2015).
[162] 〈http://apps.who.int/iris/bitstream/10665/179184/2/WHO MERS RA 15.1
eng.pdf〉 (accessed 25 July 2015).
[163] Cotten M,Watson SJ, Kellam P, Al-Rabeeah AA, MakhdoomHQ, Assiri A, et al.
Transmission and evolution of the Middle East respiratory syndrome coro-
navirus in Saudi Arabia: a descriptive genomic study. Lancet 2013;382(Dec
(9909)):1993–2002, http://dx.doi.org/10.1016/S0140-6736(13)61887-5.
[164] Hui DS. Tracking the transmission and evolution of MERS-CoV.
Lancet 2013;382(Dec (9909)):1962–4, http://dx.doi.org/10.1016/S0140-
6736(13)61955-8.
[165] Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive
immunotherapy with dromedary immune serum in an experimental animal
model for Middle East respiratory syndrome coronavirus infection. J Virol
2015;89(Jun (11)):6117–20.
[166] Lessler J, Rodriguez-Barraquer I, Cummings DA, Garske T, Van Kerkhove
M, Mills H, et al., The MERS-CoV Scenario Modeling Working Group. Esti-
mating potential incidence of MERS-CoV associated with Hajj Pilgrims to
Saudi Arabia, 2014. PLoS Curr 2014;(November), http://dx.doi.org/10.1371/
currents.outbreaks.c5c9c9abd636164a9b6fd4dbda974369. Edition 1.
[167] Ebola Situation Report—22 July 2015 〈http://apps.who.int/ebola/current-
situation/ebola-situation-report-22-july-2015〉 (accessed 25 July 2015).
[168] Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Mar-
ianneau P, et al. Nipah virus: vaccination and passive protection studies
in a hamster model. J Virol 2004;78(Jan (2)):834–40, http://dx.doi.org/
10.1128/JVI.78.2.834-840.2004.
[169] Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW. DNA vaccine-
generated duck polyclonal antibodies as a postexposure prophylactic to
prevent hantavirus pulmonary syndrome (HPS). PLoSONE2012;7(4):e35996,
http://dx.doi.org/10.1371/journal.pone.0035996.
[170] Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE,
et al. Postexposure antibody prophylaxis protects nonhuman primates
from filovirusdisease. Proc Natl Acad Sci USA 2012;109(Mar (13)):5034–9,
http://dx.doi.org/10.1073/pnas.1200409109.
[171] Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive trans-
fer of antibodies protects immunocompetent and imunodeficient mice
against lethal Ebola virus infection without complete inhibition of viral
replication. J Virol 2001;75(May (10)):4649–54, http://dx.doi.org/10.1128/
JVI.75.10.4649-4654.2001.
[172] Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, et al.
Evaluationof immuneglobulinandrecombinant interferon-alpha2b for treat-
ment of experimental Ebola virus infections. J Infect Dis 1999;179(Feb (Suppl.
1)):S224–34, http://dx.doi.org/10.1086/514310.
[173] Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV.
Preparation and use of hyperimmune serum for prophylaxis and therapy
of Ebola virus infections. J Infect Dis 1999;179(Feb (Suppl 1)):S218–23,
http://dx.doi.org/10.1086/514294.
[174] Borisevich IV, Mikhaı˘lov VV, Krasnianskiı˘ VP, Gradoboev VN, Lebedinskaia
EV, Potryvaeva NV, et al. Development and study of the properties of
immunoglobulin against Ebola fever. Vopr Virusol 1995;40(6):270–3.
[175] Mikhaı˘lov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskiı˘
VP. The evaluation in hamadryas baboons of the possibility for the specific
prevention of Ebola fever. Vopr Virusol 1994;39(2):82–4.
[176] Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins
JW, et al. Passive immunization of Ebola virus-infected cynomolgus
monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl
1996;11:135–40.
[177] Zhou L, Ni B, Zhao G, et al. Inhibition of infection caused by severe respiratory
syndrome-associated coronavirus by equine neutralizing antibody in aged
mice. Int Immunopharmacol 2007;7:392–400.
[178] Zhao G, Ni B, Jiang H, Luo D, Pacal M, Zhou L, et al. Inhibition of severe
acute respiratory syndrome-associated coronavirus infection by equine neu-
tralizing antibody in golden Syrian hamsters. Viral Immunol 2007;20(Spring
(1)):197–205.
[179] Luo D, Ni B, Zhao G, Jia Z, Zhou L, Pacal M, et al. Protection from infectionwith
severe acute respiratory syndrome coronavirus in a Chinese hamster model
by equine neutralizing F(ab’)2. Viral Immunol 2007;20(Sep (3)):495–502.
53
	
					
				


54
55
CORRIGENDUM
Corrigendum to Benefits of using heterologous polyclonal antibodies and potential 
applications to new and undertreated infectious pathogens. 
Vaccine. 2016 Feb 24;34(9):1152-61. 
Dixit R1, Herz J2, Dalton R3, Booy R4. 
a
 
1. The Children's Hospital, Westmead, Sydney, Australia 
b
 
2. Biointelect, Sydney, Australia 
c
 
3. University of Southampton, Southampton, United Kingdom 
The authors regret that under section 5: "Polyclonal antibodies for emerging and neglected 
viral diseases", the line reads: 'In another study, four H5N1 avian influenza 
equine F(ab′) 2preparations demonstrated cytopathic effect against cultured Madin–Darby canine 
kidney (MDCK) cells infected with H5N1 and protected mice against lethal challenge, both 
given prior (prophylaxis) or post (therapeutic) exposure'  [146]  
  
However, the line should read: "In another study, four H5N1 avian influenza equine 
F(ab′) 2preparations prevented cytopathic effects of H5N1-infection of cultured Madin–Darby 
canine kidney (MDCK) cells, and protected mice against lethal challenge, both given prior 
(prophylaxis) or post (therapeutic) exposure". 
  
Likewise…  the isolated “1” after reference 167 should not be there,  
Likewise, the authors regret that under section 5: “Polyclonal antibodies for emerging and 
neglected viral diseases”, the line reads: “E. Bola on page 1157 reads : ‘Similar results 
were obtained from injecting Ebola infected mice with polyclonal sera from E. bola immu-
nised mice [171]’. 
However, the line should read: ‘Similar results were obtained from injecting Ebola infected 
mice with polyclonal sera from Ebola immunised mice [171]’
The authors would like to apologise for any inconvenience caused. 
____________________________ 
DOI of original article: 10.1016/j.vaccine.2016.01.016. Epub 2016 Jan 20. 
Dr Rashmi Dixit 
rushmi7@gmail.com 
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4.3 Chapter 3 Synopsis 
Benefits of Using Heterologous Polyclonal Antibodies and Potential Applications to 
New and Undertreated Infectious Pathogens – Synopsis 
 
Heterologous Polyclonal Antibodies have been used for over a century in the pre-antibiotic 
age to treat influenza and other infectious pathogens, and were subsequently developed for 
application to neutralise rabies virus, treat toxicities and as antivenin again snake, scorpion 
and other animal bites. Initial limitations of their use to hypersensitivity reactions to animal 
proteins have been overcome with modern purification techniques. They are cheaper and 
more rapidly generated to a range of infectious illnesses than monoclonal antibodies. There 
has been resurgence in their interest in application to neglected and emerging viral diseases, 
such as avian influenza, E-bola and Zika virus. For the purposes of this thesis, they may 
provide an alternative to neuraminidase inhibitors in the event of the predominance of a 
resistant seasonal strain predominating, or pandemic strains that may be inherently resistant. 
Proof of concept studies, in cell cultures and in mice, have been promising, and Phase 1 
safety studies have been successful. Further development for clinical application is awaited. 
 
These three chapters concluded my examination of the risk posed by oseltamivir-resistance 
to the general populous, but particularly to those vulnerable to influenza infection. In the 
subsequent three chapters, I examine three subgroups vulnerable to influenza infection and 
severity –the elderly, infants and colonised populations – specifically Indigenous Australians. 
 
 57
5.1 Chapter 4 Preamble 
A Protocol for a Randomised Controlled Trial of Oseltamivir Treatment and Prophylaxis During 
Influenza Outbreaks in Aged Care Facilities in the Context of Optimal Influenza Vaccination 
and Infection Control 
 
Elderly citizens, particularly of aged care facilities (ACFs), are at a heightened risk of acquiring 
influenza and dying from it. Moreover, communal living arrangements, and sharing of both staff and 
amenities, promote influenza outbreaks. Aged care facilities are also a potential source of community 
outbreaks.  
The Australian Communicable Diseases Network of Australia guidelines on influenza outbreak 
management in resident-care facilities advise ‘consideration’, only, of oseltamivir for treatment of 
cases plus treatment of contacts (prophylaxis) during outbreaks, as opposed to no prophylaxis of 
contacts. The lack of firm recommendations reflects the paucity of evidence.  
In this study, we proposed a cluster-randomised, unblinded, controlled trial of residents and staff of 
70-100 ACFs with partnership between various stakeholders: aged care facilities, clinical researchers, 
general practitioners, government public health bodies, and relevant industry partners. There will be a 
programme of information sessions held on preventing and detecting possible influenza, and 
institution of active computerised surveillance. Point-of-care testing will be used to diagnose cases, 
following screening for influenza-like illness. ACFs will be randomised to receive either oseltamivir 
treatment of cases, or treatment of cases plus treatment of contacts (prophylaxis). Primary outcome is 
information on the attack rate of influenza in treatment (T) vs. treatment and prophylaxis (T & P) 
groups, and hospital admission incidence. Secondary outcome measures will be rates of case fatality, 
pneumonia rates, adverse events, and influenza outbreak duration. 
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5.2 Chapter 4 
A Protocol for a Randomised Controlled Trial of Oseltamivir Treatment and Prophylaxis During 
Influenza Outbreaks in Aged Care Facilities in the Context of Optimal Influenza Vaccination 
and Infection Control 
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5.2.1 Abstract:  
Background 
Influenza outbreaks in aged care facilities (ACFs) affect up to 40% of elderly residents, and involve 
residents and staff as well as foster influenza transmission to the community. They are a significant 
cause of hospital admissions and deaths each influenza season. Surveillance for respiratory 
infections is recommended by various national and international public health bodies and would 
inform outbreak management. Co-ordinated surveillance activity is sparse. Currently, there are scant 
data about the role of anti-viral therapy in influenza outbreaks in ACFs on which to base national 
recommendations. This study has two main purposes: firstly, to examine the impact of oseltamivir, as 
treatment only, versus treatment and prophylaxis, for residents and staff of ACFs during influenza 
outbreaks with respect to morbidity, mortality and outbreak size; secondly, to develop and test an 
enhanced surveillance system, utilising bedside rapid point-of-care tests with laboratory confirmation, 
for respiratory infection outbreaks in ACFs; both in the context of promoting influenza vaccine uptake 
and infection control measures. 
Methods 
This protocol proposes a cluster-randomised, unblinded, controlled trial of residents and staff of 70-
100 ACFs with partnership between various stakeholders: aged care facilities, clinical researchers, 
general practitioners, government public health bodies, and relevant industry partners. Over one 
influenza season, screening of symptoms to identify influenza-like illness will be followed up by rapid 
point-of-care tests to diagnose influenza. ACFs will be randomised to receive either oseltamivir 
treatment in cases or oseltamivir treatment in cases plus prophylaxis in contacts.  
Results 
The primary outcome measures will be a comparison between the two groups of the attack rate of 
influenza in treatment (T) vs. treatment and prophylaxis (T & P) groups, and hospital admission 
incidence within four weeks from onset of Influenza symptoms. Secondary outcome measures will be 
case fatality rate within 4 weeks from the onset of an influenza outbreak, pneumonia in subjects within 
4 weeks from outset of influenza symptoms, adverse events in subjects within 4 weeks of 
commencing oseltamivir and outbreak duration: date of the onset of the first symptomatic resident in a 
confirmed influenza outbreak to date of onset of last case.  
Conclusions 
Our proposed study aims to inform policy decision makers in formulating recommendations for the 
use of oseltamivir in influenza outbreaks in ACFs. This study presents an opportunity to develop and 
test active surveillance systems for respiratory and other infections.  The overall aim is to prevent and 
better manage influenza outbreaks in aged care facilities. 
Trial Registration: ACTRN12615000638538 
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5.2.2  BACKGROUND 
In developed countries, the highest rates of influenza-related hospitalisation and death occur in 
people aged more than 65 years who either have comorbidities and/or reside in aged care facilities 
(1,2). Attack rates of 20-40% have occurred in aged care facility (ACF) influenza outbreaks (3–5). 
The proportion of the Australian population aged over 65 years is projected to rise from 14% now to 
25% by 2045 [6,7]. The proportion of the population aged over 85 years is projected to increase four-
fold from 1.8% in 2011 (approximately 420,000) to 5.0% (approximately 1.7 million) by 2045 (6–9). 
Chance of residing in an ACF rises with age; currently <1% of those aged 65 years and 15% in those 
aged 85 years or older reside in ACFs (9). Thus, the health needs of this demographic will require far 
greater attention and research. 
Oseltamivir, a neuraminidase inhibitor that acts to prevent release of viral progeny from host cells and 
thus avert subsequent infection of uninfected cells, is the antiviral agent of choice against seasonal 
influenza (10). It is registered for treatment and prophylaxis of influenza, but its efficacy and role are 
topics of controversy. The most recent Australian CDNA guidelines on influenza outbreak 
management in resident-care facilities were published in 2009 and updated in 2017 (11,12). Both 
advise consideration, only, of oseltamivir for treatment and prophylaxis during outbreaks, due to 
unavailability of evidence on which to base firmer recommendations. The 2017 guidelines defer the 
decision to individual general practitioners. The 2014 European “Fluresp” guidelines deem antiviral 
treatment alone as more cost-effective than application of antiviral prophylaxis during influenza 
epidemics, but did not specify applicability to institutional outbreaks, and this recommendation was 
within the context of mass population influenza vaccination (13). 
A 2014 Cochrane review of published and unpublished randomised, controlled trials concluded that 
oseltamivir reduced symptoms of influenza by 17 hours in adults and, when used as household 
prophylaxis, reduced the risk of developing symptomatic influenza, but whether there was a reduction 
in pneumonia was unresolved, and they found no reduction in bronchitis, sinusitis or otitis media or 
serious complications (14).  They reported an increase in gastrointestinal and psychiatric side effects. 
The review did not address the role of oseltamivir in institutional outbreaks. The review was criticised 
for excluding observational data, which, due to ethical constraints, was the main data type collected 
during the 2009 pandemic, and its findings were controversial.  
The UK based Multiparty Group for Advice on Science (MUGAS), presented findings of controlled 
trials and observational data to the 2014 European Scientific Working group on Influenza, in Riga 
Latvia. Roche, who manufacture oseltamivir, and who provided some funding for this review, were 
reportedly given no access to findings prior to presentation. They reported that in adults with 
confirmed influenza, oseltamivir reduced development of otitis media and pneumonia, reduced 
hospitalisation and lead to an 18% reduction in mortality. There was an increase in gastro-intestinal 
adverse events but not in neuropsychiatric events. The role of oseltamivir in residential facilities was 
not addressed. The same group later published a meta-analysis of published and unpublished 
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randomised controlled trials in 2015 (15). Their findings conflicted with Cochrane and concurred with 
their earlier review of both observational and controlled trials. There were fewer lower respiratory tract 
(LRT) complications (risk ratio RR = 0.56, 44% risk reduction) and hospitalisations (RR = 0.37, 64% 
risk reduction) in those with laboratory-confirmed influenza who received oseltamivir treatment, and 
no neuropsychiatric side effects. In those ≥ 65 years, oseltamivir did not reduce symptom duration but 
did reduce LRT complications. A 2014 meta-analysis by the same group of the observational, 
individualised data of 30,000 hospitalised patients demonstrated a reduction in mortality in those who 
received oseltamivir within 48H compared to no oseltamivir in those with laboratory-proven influenza 
(OR 0.50); oseltamivir started after 48H reduced mortality in those admitted to critical care (OR 0.65) 
(16). They also performed a 2013 meta-analysis of 25 comparative observational (case series, case-
control and cohort studies) and randomized controlled studies, which demonstrated a reduction in 
mortality (0.35) if NAIs are given within 48H (17). In 2016, Hurt  and Kelly, freshly reviewed the 
literature and concluded that oseltamivir reduces symptoms by up to 1 day, and possibly reduces 
mortality in severely ill patients; both when given within 48 hours (18). 
Booy et al. conducted a cluster-randomised study on oseltamivir for the control of influenza outbreaks 
in ACFs (3). In 16 ACFs, oseltamivir significantly reduced acute influenza attack rates and outbreak 
duration when used for treatment of cases and also prophylaxis of contacts, as compared to 
treatment of cases, alone. The study also demonstrated a trend towards lower staff infection rates, 
fewer hospitalisations and deaths and less pneumonia when oseltamivir was used as prophylaxis. In 
contrast, a recent study of 42 nursing homes in which 17 outbreaks were recorded over 2009-2013 
demonstrated that oseltamivir prophylaxis was ineffective in preventing influenza or influenza-like 
illness, but was underpowered with fewer outbreaks than anticipated (19). A retrospective comparison 
of three different prophylaxis approaches in three separate ACFs during one influenza season 
showed that prophylaxis did not reduce attack rate (26.4% prophylaxis to all residents vs. 38.3% to 
direct contacts vs. 18.9% no prophylaxis) (20). Mortality was lower for universal or selective 
prophylaxis (1.8% all, 1.6% direct contacts) compared to no prophylaxis (9.7%). Hospital admissions 
were lower in universal prophylaxis (3.6 %) compared to contact (7.8%) or no prophylaxis (16.1%), as 
was outbreak duration (8 days for universal vs. 14 days for direct contacts and 12 days for no 
prophylaxis). This was not a randomised study and only one ACF was in each cohort. Given the 
genuine uncertainty over whether oseltamivir prophylaxis is effective, it is arguable that we have 
clinical equipoise. 
An expanded study of 70-100 ACFs would provide the power needed to confirm benefits of antiviral 
prophylaxis and more accurately estimate their effects.  
Due to their relative immunosuppression, the elderly can shed the influenza virus for longer and at 
higher levels than younger adults, providing a potential source of infection to staff, visitors and fellow 
residents (21). Annual influenza vaccination remains the primary method of influenza prevention in 
the elderly (22). However, the immune response to vaccination is lower in the elderly compared to 
younger adults and does not always protect against transmission (23,24). Immunisation of ACF staff 
can provide protection to them and to residents via herd immunity, and reduces transmission of 
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influenza between ACFs and the community. Data from 2009-2012 demonstrated that in hospital 
settings in California, for every 15 health care providers vaccinated against influenza, one fewer 
person in the community contracted an influenza-like illness (25). 
The Australian Aged Care Quality Agency require ACFs to incorporate infection surveillance within 
their infection control programmes, but no specific directives are provided as to the nature of such 
surveillance systems (26). There is international recognition of the role of influenza surveillance, with 
the 2014 European “Fluresp” guidelines recommending electronic surveillance systems for early 
recognition and intervention in influenza epidemics (13). There are currently no systematic 
surveillance systems for infectious diseases across ACFs in Australia, although the majority of ACFs 
have indicated that some internal surveillance is carried out (27).  Improved surveillance of infectious 
diseases in this setting can enable earlier outbreak identification and institution of infection control 
processes plus treatment +/- prophylaxis to limit morbidity, mortality, hospitalisations and health care 
costs (27). An influenza A outbreak in six ACFs with 324 residents in the Hunter region during 2004 
resulted in a 41% attack rate and a mortality rate of 4% among those infected; late recognition and 
notification of the outbreaks were considered modifiable risk factors (5). The recent study in Sydney 
ACFs with enhanced surveillance found an annual influenza outbreak incidence of nearly 20%, more 
than ten-fold greater than routine reporting of outbreaks in NSW ACFs suggested (3). This has been 
brought into high relief by the occurrence of over 100 separate ACF influenza outbreaks during the 
2017 season (28). Improved surveillance data can inform infection control programmes and enable 
better planning of aged care health services. 
This study has dual aims: to investigate the role of antiviral treatment and prophylaxis in ACFs during 
influenza outbreaks, and to implement a systematic surveillance system with rapid point-of-care 
testing to identify and intervene during influenza outbreaks.  These will be on a background of 
optimised immunisation and infection control measures.  
Funding is proposed to come from a National Health and Medical Research Council partnership grant, 
with partnership with NSW Health, local aged care facilities and possibly industry as potential 
partners. This study protocol proposes an ambitious but worthwhile undertaking to clarify the utility of 
oseltamivir in influenza outbreaks in aged care facilities and to trial a systematic surveillance system 
for influenza-like illness, which may then be applied to other infectious diseases. 
 
5.2.2.1 Aims 
5.2.2.1.1 Primary  
• To assess the value of the anti-influenza medicine, oseltamivir, as treatment only, versus 
treatment and prophylaxis, for residents and staff of ACFs during influenza outbreaks, against 
a background of best practice of outbreak management  
• To develop and test an enhanced surveillance system for outbreaks of respiratory infection in 
ACFs 
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5.2.2.1.2 Secondary 
• To optimise immunisation uptake and infection control training and practices to reduce 
incidence and duration of influenza outbreaks 
• To collect data about the emergence of drug resistance to oseltamivir 
5.2.3. METHODS 
5.2.3.1 Study Design 
A cluster- randomised trial of oseltamivir use in aged care facilities during influenza outbreaks. 
All aged care facilities in the Western Sydney Local Health District and South Western Sydney Local 
Health District will be approached to participate in the trial. A member of the study team will visit each 
facility whose management agree to participate, to assess the structural characteristics and the 
capacity of the facility to engage in the. Where the site is deemed suitable information will be provided 
to staff, residents and GPs. GPs will be encouraged to maximise staff and resident vaccination. The 
study will fund staff vaccination in facilities where cost is a barrier to uptake.  
5.2.3.2 Participants 
• Any person residing in a study ACF in New South Wales (NSW) 
• Any staff working in a study ACF in NSW: clinical or non-clinical. 
5.2.3.2.1 Inclusion Criteria 
• Any resident or staff member from a participating ACF, aged over 18 years, who has been 
diagnosed with influenza  
• Any resident of staff member, aged over 18 years, from a participating ACF who has been in 
contact with another ACF resident or staff member diagnosed with influenza 
5.2.3.2.2 Exclusion Criteria: 
• Subjects who have a known hypersensitivity to oseltamivir or any of its components (see 
Appendix) 
• ACFs who do not agree to participate in the study 
• Residents or staff who have had symptoms suggestive of influenza for longer than 72 hours, 
as from then, there is an incremental reduction in the efficacy of oseltamivir  
• Staff who are pregnant or currently breastfeeding 
• Residents of staff who are known to have acute or chronic renal insufficiency 
5.2.3.2.3 Consent 
The current standard of care for influenza in ACFs (outlined in the 2009 guidelines) is either to treat 
only cases with oseltamivir or to treat both cases and contacts to control outbreaks and prevent 
influenza transmission; the great majority of public health physicians more often only provide 
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treatment for cases (11). Thus, to scientifically address this question and provide an answer that will 
inform policy makers one way or the other, a large number of ACFs will be randomised to either 
treatment of cases only or treatment of both cases and contacts.  
 Each ACF is a cluster/group, which will be randomised to a particular approach for all its residents 
and staff, understanding that there will be some patients and their health care practitioners who may 
decline to be involved. 
Agreement to participate occurs at the level of the ACF in cooperation with General Practitioners 
serving the facility and Nursing Directors of ACFs. Information about the study protocol will be 
distributed. An information letter to the residents and their next of kin constructed in English and other 
main language groups in Australia will be distributed to participating residents informing them of the 
study protocol and how residents and staff in the ACF will be managed in the event of an influenza 
outbreak. 
The conduct of this study does not alter the right of any resident or their health care practitioner to, 
where applicable, receive, prescribe or dispense oseltamivir. General Practitioners and Public Health 
Specialists retain full rights to implement, cease or alter any aspect of influenza case or outbreak 
management. 
5.2.3.3 Interventions 
This study is designed to test institution of a surveillance system for influenza-like illnesses with 
application of a specific rapid diagnostic test for influenza (and potentially RSV) infections, as well as 
the most effective way to utilize oseltamivir in an influenza outbreak: as either T or T & P.  
5.2.3.3.1 Surveillance  
Active surveillance for an influenza-like illness (ILI) will be carried out, as described below.  
ILI definition: 
• Acute onset of fever of ≥ 37.8°C (or patient feels hot to touch) OR an acute deterioration in 
cognitive or physical health or abilities, PLUS 
• Acute cough or any other respiratory sign or symptom in a resident or staff member OR 
worsening of chronic respiratory symptoms.  
Elderly patients may not mount a fever in the context of a viral illness and symptoms may be less 
specific than in younger patients (29). This is taken into account in the ILI definition. 
Research staff will visit participating ACFs to explain the study. At each ACF, selected ACF staff 
members will be designated as ILI surveillance officers for that facility and be trained in active ILI 
surveillance and in the rapid point-of-care testing (POCT; e.g. SOFIA / QUICKVUE Influenza A+B 
Test; Quidel Corp., San Diego, CA., USA; or BinaxNOW® Influenza A&B; Alere Inc., Florida, USA see 
below: “Collection and Testing of Samples”). A recent evaluation of the Sofia Influenza A+B 
fluorescent immunoassay of 209 adult respiratory samples during the 2013 Southern Hemisphere 
 65
influenza season demonstrated that the assay performed well (30). Compared to RT-PCR, the 
sensitivity and specificity of the Sofia Influenza A+B FIA for detection of influenza A was 72.4% and 
98.3%, respectively. 
Research nurses will email or text-message each nursing home twice a week leading up to the 
influenza season and three times a week during the influenza season to ask about any residents 
exhibiting symptoms consistent with ILI. If an ILI is identified, the ACF will be contacted daily until 
either an influenza outbreak is identified or until eight days after the last ILI case (five days for 
duration of infectiousness plus three days for incubation period). When an ILI is identified, POCT will 
be performed; if this is positive, either a research doctor or a GP will collect confirmatory swabs and 
prescribe oseltamivir treatment. If an outbreak is identified, the GP and /or PHU staff will collect 
confirmatory swabs for NAT testing and prescribe oseltamivir treatment +/- prophylaxis. An outbreak 
management team (OMT) consisting of ACF staff and GPs will be assigned within each ACF 
experiencing an influenza outbreak, to supervise and coordinate the response. They should meet 
daily during the outbreak to discuss, delegate and review the infection control and therapeutic 
activities being undertaken, ensure records are up to date and co-ordinate communication with all 
agencies. This is as recommended by the 2009 CDNA Australian guidelines regarding influenza 
outbreak management in resident-care facilities (11). 
An attempt will be made to identify the ‘first case’ in each ILI outbreak by establishing the apparent 
sequence of transmission. The dates of symptom onset for all residents and staff who have an ILI 
within an ACF will be determined and temporally sequenced. An apparent sequence of transmission 
is accepted when there were no more than three days between the onset dates of a probable 
influenza case and the next probable influenza case. 
5.2.3.3.2 Collection and testing of medicine 
Nose and throat swabs will be collected from each participating resident and staff member during 
screening by ACF staff using flocked swabs for rapid point-of-care testing (SOFIA / QUICKVUE 
Influenza A+B Test; Quidel Corp., San Diego, CA., USA or BinaxNOW® Influenza A&B; Alere Inc., 
Florida, USA).  
Where feasible, a second nasal swab from a sample of patients affected by the outbreak will be 
collected for nucleic acid testing for influenza virus resistance testing; study staff may assist with this. 
These will be transported to the laboratory at 4°C in viral transport medium.  
Paired serum samples will not be collected to determine rise in influenza antibody titres, given the 
large number of study subjects. 
Laboratory methods 
Where feasible, a second nasal swab from a sample of patients affected by the outbreak will be 
collected for oseltamivir resistance testing; study staff may assist with this. These will be transported 
to the laboratory at 4°C in viral transport medium. 
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Nasopharyngeal (NP) swabs (or a throat swab if NP swab were not obtained) will be collected from 
cases with an ILI by ACF staff using Copan Nylon® Flocked swabs placed in viral transport medium 
(Universal Transport Medium, UTM™ [Copan Italia, Brescia, Italy]). Swabs are frozen at -80°C within 
the same day of collection, prior to transport to the laboratory for testing 
Nucleic acid testing will be performed at the Institute for Clinical Pathology and Medical Research 
(ICPMR) viral laboratory at Westmead Hospital.  
Nucleic acid extraction will be performed using the QiagenbioROBOT EZ instrument (Qiagen, 
Valencia, CA), and amplification carried out using the Roche LC 480 (Roche Diagnostics GmbH, 
Mannheim, Germany) real-time instrument. 
Influenza virus isolation (culture) will be undertaken on MDCK cells. After four days incubation (35°C) 
the cells are to be stained with fluorescent influenza A & B monoclonal antibodies (SimulFluor 
FluA/FluB MoAb, Light Diagnostics, Temecula, CA, USA). The WHO Collaborating Centre will perform 
virus subtyping for Reference and Research on Influenza (Melbourne, Victoria, Australia) on a sub-set 
of isolates. 
Resistance testing 
• A rolling-circle amplification method confirmed the presence of the H275Y resistance mutation 
on selected samples nasal swabs: 
o from start of an influenza outbreak 
o in those whom ILI is diagnosed beyond 1 week after the first case 
o of those receiving prophylaxis who have break through ILI. 
5.2.3.3.3 Study medicine 
Oseltamivir is currently registered in Australia for treatment and prophylaxis of influenza. NSW Health 
uses it routinely to manage outbreaks. Roche, Australia may supply the medicine or we will purchase 
it.  
Study staff will prompt ACFs to brief GPs / PHUs of outbreaks, as above, and request that a standing 
order to dispense oseltamivir for treatment or prophylaxis be enacted.  
Treatment of influenza cases by GPs will proceed, as normal. Ethics approval will be sought to 
request agreement from ACF GPs and Nursing Directors to participate in the study to prescribe and 
dispense oseltamivir to contacts of cases in those ACFs assigned to the T & P group, as consistent 
with current guidelines for influenza outbreaks in ACFs (11). 
5.2.3.3.4 Influenza Case Definition 
• Definite: Positive nasopharyngeal swab for influenza as tested by POCT, direct 
immunofluorescence, nucleic acid testing or viral culture 
• Probable: 
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o ILI epidemiologically linked to confirmed case if either NOT TESTED or NEGATIVE 
RESULT 
Epidemiological linkage is ACF-specific and is determined by the opportunity for contact amongst 
residents or between staff and residents. For example, an ACF where all residents frequently share 
facilities such as lounge rooms or outdoor decks may be linked epidemiologically, versus ACFs in 
which there are distinct geographical wings with no mixing of staff or residents between wings. PHUs 
will, as per the 2009 CDNA guidelines, assist ACFs in determining and managing an outbreak (11). 
5.2.3.3.5 Influenza Outbreak Definition 
The definition of an influenza outbreak is derived from the 2009 CDNA guidelines for managing 
influenza outbreaks in aged care facilities (11). 
“Potential influenza outbreak alert: 
• Three or more cases of ILI in residents or staff of the facility within a period of 72 hours. 
Influenza outbreak: 
• Three or more epidemiologically linked cases of ILI in residents or staff of the facility within a 
period of 72 hours PLUS: 
o at least one case having a positive laboratory test OR 
o at least two having a positive point-of-care test.”  
 If an ILI is identified, then the interventions are instituted and infection control processes reiterated 
and documented. 
There will be no restrictions on relief medications or other drugs prescribed by clinical staff. Limited 
data are available regarding drug interactions and oseltamivir (31). The manufacturers of Tamiflu 
(oseltamivir), Roche®, state that drug interactions are unlikely and that no interactions have been 
observed with co-administration of paracetamol (32). Booy et al. demonstrated good tolerability of 
oseltamivir in ACF residents, with no cessation of either treatment or prophylaxis courses due to 
adverse events (3).  
Standing orders for oseltamivir treatment and prophylaxis will be enacted, and ongoing courses 
prescribed, as follows. If there are no standing orders the OMT coordinator will liaise with GPs 
covering the ACFs to arrange oseltamivir prescriptions and generate standing orders for execution in 
the event of an influenza outbreak. 
Arm 1: Treatment only Arm 
• Oseltamivir for treatment of residents and staff with confirmed Influenza  
o 75mg p.o. b.d. oseltamivir for five days diagnosed within 48 hours of symptoms by 
POCT or laboratory testing 
o Medication to be given with a snack or at bedtime. 
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Arm 2: Treatment and Prophylaxis Arm 
• Treatment as above 
• Prophylaxis of resident and staff in an ACF when an influenza outbreak is identified 
o 75mg p.o. daily oseltamivir for ten days or until outbreak is declared over, whichever 
is longer 
o Medication to be given with a snack or at bedtime. 
Renal impairment and dosage adjustment:  
No dose adjustment is necessary for calculated creatinine clearance of > 30 mL/min. 
For those with calculated creatinine clearance of 10-30 mL/minute, treatment dose of oseltamivir is 75 
mg once daily for five days, and prophylaxis dose is 75 mg every other day for 10 days or until 
outbreak is over. For those receiving renal dialysis, study medical staff can guide dosing, which may 
differ depending on type of dialysis (high-dose continuous renal replacement, continuous veno-
venous haemodialysis, intermittent haemodialysis). 
Residents whose renal function is unknown or in whom a normal serum creatinine is determined 
receive standard dose of oseltamivir (11). 
If respiratory symptoms develop in a resident receiving prophylaxis in the trial, the dose should be 
changed to treatment dose and the following should be tested for and documented for the case: 
• POCT for influenza 
• Nucleic acid testing of nasopharyngeal swab for respiratory viruses (‘respiratory panel’) 
• Oseltamivir resistance.  
If the local PHU determines that the outbreak has not been contained in a reasonable time frame, 
then the treatment only arm should be changed to treatment and prophylaxis, and subsequent new 
cases may be tested for: 
• POCT for influenza 
• Nucleic acid testing of nasopharyngeal swab for respiratory viruses (‘respiratory panel’) 
• Oseltamivir resistance pre-treatment. 
5.2.3.4 Outcomes of Interest  
5.2.3.4.1 Primary 
• Attack rate of Influenza in treatment (T) vs. treatment and prophylaxis (T & P) facilities 
• Hospital admission incidence within four weeks (4/52) from onset of Influenza symptoms. 
5.2.3.4.1 Secondary 
• Case fatality rate within 4/52 from onset of an outbreak 
• Pneumonia in subjects within 4/52 from outset of influenza symptoms 
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• Adverse events in subjects within 4/52 of commencing oseltamivir 
• Outbreak duration: date of the onset of the first symptomatic resident in a confirmed influenza 
outbreak to date of onset of last case. 
5.2.3.5 Sample size calculations 
A sample size of 37 ACF per treatment arm would give 90% power at a two-sided alpha of 0.05 to 
detect a reduction in attack rate from 10% to 3%, assuming an average of 45 residents per ACF and 
intra-cluster correlation coefficient (ICC) of 0.1.  
5.2.3.6 Randomisation Procedure 
The unit of randomisation will be at the ACF level; each facility randomised to either arm 1 or arm 2.  
There are two types of ACF, stratified based on architecture type, which influence risk of infection 
transmission (see below). Within each stratum, participating ACFs are randomised to one of the two 
arms of the trial.  
Type A: dormitory style ACFs with shared toilets and bathrooms (these facilities tend to be ‘more 
crowded’) 
Type B: ACFs with mostly single rooms: some shared facilities, staff and resident movements.  
Cluster-randomisation will be in a 1:1 ratio to each arm. Computer-generated random numbers will be 
elicited by a research partner who is not involved in the recruitment or assessment of participants.  
5.2.3.7 Blinding 
Neither ACF nor study-staff are blinded once to study group allocation. There will be no placebo used. 
5.2.3.8 Data collection 
Data for each ACF will be collected and recorded in Excel. 
• Treatment arm 
• Category of ACF 
• Bed numbers / assisted living unit numbers. 
Frequency of contact with ACFs is described above (see “Surveillance”). 
Surveillance phone calls/emails to each ACF will document the date, contact person, phone call 
number (1st, 2nd etc.), incidence and total numbers of any staff / resident with ILI, date of onset, and 
results of rapid POCT.  
Data will be collected on a study form from any recruited resident and staff and with a daily follow up 
form for each participant, staff or resident. Both initial data and follow up data will be recorded on 
Excel for each resident receiving treatment or prophylaxis. 
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Information about serious adverse events (SAE) will be collected throughout the trial by the study 
team members and assessed by the chief investigators and reported using the SAE initial and follow-
up forms in a timely fashion e.g. on the day of reporting of the SAE. These will be updated with 
outcome, medical history, results of investigations, copy of hospital reports and discharge summaries. 
The chief investigators will assess any causal relationship between the SAE and oseltamivir use. 
Data for each participant will be collected and recorded (Appendix). Information gathered will be 
identifying details- de-identified by re-identifiable, demographic data, geographical location within 
ACF, background medical history / comorbidities / immunisation status, current respiratory symptoms 
and signs, systemic symptoms, point-of-care and laboratory data, isolation date, oseltamivir regimen 
and any adjustments made, adverse events, outcome (resolution / hospitalisations / complications / 
mortality). Only data that pertains to the outcomes of interest, and which allows comparison of 
baseline demographic characteristics between the two arms of the study, will be collected. 
5.2.3.9 Statistical methods 
To compare study group baseline characteristics of ACFs, two-sample t-test for continuous data with 
normal distribution will be used.  
5.2.4. FUNDING 
A partnership project grant from the National Health and Medical Research Council (NHMRC) is 
proposed to request funding for this study, with Health Protection NSW, local PHUs, GPs serving 
ACFs, industry collaborators such as Quidel and Roche as proposed partners, if they agree. This 
study fits the aims of the NHMRC partnership project grant very well, of supporting research that 
informs health policy or practice and service delivery (use of oseltamivir in influenza outbreaks in 
ACFs), of improving programmes currently in place (surveillance and outbreak management), of 
evaluating new approaches (rapid point-of-care testing for influenza outbreak identification), and of 
studying knowledge exchange (information sessions and electronic surveillance databases) in a 
community setting (ACFs) (27).  
We aim to apply for funding to pay for staff salaries, laboratory services and transport and equipment 
costs.  
5.2.5. DISCUSSION 
This study of oseltamivir treatment of cases versus treatment of cases plus prophylaxis of controls for 
influenza in staff and residents of ACFs will help bridge a gap in the evidence deficit for the role of 
oseltamivir in these contexts. It poses several challenges, but is an opportunity to inform best practice 
for prevention of influenza outbreaks in this vulnerable population.  
The study requires coordination and cooperation between several different agencies, all of which are 
stakeholders in the outcome of interest. This is a logistical challenge for the study staff, and will 
require tight adherence to screening and follow up schedules. The study team are highly experienced 
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in administering such studies and have already published a similar but smaller study of oseltamivir in 
ACFs (3). 
The lack of blinding introduces a potential source of bias. This is mitigated somewhat by the 
application of a definition for ILI and deployment of a rapid point-of-care test. The definition itself has 
been broadened to take into account the non-specific nature of symptoms of ILI in the elderly. For 
example, those without a fever who have other signs of clinical deterioration will be screened; this 
relies on ACF staff observations, which can limit data quality. Leading up to the commencement of the 
study, education sessions will be conducted by study staff to train ACF staff in how to screen patients 
and conduct rapid POCTs. A selection of cases with rapid POCT will be confirmed by laboratory-
based testing, and provide information on the point-of-care test sensitivity and specificity in this 
context. 
Calculating sample size in order to generate enough statistical power relies on some assumptions 
about influenza outbreak incidence in ACFs. However, the severity of any given influenza season is 
variable and not always predictable based on outcomes of the preceding influenza season in the 
other hemisphere. Therefore, there remains a degree of uncertainty in sample size calculations to 
generate statistical power to draw meaningful conclusions. 
5.2.6. CONCLUSION 
Our proposed study of the role aims to inform policy decision makers with formulation of 
recommendations for the role of oseltamivir during influenza outbreaks in ACFs. This study presents 
an opportunity to develop and test active surveillance systems for respiratory infections, which may in 
time be applied to other infections e.g. gastrointestinal. Both of these aims will be conducted in the 
context of optimising immunisation uptake and infection control measures. The overall aim is to 
prevent and better manage influenza outbreaks in aged care facilities. 
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5.2.8 Appendix: Data Collection for study participants 
• Patient identifier 
• Staff or Resident 
• DOB 
• Gender 
• Ethnicity: Aboriginal and Torres Strait Islander Peoples/ Anglo-Celtic/Other 
European/Asian-Indian Subcontinent/Asian-South or South East Asian/South 
American/Middle Eastern/African 
• Room occupied (Resident) or main work area (Staff) 
• Comorbidities/Medications 
• Flu Vaccine status last 3 years 
• Pneumococcal Vaccine status  
• ILI onset date / measured T / respiratory signs and symptoms/ duration (any of the 
below recorded in space) 
o Sore throat 
o Cough 
o SOB 
o Sneezing 
o Increased RR 
o Chest pain 
o Sputum 
o Blocked or runny nose 
o Systemic signs and symptoms 
1. Fatigue 
2. Myalgia 
3. Headache 
4. Chills 
o Changes in mentation 
• POCT result 
• Lab data: 
o Date of diagnosis 
o Result of 
1. Quickvue POCT/SOFIA 
2. DIF (from index or sample cases in outbreak) 
3. NAT PCR (from index or sample cases in outbreak) 
4. Viral culture (from index or sample cases in outbreak) 
5. Complement fixing antibodies titres (from index or sample cases in 
outbreak) 
• Date when Resident Isolated OR Last Working Day of Ill Staff Member 
• Oseltamivir Dose 
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• Adverse events 
o Nausea 
o Vomiting 
o Diarrhoea 
o Abdominal pain 
o Headache 
o Light headedness / dizziness 
o Rash 
o Insomnia 
• Patient on prophylaxis:  
o date developed respiratory symptoms 
o date changed to treatment dose 
o POCT result  
• Hospitalisation:  
o Date of hospitalisation  
o Duration 
o Treatment 
o Outcome  
• Pneumonia 
o Diagnosis date 
o Treatment 
o Outcome 
• Death 
o Date 
• G.P. visits 
  77
5.3 Chapter 4 - Synopsis 
A Protocol for a Randomised Controlled Trial of Oseltamivir Treatment and 
Prophylaxis During Influenza Outbreaks in Aged Care Facilities in the Context of 
Optimal Influenza Vaccination and Infection Control 
 
This cluster-randomised study protocol of the role of antiviral medication in outbreak 
prevention in aged-care facilities remains unpublished as details of the consent processes are 
being resolved. A prospective observational study similar to this is being conducted in Aged 
Care  As I elaborate in the thesis discussion, the difficulty is in obtaining consent from 
potentially large numbers of patients in order to compare the two treatment arms, and the 
requirement for such specific consent beyond that obtained routinely by a treating doctor, 
given that both options are “on protocol”.  
 
Extremes of age both confer vulnerability to seasonal influenza. Influenza causes the highest 
rates of morbidity and mortality in the elderly, but infants are also vulnerable (3). In my next 
chapter, I present a pharmacological observational study of the pharmacokinetics and 
pharmacodynamics of oseltamivir in infants in the intensive care unit. 
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6.1 Chapter 5 Preamble 
Pharmacokinetics of Oseltamivir in Infants Under the Age of One Year  
 
Infants are a particular risk group for influenza, with high rates of morbidity and mortality compared to 
the general population. Infants admitted with influenza to critical care facilities are often administered 
oseltamivir. There is a paucity of pharmacokinetic data for oseltamivir use in infants under one year of 
age. The recommended dose by the Communicable Diseases Committee of the USA has been 
extrapolated from adult data.  This may or may not be appropriate, given differences in developmental 
physiology of infants affecting parameters such as absorption, volume of distribution and clearance. 
Before this series, only one data set was published by Kimberlin et al, which endorsed the use of 3.0 
to 3.5 mg/kg/dose in infants (2).  
This study undertook to confirm these recommendations by analysing pharmacokinetic data from 
infants who received oseltamivir. We sampled blood at set time points post oseltamivir administration 
of infants admitted to critical care facilities and reported oseltamivir and it’s metabolite levels and 
adverse events.  
 
 
Dixit et al. Clin Trans Med  (2016) 5:37 
DOI 10.1186/s40169-016-0118-1
RESEARCH
Pharmacokinetics of oseltamivir 
in infants under the age of 1 year
Rashmi Dixit1,2*, Slade Matthews2, Gulam Khandaker1, Karen Walker1,2, Marino Festa1,2 and Robert Booy1,2
Abstract 
Background: Oseltamivir is the only antiviral treatment recommended for influenza in young children over the age 
of 1 year. There is scant data on oseltamivir pharmacokinetics (PK) in infants <1 year. We set out to perform PK meas-
urements in infants who received oseltamivir.
Methods: This study was a prospective, uncontrolled, open label evaluation of the pharmacokinetics of oseltamivir 
metabolism, safety of oseltamivir, viral clearance in infants <12 months diagnosed with influenza by nasopharyn-
geal influenza nucleic acid antigen test (NAAT). Blood levels of the prodrug oseltamivir and its active carboxylate 
were measured prior to a dose of oseltamivir and at 4 time points afterwards, to calculate Cmax (ng/mL), Tmax (h), 
AUC0−t (ng h/mL) and time for AUC (h).
Results: Four children with influenza A received oral oseltamivir, 2.35–3 mg/kg/dose. This dose range produced a 
target oseltamivir carboxylate plasma concentration in excess of the proposed 12-h target AUC of 3800 ng h/mL, 
selected from earlier studies to avert resistance. One patient developed GIT adverse event: dry retching.
Conclusion: Oseltamivir was well tolerated at a dose of 2.35–3 mg/kg/dose twice a day in infants under the age of 
1 year. In general agreement with earlier data, these doses produced a target oseltamivir carboxylate plasma exposure 
in excess of the proposed 12-h target exposure of AUC equal to 3800 ng h/mL in two patients. The limited plasma 
concentration data in the remaining two patients were not inconsistent with the target exposure being reached.
Keywords: Oseltamivir, Infants, Influenza, Paediatrics
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Infants and young children are particularly prone to 
influenza morbidity [1–3]. Influenza morbidity in young 
children and infants ranges from school absenteeism to 
acute respiratory distress requiring hospitalisation, and 
can result in death from complications [1]. Oseltamivir 
is currently the only antiviral treatment recommended 
in young children, usually for those aged 1–5 years [4–6]. 
It inhibits the envelope protein neuraminidase, blocking 
release of viral progeny from infected cells, preventing 
subsequent entry into uninfected cells [7]. If commenced 
within 48 h of symptom onset, oseltamivir reduces both 
duration and complications of influenza [8, 9], although 
some dispute this [10, 11]. In December 2012, the use of 
oseltamivir for influenza treatment, but not for prophy-
laxis, was approved by the FDA for infants as young as 
2 weeks, previously having temporary approval for use 
in infancy during the 2009 pandemic, from April 2009 
to June 2010 [12, 13]. Routine use of oseltamivir in 
infants <1 year of age has been limited by both a lack of 
pharmacokinetic (PK) data and concern about adverse 
events [14–17].
The ontogeny of pharmacokinetic functions has 
potential dosing implications in infants [18, 19]. 
Oo et al. proposed a dose of 2–3 mg/kg in infants 
6–12 months of age, given that renal and hepatic clear-
ance of oseltamivir adjusted for body surface area reach 
adult levels by 6–9/12 of age [20]. The only known pub-
lished data regarding oseltamivir pharmacokinetics in 
infants <1 year old is by Kimberlin et al. [21]. They rec-
ommended doses of 3.0 mg/kg twice a day (BID) for 
infants less than 8 months old, and 3.5 mg/kg BID for 
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infants 9–11 months, based on evidence that these doses 
achieve an oseltamivir carboxylate 12 h area-under-the-
curve (AUC) target of 3800 ng h/mL, and promote less 
oseltamivir resistance than lower doses [21–24]. The 
FDA recommends 3 mg/kg BID for infants <1 year of age 
[25].
During the 2011 influenza season at the Children’s Hos-
pital, Westmead (CHW) in Sydney, Australia, pharma-
cokinetic data was collected from a series of four infants 
admitted to intensive care and treated with oseltamivir.
Methods
Study population
Infants aged <12 months who warranted treatment with 
oseltamivir for influenza-like illness were included. The 
Sydney Children’s Hospitals Network Human Research 
Ethics Committee provided ethics approval (approval 
number: HREC/10/CHW/61). All patients or caregivers 
signed informed consent forms.
Study design and end points
This study was a prospective, open label evaluation of 
the pharmacokinetics of oseltamivir metabolism, safety 
of oseltamivir, viral clearance. The oseltamivir dose pre-
scribed was at the attending clinician’s discretion.
Pharmacokinetic analysis
Specific recommendations were made for the timing 
of blood samples to measure levels of oseltamivir and 
oseltamivir carboxylate. However, to minimize the num-
ber of tests and patient discomfort, samples were col-
lected at the same time as clinically required samples, 
whenever possible. Recommended times of sample col-
lection were within 15 min prior to an oseltamivir dose, 
1 h ± 15 min, 2–3 h, 5–7 h and 10–12 h post dose. The 
blood volume required for plasma level determination 
was 500 µL. Blood was collected into a sodium fluoride/
EDTA collection tube, placed on ice and centrifuged 
(1500 g at 4 °C for 10 min). Plasma was stored at −70 
to −80 °C before despatch to the laboratory (PRA Early 
Development Services, Inc. Kansas, USA). Oseltamivir 
and oseltamivir carboxylate concentrations were deter-
mined by high-performance liquid chromatography with 
tandem mass spectrometric detection [18].
We adopted a desirable target exposure value proposed 
by Kimberlin of an AUC12 for oseltamivir carboxylate of 
3800 ng h/mL [21]. For computational purposes, concen-
trations at t = −15 min were taken as concentration at 
zero time. Non-compartmental analysis was conducted 
using PKSolver, a published pharmacokinetic analysis 
Excel plugin [26] to obtain estimates of exposure includ-
ing AUC0−t and Cmax. A set of 5 time-points from zero 
to 10 h in the 6th dose cycle was available for two of the 
four patients while for the other two patients only two 
time-points were available each, for one patient in the 7th 
dose-cycle and for the other patient in the 8th dose-cycle. 
It can be assumed that the patients were at steady-state 
by this time hence the sparsely sampled data may still 
give an impression of the exposure to oseltamivir carbox-
ylate in these patients.
Virological analysis
Each nasopharyngeal swab or aspirate was obtained 
using a sterile synthetic tip swab, with a plastic or alu-
minium shaft, and inserted into vials containing sterile 
viral transport medium. These were collected at treat-
ment initiation and analysed at the Children’s Hospital, 
Westmead; Sydney, Australia. Influenza was diagnosed 
and strain type determined using nucleic acid amplifica-
tion testing (NAAT) by polymerase chain reaction (PCR).
Safety evaluation
An adverse event was defined as any untoward medi-
cal occurrence in a patient which may or may not have 
a causal relationship with the administered oseltamivir. 
The following biomarkers were assessed during oseltami-
vir treatment and compared to pre-treatment levels: 
serum creatinine, electrolytes, liver transaminases (AST, 
ALT), alkaline phosphatase, total bilirubin level and full 
blood count.
Results
Four children received oral oseltamivir: three at 3 mg/kg 
twice a day (bd) and one at 2.35 mg/kg bd.
All four patients were infected with influenza A, 
patients 1–3 were H1N1 and the strain was not docu-
mented for the patient 4.
The following table presents the pharmacokinetic 
parameters for oseltamivir in these four patients 
(Table 1).
From the AUC0−t estimates, the first two patients (1 
and 2) attained oseltamivir carboxylate plasma concen-
trations in excess of the proposed 12-h target AUC value 
for antiviral therapy during the 0 to approximately 10-h 
period; it can be surmised that a 0–12 h AUC exposure 
value would also be in excess of the proposed thera-
peutic target given these AUC0−t values (Fig. 1). The 
two patients with only two samples per dose cycle were 
exposed to 1747 and 2156 ng h/mL for periods of 2.3 
and 6.5 h, respectively. These levels of exposure are not 
inconsistent with adequate oseltamivir carboxylate expo-
sure sufficient to provide effective therapy given the pro-
posed target AUC12 of 3800 ng h/mL, but further plasma 
time points would have allowed for confirmation.
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All patients recovered from acute influenza during 
their intensive care unit admissions. One infant suffered 
an adverse event: self-limited dry retching (Table 2).
Discussion
Our results are consistent with the proposition that a 
dose of 2.35–3 mg/kg produced a target oseltamivir car-
boxylate plasma concentration in excess of the proposed 
12-h target AUC of 3800 ng h/mL.
Oseltamivir is well absorbed from an early age. Ani-
mal studies demonstrate a rapid increase of the trans-
port protein at birth, and a widespread distribution for 
oseltamivir including good penetration of lung tissue, 
the middle ear and the nasal mucosa [27]. It is metabo-
lized to the active metabolite oseltamivir carboxylate by 
the liver carboxylesterase HCE1 [19, 27]. Production of 
HCE1 is lower in foetuses than in infants <1 year of age, 
who in turn have lower gene transcription than children 
1–10 years [18]. However, much inter-individual variabil-
ity exists, particularly in the younger age groups. Young 
children have greater proportionate extracellular fluid and 
thus a greater volume of distribution (VD) of oseltamivir 
carboxylate, resulting in a lower circulating plasma con-
centration compared to older children and adults [27]. 
Oseltamivir carboxylate is not extensively protein bound 
and, thus, immaturity of plasma protein levels does not 
impact on VD [27]. Animal studies indicate good pen-
etration of oseltamivir carboxylate into respiratory tissues 
[19]. Oseltamivir has been linked to neuropsychiatric side 
effects in children and young adults, especially in Japan, 
although it is unclear whether the encephalopathy was 
induced by influenza or by its treatment [28, 29]. Both rat 
and human foetus studies showed certain central nerv-
ous system (CNS) efflux pumps to be in low numbers 
at birth and increase with age, whilst others are present 
from the second trimester [19]. There was, however, no 
accumulation of oseltamivir carboxylate in the brains of 
healthy rats. Oseltamivir is filtered and actively excreted 
from the renal tubules using OAT transporter proteins 
[27]. Clearance function of these proteins is low at birth 
and increases over the first year of life, which may lead to 
reduced oseltamivir clearance in neonates [27]. Oo et al. 
demonstrated that oseltamivir carboxylate clearance 
adjusted for body surface area (BSA) reached adult levels 
by 6–9 months of age, whilst a higher BSA-to weight ratio 
in those 1–2 years resulted in higher clearance and conse-
quently lower peak plasma concentration (Cmax), time to 
reach Cmax (Tmax) and AUC compared to those 3–5 years 
Fig. 1 Plasma-time curves for oseltamivir carboxylate in four infants
Table 2 Adverse events (AE) in children receiving oral oseltamivir
GORD gastro-oesophageal reflux disease, OSA obstructive sleep apnoea, HUS haemolytic uraemic syndrome
Patient number Age
months (m) 
and days (d)
Comorbidities Clinical AE Laboratory changes
1 6 m, 23 d Tetralogy of Fallot D1
Dry-retching
Day 1 bloods: raised creatinine (48 mmol/L) 
and AST (66 mmol/L)
Attributed to cardiac condition
Normalised after frusemide dose during 
course of oseltamivir
2 5 m, 13 d Albright’s osteodystrophe
Hypothyroidism
Hypoparathyroidism
GORD
Severe OSA due to epiglottis dystrophy
Nil Nil
3 11 m, 15 d Streptococcus pneumoniae bacteraemia, 
pneumonia, meningitis
Parainfluenza 3/rhinovirus/enterovirus 
co-infection
Developed HUS
Nil Baseline bloods normal
D2 of oseltamivir: rising creatinine, urea, 
AST/ALT/GGT
All parameters normalised 10 days after first 
dose
Laboratory abnormalities attributed to HUS
4 3 m, 13 d Exomphthalmos Nil Nil
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[20]. Kimberlin et al. achieved their target AUC with doses 
of 3 mg/kg in those up to 9 months of age whereas those 
9–11 months of age required a higher dose of 3.5 mg/kg, 
due to greater oseltamivir carboxylate clearance over the 
first year of life [21]. Thus, oseltamivir clearance may peak 
around 12 months, and then reduce after 3 years.
There was one GIT side effect (dry-retching) from 
oseltamivir in our cohort. Laboratory anomalies were 
attributable to comorbidities. Likewise, a dose of 
3–3.5 mg/kg of oseltamivir was well tolerated in 87 infants 
with no premature drug discontinuation [21]. Of eight 
adverse events (AE) deemed related to oseltamivir (9.1 %), 
five were emesis, two developed a rash and one developed 
a serious AE: cutaneous hypersensitivity. There were no 
CNS AE. In another trial, 11 infants who received a rather 
high median dose of 5.5 mg/kg/dose of oseltamivir suf-
fered no serious adverse events, and all completed the 
course [30]. Two developed a rash, two gastrointestinal 
side effects and three had transiently raised liver transami-
nases that normalised within 2 weeks of completing ther-
apy. In a report of 35 patients <1 year of age who received 
oseltamivir, no AE occurred and no effect on liver function 
was detected [31]. In a report of 5 premature infants, mean 
gestational age 31 weeks, who received oseltamivir at 
2–3 mg/kg/dose, there were no treatment related AE [32].
Conclusion
Oseltamivir was well tolerated at a dose of 2.35–3 mg/kg/
dose twice a day in infants under the age of 1 year. These 
doses were confirmed to produce a target oseltamivir car-
boxylate plasma exposure in excess of the proposed 12-h 
target exposure of AUC 3800 ng h/mL in two patients 
and the limited plasma concentration data in the remain-
ing two patients were not inconsistent with the target 
exposure being reached.
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6.3 Chapter 5 Synopsis 
Pharmacokinetics of Oseltamivir in Infants Under the Age of One Year  
 
This study of oseltamivir pharmacokinetics in infants, only the second published data, revealed results 
consistent with the recommended doses. It was hampered by a low number of recruits and data 
points. However given the difficulty of conducting such a study in infants with the requirement to 
collect blood, barriers in caregiver acceptability and sparseness of available recruits, it is likely it will 
not be oft repeated, making it an important second source of published data on infant oseltamivir 
pharmacokinetics. The ontogeny of infant physiological processes that absorb, metabolise and clear 
medications requires caution with assumptions that adult doses are extrapolatable to infants. Doses 
of 2.35–3 mg/kg produced a target oseltamivir carboxylate plasma concentration in excess of the 
proposed 12-h target AUC of 3800 ng h/m. Given the paucity of other treatment modalities, and the 
lack of influenza vaccine uptake in pregnant women, this data helps to generate clinical confidence in 
use of oseltamivir in this age group. Whilst numbers were small, the side effect profile was as 
expected – one infant had gastrointestinal side effects, and no other infants suffered adverse events. 
All infants recovered from influenza. This data may form part of a meta-analysis, were other data to 
be collected.  
The final chapter looks at another demographic group that is particularly at risk of influenza – 
Indigenous Australians. We examine the impact of the intersection of chronic conditions and 
Indigenous status on influenza incidence and severity, and, given the recognised vulnerability of 
extremes of age, we age-standardised our analysis.  
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7.1 Chapter 6 Preamble 
The Role of Chronic Diseases in Influenza Incidence and Severity Differential Between 
Indigenous Australians and Non-Indigenous Australian Populations During the 2009 
Influenza Pandemic in Australia – Preamble 
 
Along with extremes of age, those with chronic diseases and Indigenous Australians are at 
risk of influenza disease and severity. This data analysis examined the role played by the 
higher background prevalence of chronic, non-communicable diseases amongst Indigenous 
Australians in the greater incidence of severe influenza recorded amongst Indigenous 
Australians during the 2009 ‘swine flu’ pandemic. The ‘Close the Pap’ Indigenous Health 
campaign addressed the health and life expectancy gap Indigenous Australians face; this 
analysis addressed the intersection between higher rates of communicable and non-
communicable diseases that Indigenous Australians are vulnerable to. 
 
We conducted the first analysis of national data sets to examine influenza notifications, 
hospitalisations, intensive care unit admissions and deaths by Indigenous status, and by 
presence of a one of five common background conditions: chronic lower respiratory 
conditions, renal disease, cardiac disease, diabetes mellitus and obesity, amongst the four 
states and territories that we were given data access to: Western Australia, South Australia, 
Northern Territory and Queensland. We compared influenza rate ratios within the total 
population and sought to deduce if comparing influenza rates amongst those with a given 
chronic condition ameliorated the disparities in influenza incidence and severity between 
Indigenous and non-Indigenous Australians. 
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7.2 Chapter 6 
 
The Role of Chronic Diseases in Influenza Incidence and Severity Differential Between 
Indigenous Australians and Non-Indigenous Australian Populations During the 2009 Influenza 
Pandemic in Australia  
 
Dixit, Rashmi 1; Webster, Fleur2; McIntyre, Peter 1; Menzies, Robert 2. 
1. University of Sydney - National Centre for Immunisation Research and Surveillance, Children’s 
Hospital Westmead 
2. University of New South Wales 
 
7.2.1 ABSTRACT 
 
Introduction 
The 2009 H1N1 influenza pandemic (influenza A(H1N1)pdm09) disproportionately impacted 
Indigenous Australians. Indigenous Australians are also affected by a health gap in chronic diseases, 
which are associated with influenza severity. We hypothesised that the disparity in influenza severity 
is accounted for by the chronic disease health gap. 
 
Methods  
We analysed influenza data from South Australia, Western Australian, Queensland and the Northern 
Territory. We calculated population prevalence of chronic diseases in Indigenous and non-Indigenous 
Australian populations using nationally collected health survey data, reported to the Australian 
Department of Health. We compared reported influenza case notifications, hospitalisations, intensive 
care admissions and deaths in the total population of Indigenous and non-Indigenous Australians ≥ 15 
years of age. We accessed age-specific influenza data reported to the Australian Department of 
Health National Incident Room during the 2009 swine flu influenza pandemic, classified by Indigenous 
status and stratified by presence of one of 5 chronic conditions: chronic lower respiratory conditions, 
diabetes mellitus, renal disease, cardiac disease and obesity. We calculated age-standardised rate 
ratios and confidence intervals in those ≥ 15 years.  
 
Results 
Chronic diseases are more prevalent in Indigenous Australians. Influenza notification rates were 
higher in Indigenous Australians and more frequent across all indices of severity. Restricting analysis 
to those with chronic diseases did not lower the Indigenous : non-Indigenous influenza rate ratios. 
Severity analysis did not demonstrate a reduction in Indigenous : non-Indigenous rate ratios as 
influenza became more severe within any of the chronic disease sub-populations. 
 
Conclusions 
Greater prevalence of comorbid chronic conditions was not demonstrably responsible for higher rates 
of influenza in Indigenous Australians compared to non-Indigenous Australians. Data limitations 
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included lack of comparison to those with no chronic conditions, and those with more than one. 
Social, cultural and environmental impacts of colonisation may warrant further investigation as causes 
of the disparity in influenza rates and severity between Indigenous and non-Indigenous Australians. 
 
7.2.2. INTRODUCTION 
 
The 2009 H1N1 influenza pandemic (influenza A(H1N1)pdm09) disproportionately impacted 
indigenous populations in colonised countries globally, including Australians Aboriginal and Torres 
Strait Islander peoples (Indigenous Australians) (1–15). Indigenous populations in colonised countries 
around the world have a greater burden of chronic, non-communicable diseases compared to their 
non-Indigenous counterparts (3,16–20). Both seasonal and pandemic influenza affect those with 
chronic diseases more frequently and severely (5,12,21–28). These observations beg the question: 
could the greater influenza A(H1N1)pdm09 disease burden and severity in indigenous populations be 
due simply to the larger burden of background chronic diseases? Very few studies have examined the 
role of chronic, non-communicable diseases with respect to incidence versus severity of infection 
including influenza in indigenous populations (29).  
  
While the pandemic strain appeared almost 10 years ago, the question is still relevant. Influenza 
A(H1N1)pdm09 continued to be a predominant circulating strain up until and including the 2017 
influenza season (30–32). Moreover, strains with pandemic potential continue to emerge, with the 
potential to cause greater disease severity amongst minority First Peoples populations (33,34). The 
nature of interactions between acute influenza, Indigeneity and chronic diseases during the 2009 
pandemic are also likely to be applicable to other seasonal influenza strains. 
 
If higher rates of influenza infection in Indigenous versus non-Indigenous people are largely or solely 
due to the higher prevalence of chronic non-communicable diseases, then this disparity would be 
largely or completely eliminated by comparing infection rates only amongst those with chronic 
conditions. Further, if chronic diseases predispose patients to more severe influenza disease, then 
the increasing disparity between Indigenous and non-Indigenous people with increasing influenza 
severity would be largely or solely eliminated by comparing influenza disease rates only amongst 
those with chronic disease.  
 
Acute surveillance conducted nationally in Australia during 2009 has provided us with datasets that 
enable analysis of this issue. National influenza notification rates reflect the incidence of influenza 
infection, while hospitalisation, Intensive Care Unit and mortality data reflect the incidence of 
progressively more severe outcomes, notwithstanding the limitations of these sources. Active follow 
up provided Indigenous status on individual cases. 
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The aim of this study was to determine whether the higher incidence of infection and severity of 
influenza A(H1N1)pdm09 in Indigenous compared to the general Australian population could be 
reduced or eliminated by adjusting for chronic disease prevalence. 
 
7.2.3 METHODS:  
 
Population prevalence of chronic diseases 
Prevalence data for chronic conditions were obtained by analysing the Confidentialised Unit Record 
Files of health surveys conducted by the Australian Bureau of Statistics (ABS). For Indigenous 
Australians these were from the 2012-13 National Aboriginal and Torres Strait Islander Health Survey 
(NATSIHS) (35). This was collected between April 2012 and February 2013 across 5,000 private 
dwellings across Australia. Prevalence data for non-Indigenous Australians were from the 2011-
12 National Health Survey (NHS), conducted between 6 March 2011 and 17 March 2012 from 
a sample of 15,500 private dwellings across Australia (36). Confidentiality rules set by the ABS meant 
that the results obtained represented both Indigenous and non-Indigenous peoples.  Given that the 
population of Indigenous Australians is < 3%, NHS chronic disease prevalence data for all Australians 
was used to approximate the prevalence of chronic conditions in non-Indigenous Australians (37). 
Only data for those ≥ 15 years was available from each survey, therefore our analysis was limited to 
this age group. Within the health surveys, all reported long-term medical conditions are coded to a 
classification developed for use in the ABS Health Surveys based on the 10th revision of the 
International Classification of Diseases and Health Related Problems (ICD-10) – table 1 (38).   
 
All data were self-reported except obesity, which was taken from measurements. Respondents were 
asked whether they have been diagnosed with the condition, and whether the condition is current and 
long-term, and were classified with a chronic disease if they answered positively to both questions.  
 
Percentage prevalence of each condition in both the NetEpi and the health survey data was stratified 
by the following age groups for each state and territory: 15-24 years, 25-34 years, 35-44 years, 45-54 
years, and ≥ 55 years. The survey percentages were already adjusted using weightings for age, sex 
and state / territory, provided by the ABS to adjust for differences between survey and census 
populations (37).  
 
Influenza laboratory notifications, hospitalisations, ICU admissions and deaths 
We obtained data on influenza cases during the 2009 ‘swine flu’ pandemic from the Communicable 
Diseases Network of Australia (CDNA), a division of the Department of Health and Aging (DoHA). 
Influenza surveillance data were actively collected during the 2009 pandemic, under the provisions 
specified within the National Health Agreement and state and territory public health acts. Cases of 
laboratory-confirmed Influenza A(H1N1) infections, hospitalisations, ICU admission and deaths were 
collected by states and territories from general practitioners, hospitals and laboratories and reported 
to the National Incident Room (NIR) of the Department of Health and Ageing, who entered the data 
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onto the NetEpi database, a web-based outbreak case reporting system. Data from 15 years of age 
was requested from the CDNA, in order allow NetEpi data to match the age-range of the people 
surveyed for chronic conditions. Data from 1 April 2009 to 31 December 2009 were released to us 
and examined. 
 
Indigenous status was recorded by self-reporting to health professionals. If a patient was unable to 
answer questions e.g. receiving artificial respiratory ventilation, or if they had died, their next of kin 
was asked about the Indigenous status. ‘Non-Indigenous Australians’ included those in whom 
Indigenous status was recorded as ‘not Aboriginal or Torres Strait Islander peoples’. Data in which 
Indigenous status was not specified was omitted from this analysis. 
 
The exact definitions applied to the chronic conditions were not available from NetEpi, and may have 
differed from that of the health surveys, specified above. The CDNA NetEpi database was unable to 
provide data on influenza cases without any background chronic conditions. We could not calculate 
these by simply subtracting cases with a chronic condition, as a case may have had more than one 
chronic condition.  
 
7.2.4 STATISTICS: 
 
The analyses that were conducted were limited by data availability. Data on all relevant variables – 
Indigenous status, chronic disease prevalence, state/territory and influenza - for hospitalisations, ICU 
admissions and deaths were available only from Western Australia (WA), Queensland (QLD), South 
Australia (SA) and the Northern Territory (NT). This represents 57.5% of Aboriginal and Torres Strait 
Islander peoples within Australia. Data on influenza notifications were available only from WA and NT. 
We combined data from states and territories where equivalent data were available to reduce size of 
confidence intervals and thus increase statistical significance.  
 
To obtain estimated population numbers for each chronic condition, we multiplied the percentage 
prevalence of each chronic condition reported within the health surveys for each age group, by the 
total population numbers, obtained from the 2011 ABS census.  
 
For rates of influenza within the total population and within each chronic disease subset, we used 
reported total cases of influenza for each state / territory as the numerator and ABS census 
population data as the denominator. We derived a ratio of the actual number of Indigenous influenza 
cases observed by the expected number of cases - the latter being derived from the rates observed in 
the non-Indigenous population.  
 
We calculated rate ratios for influenza notifications, hospitalisations, ICU admissions and deaths. 
These rates were then used to calculate Indigenous: Non-Indigenous rate ratios (RRs) and 95% 
confidence intervals. We performed direct age-standardisation of the influenza case data and 
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calculated 95% confidence intervals using the method described by Armitage and Berry (39). We    
defined lack of statistical significance as overlapping confidence intervals – a conservative indicator of 
statistical significance. For rates of influenza amongst those with each chronic condition, we used 
reported cases of influenza with the comorbid chronic disease within each state / territory as the 
numerator, and the estimated numbers of people with the chronic disease, as described above, for 
the denominator. We combined data from different states and territories to try to deal with the small 
number of events particularly in severe outcomes such as intensive care admissions and death. We 
also indirectly age-standardised the Indigenous influenza case numbers, using the general non-      
Indigenous Australian population as the standard population, given the small number of events in 
more severe outcomes, to reduce instability of aged-standardised rate ratios – see  Appendix 9.2. 
However, indirect standardisation requires replacement of those with background chronic conditions 
as the denominator with a general reference population (non-Indigenous Australians), thus making 
our hypothesis untestable; therefore this was not presented as our primary results. Confidence     
intervals were calculated using the Poisson process described by Liddell, via a statistical calculator 
(40).  
Chronic disease population estimates had 95% confidence intervals derived from the health surveys. 
Therefore disease rates and rate ratios in chronic disease populations were calculated using both 
the upper and lower chronic disease population estimates. Confidence intervals for the rates and 
ratios incorporated the full range generated from the upper and lower population estimates.  
Ethics Approval was granted on 17 May 2017 from the Human Research Ethics Committee of the 
University of Sydney; Project no.: 2017/356. 
7.2.5 RESULTS
General
All chronic conditions analysed – chronic lower respiratory conditions and cigarette smoking, diabetes 
mellitus, obesity, renal disease and cardiac disease – were more prevalent in Indigenous Australians 
(Table 2).  
Table 3 presents the total number of cases of influenza reported to NetEpi by state and severity with 
the total population from the ABS data, and the crude and age standardised reported number of 
cases of influenza amongst those with background chronic diseases, by state and severity. 
Amongst the total population (all reported cases of influenza), Indigenous status was most reliably 
available from WA and SA, with data less reliable from WA/SA/QLD/NT and from all of Australia 
(Table 4). Amongst those with influenza and any of the chronic diseases, Indigenous status was most 
reliable from WA/SA, with <5% of cases were missing Indigenous classification (Table 5).  When the 
four states were combined, Indigenous status was missing from up to one third of notifications, 
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hospitalisations, ICU admissions and deaths; unclassified cases were excluded from final 
analysis. These tables reflect Indigenous status data from age 0 years, whereas table 3 reflects case 
numbers from 15 years that was supplied, as described above. 
 
Rates of influenza amongst the total population were higher amongst Indigenous Australians 
compared to non-Indigenous Australians for notifications (WA/SA), hospitalisations (WA/SA and 
WA/SA/QLD/NT), ICU admissions and death (whole of Australia – not available for individual states 
and territories for total population) – Table 6.  
 
Indigenous: Non-Indigenous rate ratios for influenza in total versus chronic disease populations  
 
For influenza notifications, the Indigenous: non-Indigenous rate ratios (RR) were statistically 
significantly higher in all chronic disease populations than in the total population (Table 6). For 
influenza hospitalisations in WA/SA, Indigenous: non-Indigenous rate ratio point estimates were not 
statistically different in those with chronic lower respiratory conditions, obesity and renal disease, and 
higher (confidence intervals did not overlap) amongst those with diabetes mellitus and cardiac 
disease. However in the larger geographic region of WA/SA/NT/Qld, RR point estimates for influenza 
hospitalisation were higher in all chronic disease populations compared to the total population except 
for those with obesity, in whom there was no statistical difference.  
 
For intensive care unit admissions for influenza, Indigenous: non-Indigenous rate ratio point estimates 
were higher for populations with diabetes mellitus, renal disease and cardiac disease, compared to 
the total population, and no significant difference was noted amongst those with chronic lower 
respiratory disease and obesity. For influenza deaths, Indigenous: non-Indigenous RR were higher in 
those with diabetes mellitus and cardiac disease. There was no statistically significant difference in 
rate ratios for the other chronic conditions. RR point estimates was 3-fold higher for renal disease, but 
confidence intervals were wide and encompassed that of the total population.  
 
There was no sub-population of chronic disease patients in which the Indigenous and non-Indigenous 
rate ratio for influenza of any severity was lower than the total population. 
 
Indigenous: non-Indigenous rate ratios, by severity of influenza disease 
 
In the total population Indigenous: non-Indigenous RRs were significantly higher for influenza 
hospitalisations compared to notifications. However there was no difference between RRs in ICU 
admissions and deaths. 
 
In those with chronic disease, the Indigenous: non-Indigenous RR was significantly higher for 
hospitalisations in SA/WA and SA/WA/NT/QLD, compared to notifications in those with CLRCs. In 
those with other chronic diseases the notification and hospitalisation RRs were not different for 
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SA/WA. In WA/SA/QLD/NT, RRs were no different for obesity but were higher for diabetes mellitus, 
renal and cardiac disease hospitalisations compared to notifications. There was no difference in 
Indigenous: non-Indigenous rate ratios between hospitalisation, ICU admissions and death from 
influenza amongst those with any of the chronic diseases. Reduced disparity with increasing severity 
of influenza – as indicated by significant reduction in Indigenous: non-Indigenous rate ratios for 
influenza deaths versus ICU admissions versus hospitalisations versus notifications - was not seen 
with any chronic condition. 
 
Whilst individual results varied, there was no overall change in direction of rate-ratio comparisons 
between total population and each chronic condition for direct and indirect standardized results – that 
is there was no evidence of reduction in Indigenous and non-Indigenous influenza rate-ratios when 
comparing the total population with any of the chronic disease subsets (Appendix 3).   
 
 
7.2.6 DISCUSSION 
 
As expected, we demonstrated higher background rates of all five chronic conditions as well as higher 
rates of influenza notifications, hospitalisations, ICU admissions and deaths amongst Indigenous 
Australians compared to non-Indigenous Australians. Higher Indigenous: non-Indigenous prevalence 
rate ratios for the whole of Australia compared to the WA/SA/NT/Qld for chronic respiratory 
conditions, diabetes mellitus, renal disease and cardiac conditions may be surprising, considering that 
that our four jurisdictions include the majority of remote areas with poorest socioeconomic indicators. 
However, these results are consistent with ABS published data, showing higher prevalence for all of 
these chronic conditions except renal disease amongst Indigenous people in the areas not examined 
individually in our analysis: NSW, Victoria, ACT and Tasmania, compared to national averages for 
Indigenous people (35).  
 
We found that the rate ratios in Indigenous compared to non-Indigenous Australian total populations 
were no lower when analysis was restricted to those with chronic diseases. In fact, they were often 
statistically significantly higher. This suggests that higher background rates of the chronic diseases 
we examined do not fully explain the higher rates of influenza amongst Indigenous Australians in the 
total population. Rate ratios were lower for obesity than other chronic conditions: obese Indigenous 
patients were still more likely to be admitted, receive intensive care and die than obese non-
Indigenous patients with influenza, but the rate ratio was lower than for other those with other chronic 
conditions. This may suggest that, amongst those with obesity, the impact of obesity on influenza was 
less disparate between Indigenous and non-Indigenous Australians compared to other chronic 
diseases. Alternatively, it may suggest that, amongst those with other chronic diseases, unrelated 
factors were driving differences in severity of influenza, such as lower threshold for hospital 
admissions, other comorbidities or social factors. The unavailability of 15-24 year old data for obesity 
is unlikely to have explained Indigenous : non Indigenous influenza case rate ratios lower rate ratios. 
Most chronic diseases occur in those middle-aged and older, and a re-analysis of SA/WA/QLD/NT 
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cardiac, renal and diabetes mellitus influenza hospitalisation data excluding the 15-24 year age group 
resulted in even higher Indigenous : non-Indigenous influenza hospitalisation rate ratios. 
 
The greater disparity in more severe outcomes between Indigenous and non-Indigenous Australians 
seen in other studies was also seen in our data, with significantly higher RRs for influenza 
hospitalisations amongst Indigenous patients compared to notifications, when examining the total 
population. Higher background rates of chronic disease amongst Indigenous Australians may explain 
some of the increased disparity in the total population as influenza severity increased: when the 
analyses were restricted to Australians with chronic diseases, the WA/SA hospitalisation RRs were no 
longer higher than notification RRs for four of five chronic diseases. CLRCs were the exception, with a 
higher Indigenous to non-Indigenous hospitalisation rate ratio than notification RR.  This suggests 
higher background rates of CLRCs did not contribute to the higher rate of influenza hospitalisation for 
Indigenous people in the total population, as the rate ratio jump from notification to hospitalisation 
mirrored that of the total population in the CLRC sub-analysis. However, when both the total 
population, and in subgroups with chronic conditions, Indigenous to non-Indigenous influenza rate 
ratios did not increase further upon comparing hospitalisations, ICU admissions and death, nor did 
they decrease. Thus, the absence of a decrease in rate ratios with increasing severity in the chronic 
disease populations does not support our hypothesis that higher rates of background chronic 
diseases are responsible for higher rates of severe influenza in Indigenous Australians.  
 
There was a jump in rate ratios between 2-state data WA/SA and 4-state data WA/SA/QLD/NT 
influenza Indigenous: non-Indigenous rate ratios for hospitalisations all of the chronic conditions 
except obesity. This was due to a large number of influenza hospitalisations in the Northern Territory 
of Indigenous Australians, e.g. 73/153 (47.7%) of hospitalisations for CLRCs amongst all 4 states 
occurred within the NT (Table 3, data available upon request). A higher proportion of hospitalisations 
were Indigenous in 4-states compared to 2-states (Tables 4 and 5), which would include remotely 
located Indigenous Australians in NT.  This may reflect the fact that 72% of the Northern Territory’s 
Indigenous population live remote from hospitals, requiring hospitalisation admission for observation 
(41). Obesity was the one chronic condition that did not lead to an increase in the Indigenous : non-
Indigenous influenza hospitalisation rate ratios, between the two and four state data. This may be 
because, if not associated with a diagnosed chronic medical condition, it was not considered a risk 
factor that required admission for observation.  
Thus, overall, the presence of chronic diseases didn’t lower the rate ratios between Indigenous and 
non-Indigenous Australians with influenza in the total population. There may be other clinical reasons 
for a higher rate of influenza amongst Indigenous Australians, e.g. chronic disease being more 
clinically severe in Indigenous Australians leading to more frequent or severe influenza, or a greater 
burden of multiple chronic comorbidities e.g. concurrence of diabetes mellitus and renal disease 
(42,43). We did not have this data to perform a multivariate analysis, nor on incidence of influenza in 
those with no chronic conditions. Certain socioeconomic factors, such as overcrowding, may increase 
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influenza transmission within the Indigenous community and account for some of the disparity (44). 
Given that the Indigenous: non-Indigenous rate ratio for influenza for the total population is 
significantly lower than for each chronic disease, it could even be postulated that Indigenous 
Australians without chronic diseases are relatively protected against influenza. The ‘composite’ RR of 
1.50 for the total population could have been driven down by Indigenous: non-Indigenous RRs < 1 
amongst those with no chronic conditions, compared to the high RRs we yielded for those with a 
chronic disease. However, we do not have the data to verify this possibility. 
 
Our results concurred with other data sources, which reported 8-fold hospitalisation and 6-fold death 
rates for influenza amongst Indigenous Australians compared to non-Indigenous Australians during 
the 2009 swine flu pandemic (45). The possibility of ascertainment bias seems unlikely, given that 
universal testing during the 2009 influenza epidemic within the Top End of Australia encompassing 
the north part of the Northern Territory, a higher notification rate (RR 5.2) was reported amongst 
Indigenous Australians (46). A serological survey from the Top End revealed a differential attack rate 
ratio of 1.85 (47). These non age-standardised results may have overestimated incidence in 
Indigenous Australians, a younger population that non-Indigenous Australians, given pre-existing 
immunity in older age groups (48). Our age-standardised rates yielded a lower relative risk for 
influenza notifications than other data (RR 1.50, 95% CI 1.37 – 1.64).  
 
In contrast to our findings, which indicated that the effect of Indigenous status persisted even when 
restricting analysis to specific chronic conditions, a systematic review of -4 articles examining risk 
factors for influenza, with over 600,000 participants, did not find an independent association between 
Indigenous / First Peoples status and all-cause mortality in pandemic influenza, and in fact the 
association with chronic disease was low to very low for severe influenza (49). In contrast, Kumar et 
al revealed that 98% of all adult ICU admissions for influenza A(H1N1)pdm09 in Canada had at least 
one risk factor, such as obesity, lung disease, smoking or hypertension (23) and Aboriginal patients 
were over-represented at 25% of all ICU admissions. They commented that these conditions were 
higher in Canadian Aboriginal patients but did not determine whether the former impacted the higher 
mortality from influenza in this population.  
 
Whilst we were unable to demonstrate that restricting analysis to those with chronic diseases 
ameliorated the impact of Indigenous status on influenza, other studies have demonstrated opposing 
findings. Goggin et al from Western Australia demonstrated that Indigenous Australians were three 
times more likely to be hospitalised with influenza during the 2009 pandemic (50). However, 
multivariate analysis elicited only age and presence of 2 or more comorbidities as associated with 
hospitalisation, Indigenous status was not a stand-alone risk factor. Flint et al examined influenza 
A(H1N1)pdm09 in the Top End of Australia (22). Univariate and multivariate analyses revealed that 
Aboriginal status per se was not associated with ICU admission, despite Aboriginal people being 
more likely to be admitted to hospital (RR 5). Likewise, there was an Indigenous : non-Indigenous 
incident RR of 12 for hospitalisation, but little difference in the prevalence of obesity, respiratory, 
96
hepatic, renal, cardiac, neurological or immune disease amongst those hospitalised between the two 
groups. This suggests that the higher background rate of these chronic diseases was therefore 
responsible for overall higher rates of influenza hospitalisations amongst Indigenous Australians. 
However, smoking and heavy alcohol use remained higher amongst Indigenous Australians 
hospitalised with influenza. Verrall et al in Wellington, New Zealand observed equivalent rates of pre-
existing conditions in those hospitalised with influenza A(H1N1)pdm09 Maori and Pacifica peoples vs. 
Pakeha (European heritage), in contrast to higher background rates of chronic illness amongst 
Polynesian peoples in the general community (8). Surveillance data indicated a 3-4 fold increased risk 
of hospitalisation with influenza A(H1N1)pdm09 and a 4-fold mortality rate of American Indian / 
Alaskan Native (AI/AN) people compared to non-AI/AN , whereas background rates of comorbid 
disease were similar amongst those with severe influenza (3). The higher background rates of chronic 
illnesses therefore likely contributed to greater rates of severe illness in the AI/AN population (51,52). 
Likewise, data from the USA over the 2009 influenza season revealed a similar rate of a high-risk 
background conditions in those who perished: 81% of deceased AI/AN versus 77.6% of non-AI/AN 
(25).  
On the other hand, a minority of studies of influenza A(H1N1)pdm09H1N1 in Indigenous populations 
have concurred with our overall findings, and found disparities in prevalence of chronic disease were 
unable to explain difference in rates of severe influenza between Indigenous and non-Indigenous 
people.  For example, Zarychanski et al in Canada in 2009 showed that, even after controlling for 
comorbidity, age, sex, income and rural location, First Nations people still had greater risk requiring 
acceleration of care to ICU for influenza A(H1N1)pdm09 (5). 
Genetic and racial heterogeneity cannot fully explain the difference in susceptibility to chronic 
conditions between colonising and native populations. Both incidence of severe influenza and 
prevalence of chronic conditions are higher in unrelated colonised populations around the world, 
compared to the non-Indigenous populations, and these conditions were not evident 
pre-colonisation. Thus, there are factors relating to colonisation itself that appear to be partially 
causal in the gap between Indigenous and non-Indigenous populations (1-15,53-56).
Chronic diseases have been shown to predispose Indigenous Australians to other infections. Heart 
disease, diabetes and harmful alcohol consumption were independently associated risks in 
Indigenous Australians for septicaemia (29).  Another risk factor that emerged was crowded living 
conditions in town camps that were dislocated from their homelands. A recent presentation to from 
the Centre for Disease Control USA indicated that diabetes mellitus was driving an increase in 
hospitalized infections. Data from approximately 20% of all in-patient hospitalisations from 46 states 
within USA were analysed, and demonstrated that those with diabetes are around two to seven times 
more likely to be hospitalised with an infection, particularly urinary tract infections, sepsis and skin & 
soft tissue infections, than the general population (57). Between 2010 and 2015, infection-related 
hospitalisations rates increased 52% in those afflicted with diabetes mellitus compared to 17% in 
those without diabetes. 
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Physical health is also influenced by the downstream effects of intergenerational psychosocial trauma 
resulting from colonisation, loss of language and culture, and ongoing systemic, structural and 
personal racism (19). Chronic diseases that were rare in pre-colonial populations have become 
prevalent amongst Indigenous people. This results partly from the breakdown of traditional lifestyles 
and poor access to their modern replacements, such as 24-hour health care access, running water 
and sanitation facilities. It also results from environmental changes to which human physiology is 
maladapted e.g. drastic changes in dietary quality and caloric volume (19,58,59). Differences in health 
care access based on race has been demonstrated: once admitted to hospital for cardiovascular 
disease, Indigenous Australians received fewer medical interventions and prescriptions, but had 
poorer outcomes, than non-Indigenous Australians (19). The Australian Human Rights Commission 
identifies financial poverty, chronic stress, lack of control of health services, lack of ownership of 
traditional lands and social and political racism as social determinants of poorer health amongst 
Indigenous Australians (60). A recent report stated that connection to traditional ways of life and living 
in one’s ancestral homelands, rather than educational attainment and monetary resources, was 
protective against chronic diseases amongst Aboriginal Australians (61). Those living on their 
ancestral lands also reported less disability and lower psychological distress. Amongst Canadian First 
Nations communities, prevalence of suicide varied greatly based on presence of protective factors: 
self government (most protective), successful land claims, community control over health, police, fire 
and education services, and presence of cultural facilities (62). In New Zealand, Those who were 
socioeconomically deprived had higher rates of pandemic influenza mortality in NZ (63). Attention to 
these upstream determinants of health may reduce the stigma of aiming specific policies at 
Indigenous communities (64).  
 
Our analysis demonstrated that individual chronic conditions were not necessarily associated with 
higher rates of influenza infection and severity amongst Indigenous Australians. This suggests that 
broader models of health, and both traditional and innovative Indigenous approaches to health, and 
collaboration with and empowerment of community leaders elders, may be more effective than the 
‘discrete disease’ or ‘clinical risk factor’ based approach at reducing the gap in severe influenza 
between Indigenous and non-Indigenous Australians (19, 58, 64). One recent initiative is the 
integration of traditional Aboriginal healers into tertiary hospitals in South Australia, the Ngangkari 
healers (65). They utilise a mix of bush medicine, ceremonies, and laying on of hands to impart 
spiritual remedies.  
 
Our study had certain limitations. Tabulated influenza data from NetEpi assigned to various chronic 
conditions, may not have perfectly matched the ICD10 coded cases from the health surveys on 
prevalence of chronic conditions. Data were only available for adults ≥ 15 years. There were small 
numbers of ICU admissions and deaths from influenza, causing substantial sensitivity to small errors 
or changes in data; for example large confidence intervals as numbers became small for ICU 
admissions and death - table 6. Differential influenza testing rates and non-clinical reasons to admit to 
hospital may also have skewed rate ratios. However, Indigenous : non-Indigenous RRs remained high 
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for escalation to intensive care and for deaths, which would be more objectively determined. 
Collection of complete Indigenous status data is a recognised challenge. Amongst WA/SA/QLD/NT 
total population,  31.3% of influenza notifications reported to NetEpi did not record Indigenous status 
– Graph 1. Age-specific data for the total population was only available for those in whom Indigenous 
status was specified; we were not supplied age-specific data on those who were not classified by 
Indigenous status. For those with chronic conditions, age-specific data was provided for those with 
and without Indigenous status reported. We ran a test-analysis for CLRC hospitalisations in which this 
was reclassified as Indigenous, and non-Indigenous respectively, and directly and indirectly age-
standardised this data. Point estimates became higher when reclassified as Indigenous and lower 
when reclassified as non-Indigenous, but no Indigenous: non-Indigenous rate ratio point estimates 
became lower than that of the total population. However, we do not know the status of those 
unreported, what biases may have been introduced in the statistical analyses. Likewise, the lack of 
access to data on multiple co-morbidities, and to data from those with no background chronic 
diseases, also prevents ability to account for multiple morbidities through multivariate analyses.  
 
7.2.7 CONCLUSIONS 
 
We are the first investigators to access and analyse a national database, NetEpi, to analyse the 
coexistence of influenza and chronic diseases, and relate it to national health survey and Australian 
population census data. We demonstrated that there is an increased prevalence of major categories 
of chronic diseases amongst Indigenous Australians compared to non-Indigenous Australians. We 
also confirmed that there was a higher rate of influenza notifications, hospitalisations, ICU admissions 
and death amongst Indigenous compared to non-Indigenous Australians. Importantly, once 
adjustments were made for the higher rates of chronic conditions amongst Indigenous Australians, 
substantially higher rates of influenza diagnosis, hospitalisation, ICU admission and death, remained 
amongst Indigenous compared to non-Indigenous Australians. This suggests that there are other 
factors associated with high rates of influenza amongst Indigenous Australians, which may include 
comorbidities not examined, presence of multiple morbidities, socioeconomic disadvantage, cultural 
disruption from colonisation or health care access. Data limitations include a lack of information on 
multiple or no chronic diseases in individual cases, given that the data were de-identified and 
aggregated, as well as limitations with reporting of Indigenous status, and potential ascertainment 
bias. Collecting prospective data with completeness of diagnostic testing, attention to complete 
recording of Indigenous status, and presence of no, one or multiple comorbidities, would be useful in 
resolving these uncertainties that result from such data limitations. Synchronising the parameters of 
health survey data to clinically collected data would enable more aligned numerators and 
denominators for generation of rate ratios. Further research on broader social and cultural factors 
which may impact differences between Indigenous and non-Indigenous populations in influenza 
diseases and severity, may be illuminating. For example, the role that the strength of cultural 
identification, access to ancestral homelands, economic and educational empowerment, and 
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provision of traditional and modern models of health care may be explored with qualitative and 
quantitative research on influenza rates and severity. 
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7.2.9 Tables 
Table 1  
Diseases included under each condition analysed as per ICD10 WHO coding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic Lower Respiratory Conditions Current or Long Term: 
bronchitis 
asthma 
emphysema 
 
Diabetes mellitus - excluding gestational 
diabetes 
types 1 diabetes mellitus 
type 2 diabetes mellitus, and  
type unknown diabetes mellitus 
high blood or urine glucose 
 
Renal disease chronic, long-term renal disease  
- defined by reduction in glomerular filtration rate 
Cardiac disease  Current or long term: 
‘ischaemic heart disease’  
- angina 
- heart attack 
- heart failure 
- ‘other heart diseases’ 
Obesity Measures BMI > 40 
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Table 2 
Relative Risk of chronic disease prevalence in Aboriginal and Torres Strait Islander Peoples vs. All Australians ≥ 15 years of age 
 
Chronic Disease State/ Territory Relative Risk 95% CI 
Chronic Lower 
Respiratory Conditions 
WA/SA 1.51 1.34 - 1.70 
WA/SA/QLD/NT 1.31 1.21 - 1.43 
All Australia 2.23 2.11 - 2.36 
Smoking 
WA/SA 2.40 2.21 - 2.60 
WA/SA/QLD/NT 2.41 2.28 - 2.55 
All Australia 2.50 2.39 - 2.61 
Diabetes Mellitus 
WA/SA 3.05 2.62 - 3.55 
WA/SA/QLD/NT 2.86 2.54 - 3.21 
All Australia 4.04 3.73 - 4.38 
Obesity 
WA/SA 2.59 1.98 – 3.38 
WA/SA/QLD/NT 2.09 1.75 – 2.51 
All Australia 2.45 2.13 - 2.82 
Renal Disease 
WA/SA 2.70 1.80 – 4.05 
WA/SA/QLD/NT 2.62 1.97 – 3.49 
All Australia 4.43 3.66 - 5.35 
Cardiac Disease 
WA/SA 1.93 1.60 - 2.34 
WA/SA/QLD/NT 1.51 1.30 - 1.75 
All Australia 2.13 1.92 - 2.36 
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Table 3 
Influenza cases >= 15 years of age for the Total Cohort and for each Chronic Condition 
 
Chronic 
Disease 
State/ Territory Category Indigenous Australians 
Age Standardised 
Indigenous Australians 
Other Australians 
Total 
Cohort 
WA/SA 
Population 81,700 81,700 3,167,603 
Notifications 517 483 12,516 
Hospitalizations 148 172 893 
WA/SA/QLD/NT 
Population 246,189 246,189 6,766,712 
Hospitalizations 490 569 1,675 
All Australia 
Population 429,261 429,261 17,677,150 
ICU admissions 72 84 367 
Deaths 22 33 157 
Chronic 
Lower 
Respiratory 
Conditions 
WA/SA 
 Background Cases* 14,663 (13,235-16,226) 17,137 (15,613-18,783) 439,754 (408,304-473,240) 
Notifications 65 83 763 
Hospitalizations 44 60 319 
WA/SA/QLD/NT 
 Background Cases* 37,322 (34,639-40,178) 44,779 (41,901-47,835) 937,016 (887,116-989,293) 
Hospitalizations 153 205 377 
ICU admissions 31 36 62 
Deaths 5 8 20 
Diabetes 
Mellitus 
WA/SA 
 Background Cases* 9,283 (8,113-10,588) 15,408 (14,093-17,157) 195, 822 (174,218-219,831) 
Notifications 61 88 199 
Hospitalizations 37 58 97 
WA/SA/QLD/NT 
 Background Cases* 25.984 (23,708 -28,459) 38,877 (36,141-41,778) 374,113 (341,719 –409,386) 
Hospitalizations 135 201 114 
ICU admissions 20 31 22 
Deaths 4 8 3 
Obesity 
Data only 
available 
from >25 
years 
onwards  
WA/SA 
 Background Cases* 4,368 (3,540-5,372) 5,562 (4,625-6,667) 83,783 (69,172-101,646) 
Notifications 35 35 162 
Hospitalizations 24 24 84 
WA/SA/QLD/NT 
 Background Cases* 12,235 (10,630-14,054) 15,526 (13,730-17,546) 206,383 (180,718 -235,327) 
Hospitalizations 38 39 101 
ICU admissions 7 8 30 
Deaths 2 3 7 
Renal 
Disease 
WA/SA 
 Background Cases* 1,515 (1,070-2,141) 2,281 (1,748-3,047) 32,774 (24,391-43,713) 
Notifications 18 29 47 
Hospitalizations 13 21 39 
WA/SA/QLD/NT 
 Background Cases* 4,332 (3,422-5,465) 6,707 (5,736-8,297) 70,243 (56,840-87,291) 
Hospitalizations 72 108 42 
ICU admissions 12 18 9 
Deaths 2 4 2 
Cardiac 
Disease 
WA/SA 
 Background Cases* 4,978 (4,126-5,997) 8,283 (7,247-9,616) 165,974 (150,461-193,224) 
Notifications 40 67 144 
Hospitalizations 27 47 100 
WA/SA/QLD/NT 
 Background Cases* 12,202 (10,635-13,984) 18,170 (16,667-20,754) 331,543 (297,059-360,666) 
Hospitalizations 82 125 115 
ICU admissions 18 24 22 
Deaths 4 7 4 
*Number of cases of chronic condition >= 15 years of age calculated from health survey data and ABS census population data (with 95% confidence intervals) 
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Table 4 
Indigenous Status Distribution (by State/ Territory) – Total Cohort Notifications 
 
State/ Territory Indigenous Non - Indigenous Indigenous status not specified 
WA/ SA 6.4% 75.0% 18.6% 
WA/SA/QLD/NT 13.9% 54.8% 31.3% 
All Australia 10.8% 49.9% 39.3% 
 
 
 
Table 5 
Indigenous Status Distribution (by State/ Territory) – Chronic Diseases 
 
State/ Territory Indigenous Status Notifications Hospitalizations ICU Deaths 
WA/ SA 
Indigenous 13.7% 18.2%     
Non - Indigenous 82.1% 80.7%     
Indigenous status not specified 4.3% 1.1%     
WA/SA/QLD/NT 
Indigenous   30.1% 26.7% 20.5% 
Non - Indigenous   41.3% 44.1% 44.6% 
Indigenous status not specified   28.6% 29.1% 34.9% 
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Table 6 
Relative Risk of influenza incidence amongst those with the total cohort and chronic diseases – Age standardized 
 
Chronic Disease State/ Territory 
Notifications Hospitalisations Intensive Care Admissions Deaths 
Relative 
Risk 
95% CI Relative Risk 95% CI 
Relative 
Risk 
95% CI 
Relative 
Risk 
95% CI 
Total Cohort 
WA/SA 1.50 1.37 – 1.64 7.48 6.35 – 8.80         
WA/SA/QLD/NT     9.34 8.50 – 10.27         
All Australia         9.46 7.47-11.99 8.71 5.99 -12.67 
Chronic Lower 
Respiratory 
Conditions 
WA/SA 3.26 2.60 - 4.09 5.62 4.26 - 7.40         
WA/SA/QLD/NT     13.63 11.50 - 16.15 14.63 9.71 - 22.05 10.13 4.47 - 22.94 
Diabetes Mellitus 
WA/SA 9.37 7.30 - 12.03 12.68 9.17 - 17.54         
WA/SA/QLD/NT     25.39 20.19- 31.94 34.88 20.23 - 60.15 68.40 18.30 - 255.55 
Obesity 
WA/SA 4.14 2.88 - 5.96 5.55 3.49 - 8.63         
WA/SA/QLD/NT     6.55 4.53 - 9.46 4.50 2.07 - 9.82 7.19 1.85 - 27.86 
Renal Disease 
WA/SA 13.26 8.37 - 21.03 11.56 6.81 - 19.62         
WA/SA/QLD/NT     41.51 29.09 - 59.22 32.11 12.42 - 71.53 29.01 5.16 - 163.88 
Cardiac Disease 
WA/SA 15.46 11.85 - 20.64 15.82 11.21 - 22.33         
WA/SA/QLD/NT     29.52 22.93 - 38.01 30.16 16.96 - 53.64 48.71 14.34 - 165.48 
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7.3 Chapter 6 Synopsis 
The Role of Chronic Diseases in Influenza Incidence and Severity Differential Between 
Indigenous Australians and Non-Indigenous Australian Populations During the 2009 
Influenza Pandemic in Australia – Synopsis 
This data analysis examined the role played by the higher background prevalence of chronic, 
non-communicable diseases in the greater incidence of severe influenza recorded amongst 
Indigenous Australians during the 2009 ‘swine flu’ pandemic.  
We confirmed that both chronic conditions and influenza are more common in Indigenous 
Australians, but we were unable to demonstrate a distinct impact from higher rates of 
background chronic diseases. These results may have been affected by data collection and 
access limitations, which I have discussed. This provides an opportunity to reflect on how 
such national data collection may be best coded and organized to enable minimization of 
biases and confounders. This suggests other factors associated with colonization are 
predisposing Indigenous Australians to more frequent and severe influenza – genetic pre-
disposition being unlikely given disparate colonised populations globally suffer from higher 
influenza morbidity and mortality. These may include multiple comorbidities, which we could 
not adjust for with the data supplied,  
Our results conflicted with other published analyses. Most - but not all - other analyses, both 
locally and internationally, indicated that the higher prevalence of a range of chronic con-
ditions was responsible for higher rates of severe influenza amongst First Peoples in many 
colonized nations around the world during the 2009 ‘swine flu’ pandemic.  
These findings highlight the importance of addressing upstream determinants 
of communicable diseases in Indigenous populations.  
This analysis suggested a role for a prospective data analysis of influenza risk factors, in 
which data for communicable and non-communicable diseases is better synchronised, and 
Indigenous status more accurately and completely collected. It also suggests a place for 
qualitative and quantitative research of broader social, cultural and environmental factors that 
result from colonization, which may affect differential influenza rates and severity between 
Indigenous and non-Indigenous Australians. 
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8. INFLUENZA IN VULNERABLE POPULATIONS - DISCUSSION 
 
My thesis examined different aspects of influenza in vulnerable populations. I started by 
looking widely at an issue that places whole populations, particularly the immunologically 
impaired, at risk of influenza morbidity and mortality: the prevalence of oseltamivir-resistant 
strains and strategies to address them. Next, I examined different aspects of three different 
demographics that are over-represented in influenza incidence and severity – the very young, 
the very old, and Indigenous Australians. 
 
I performed an original literature search, which showed that, for current circulating viruses, 
resistance to oseltamivir remains relatively low, but is increasing. I wrote this review in 2013 
(published 2014) in the post-2009 pandemic era, when the role of oseltamivir was being 
scrutinised heavily with respect to its efficacy, effectiveness and safety. That an oseltamivir-
resistant strain of influenza was able to dominate in the 2007–2008 season suggested the 
acquisition of additional mutations that conferred a selective advantage over wild-type 
oseltamivir-sensitive strains, despite the mutation compromising replicative fitness.  Since 
2009, the most common circulating strains, pandemic influenza A/H1N1 2009 and seasonal 
influenza A/H3N2, are generally oseltamivir-sensitive, although resistance is being 
increasingly detected.  Zanamivir is an option in those over 5 years of age, although dual 
oseltamivir-zanamivir resistance has been detected in some isolates. I demonstrated that 
oseltamivir resistance was rising both independently and locally, and spreading globally, 
amongst pre-pandemic influenza A (H1N1) (1). Immunocompromised patients, a group 
vulnerable to influenza, were over-represented in those harbouring oseltamivir resistant 
strains, due to prolonged shedding and receipt of oseltamivir, leading to selective drug 
pressure. Since publication, levels of oseltamivir resistance remain low in circulating strains, 
indicating that the data presented in this review remains relevant (2). Stockpiling of 
oseltamivir is advised by the World Health Organization (3). Constant surveillance is required 
to detect a change in strain type and oseltamivir sensitivity (4). This was evident during the 
2017 season when influenza vaccine effectiveness was noticeably lower at 33% due to 
vaccine–wild-type strain mismatch, with larger national influenza epidemics as a result, and 
reliance on oseltamivir treatment in severely affected patients (5, 6). To date, this paper – my 
first ‘first-author’ publication – has been cited 21 times, reflecting both the need for such a 
review and the interest in this topic. This paper is a useful summary of oseltamivir resistance 
to date and presents a starting point for further assessment and synopses of antiviral-
resistant strains. It also highlights the vulnerability in our antiviral armament: the dependence 
upon oseltamivir susceptibility in influenza strains. It begs the question, what can we do to 
reduce development of resistant strains and develop new antiviral strategies? 
 
One such strategy is different oseltamivir dosing regimens to potentially promote more rapid 
virological clearance and hopefully reduce emergence of resistant strains. I presented an 
unblinded, randomised controlled study of a double dose regimen of oseltamivir compared to 
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the standard dose in the community setting. This distinguished this paper from those that 
studied hospitalised cases.  If the results of this study demonstrated a clinical advantage 
without increased adverse events, it could provide a case for extrapolating such a study to 
those with predisposing health conditions. However, we demonstrated no difference in clinical 
or virological outcomes between the two dosing groups, but a significant difference in adverse 
events, with the double dose experiencing more gastro-intestinal side effects. Our study adds 
to the body of research and demonstrates similar findings, but uniquely dealt with many 
patients with milder disease, whom could be cared for outside of hospital (7,8). Only one case 
developed resistance in each arm of the study. However, we recruited an oseltamivir-resistant 
case at enrolment that was genotypically-related to a 29-case cluster from Hunter New 
England, New South Wales; our case was able to be included in published reports regarding 
this cluster (9, Appendix 9.3).  We aimed to recruit 125 patients but recruited only 52. We 
recruited at two sites – a Western Sydney general practice by Peter Hay, co-author and 
general practitioner, and myself at the Children’s Hospital, Westmead Emergency 
Department. Not meeting our recruitment target was likely due to a mix of factors. Influenza is 
a self-limiting illness that, in most cases, does not warrant treatment. Therefore, in this 
healthy, community-based population that we received ethics approval for, cases that were 
recruited participated for altruistic reasons, and potential recruits may be less motivated than 
the ill, hospitalised patients in other studies of double dose oseltamivir. However, this gave us 
a unique point of distinction from other studies, in that we were studying oseltamivir in 
influenza in the community, where influenza is most often diagnosed and managed. In a 
paediatric population, in the Children’s Hospital, Westmead, caregivers were consenting on 
behalf of a child, which means we came up against the natural barrier of parental protective 
instinct. This is overcome more easily in a GP setting, where the doctor has a pre-existing 
relationship with potential recruits; thus about two thirds of our recruitment ended up being 
from the general practice. On the other hand, inclusion criteria were for symptoms of less 
than 48 hours duration. This condition is met infrequently in people who present to a family 
doctor, as most usually attend when symptoms don’t rapidly resolve. The study was 
conducted fairly close to the 2009 ‘swine flu’ epidemic and some people had firm fixed ideas 
about its manifestations, and denied it was a diagnostic possibility in themselves or their child, 
and refused point-of-care testing. The test itself was somewhat invasive, requiring a nasal 
swab, which can be uncomfortable. Nonetheless, we recruited 52 cases despite these 
obstacles. In future such studies, being proactive and advertising the study in the lead up to 
the influenza season may encourage people to present earlier. Focusing on general practices 
may be helpful due to the pre-existing relationship, but we found it very helpful to include the 
somewhat more symptomatic cases that present to an outpatient emergency department. 
Performing the study over more than one season may also be warranted. 
 
Our study did not support any advantage to doubling the dose of oseltamivir, at least in the 
healthy population. However, there was non-significant finding of more rapid virological 
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clearance by nucleic acid testing (NAT), particularly in those with influenza A, in the double 
dose group (p = 0.16), suggesting conditions for oseltamivir resistance - prolonged viral 
shedding - may be mitigated by double dose regimens. This didn’t reach statistical 
significance, however, and may be a spurious finding. Two other studies of double dose 
oseltamivir examined virological clearance: one study of 326 cases revealed no difference by 
NAT testing (p =0.42) whereas the other study of 155 patients claimed ‘a trend towards more 
rapid clearance in influenza B’ (p = 0.05) (10, 11). Therefore, there isn’t a clear role for 
oseltamivir double dose to hasten virological clearance or reduce emergence of oseltamivir 
resistance, but future, perhaps larger, studies may clarify this, further. 
 
An area for further research is to repeat this study amongst those with immune deficiencies 
and those under age 5, given that adverse events, whilst higher in the double dose group, 
were self-limiting. Oseltamivir prevents release of virus from cells and thus invasion of 
uninfected epithelial cells. It is thus most effective in the first 48 hours after onset of influenza 
symptoms, before most target cells have become depleted. Oseltamivir pharmacokinetics are 
influenced by the interactions between viral load, target cell dynamics, and innate and 
adaptive immune responses (12). Thus, the results of this study may not be extrapolatable to 
immunocompromised populations who shed virus for longer and have weakened immune 
responses. Nonetheless, other studies have focused on these populations, whilst we were the 
first to look at double dose oseltamivir treatment of community-based cases. Like the other 
studies of hospitalized populations, even in our relatively healthy population, there was no 
evident advantage to double dose oseltamivir. Recent studies on high dose influenza vaccine 
show, promisingly, that immunogenicity improved in cardiac patients, cancer sufferers and 
elderly recipients (13-15). However, other specific antivirals have not yet been developed. An 
old strategy, application of heterologous antibodies, currently used in rabies infection and 
snake and arachnid venom toxicity, was the focus of my next paper. By targeting multiple 
epitopes, they are an effective strategy for overcoming mutations in influenza strains that may 
otherwise be treatment-resistance. 
 
The major limitations of heterologous polyclonal antibody therapies are that they are 
extracted from the serum of non-human species, which creates the potential for 
hypersensitivity reactions to animal proteins. In my review I demonstrated how the 
introduction of filtration, pasteurisation and chromatography steps remove animal proteins 
and impurities from the final product, which has resulted in very low rates of hypersensitivity 
reactions. This treatment modality is being developed for avian influenza strains, to which 
those who are elderly, and those with chronic conditions, are particularly susceptible to 
clinical disease manifestation (16). Against avian influenza, there are promising early results 
in terms in immunogenic and safety studies of efficacy and tolerance. They can also be 
rapidly generated to new strains of influenza virus, resulting from antigenic shift, requiring less 
technical prowess and lower cost than monoclonal antibodies, and overcoming the 
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disadvantages of epitope mutations that make monoclonal antibody therapy vulnerable to 
antigenic drift (17, 18). Polyclonal antibody therapies can also be applied to a range of 
undertreated tropical illnesses ravaging different parts of the globe: Ebola virus, Zika virus, 
and Dengue virus, for example. The data from this extensive review was reassuring. 
Successful in-vivo proof-of-concept studies, and phase 1 safety trials, indicate that 
heterologous polyclonal antibody therapy may be developed to treat and even prevent 
oseltamivir resistant influenza, avian influenza strains, other ‘drifted’, re-assorted strains, and 
eventually become part of the pandemic planning strategy. Their utility may extend to other 
undertreated infectious pathogens. This undertaking was a collaboration between myself, 
medical librarians, Biointelect (a consultancy firm specialising in biological product 
development), and Fab’entech (a pharmaceutical company currently testing polyclonal 
antibodies against avian influenza). It was noted by a marker that the phrase ‘equine 
F(ab′) 2preparations demonstrated cytopathic effects against cultured Madin–Darby canine 
kidney (MDCK) cells infected with H5N1’, should perhaps read ‘cytoprotective effects’. I 
checked the reference, and submitted a correction ‘prevents cytopathic effects’, to the 
publishers Elsevier, of the journal VACCINE, who have published a Corrigendum on their 
website, included after the article. A poster summary of this paper was selected be presented 
verbally to the 2014 conference of the European Scientific Working group on Influenza in 
Riga, Latvia; (Appendix 2).  This literature review can form a basis for ongoing updates in the 
development, clinical testing, registration and post-marketing surveillance of polyclonal 
antibody therapies in influenza.  
 
One issue with conducting any type of research in the field of influenza management is 
ethical considerations in the study design; given how rapidly fatal influenza can be in 
vulnerable populations. My third offering was a protocol for a cluster-randomised controlled 
trial on the use of oseltamivir treatment of cases, versus treatment of cases plus contacts 
(prophylaxis), for the prevention of influenza outbreaks in aged care facilities (ACFs). This is 
distinct from another earlier study by introduction of information sessions to education 
influenza, prevention strategies, infection control, and then coach ACF staff on surveillance 
for influenza-like illness, recorded through active computer surveillance systems, as well as 
conduct of point -of-care tests. We liaised with Dr Liz Barnes, statistician at National Centre of 
Immunisation Research and Surveillance, Children’s Hospital, Westmead, who suggested 74 
ACFs to give statistically significant findings. On advice, we consulted Professor Christopher 
Triggs, Head of Department of Statistics at University of Auckland, to obtain a sample size 
calculation. We used the following assumptions: 
 
AVERAGE SIZE of ACF: mean number of residents in Booy et al: 66 patients with 86 bed 
capacity; so I think it is safe to say 75 residents. 
INFLUENZA SEASON DURATION:  June to September: 121 days. 
INCUBATION TIME: 1-4 days - average 2. Infectivity time 7 days (without treatment). 
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CONTACT NUMBER: varies ACF to ACF but Booy et al study was 6-7 contacts per case on 
average 
CHANCE OF ACF resident contacting influenza during a season: Based on Booy et al paper: 
‘Confirmed influenza cases in residents were 19.6% (T only) – therefore I extrapolated to 
20%. 
At the time of this PhD submission, Professor Triggs has not finalised this exercise, and is 
out of the country. I anticipate liaising with him to obtain the results of his statistical model 
for sample size.  I have also organised a meeting with statistician, Mr Jim Matthews, from 
the University of Sydney - the organisation of this meeting was delayed due to administra-
tive errors on the part of the university and is now scheduled for 11 November 2018. I will 
seek input on sample size and appropriate statistical testing. We are also looking forward 
to the results of an observational study underway by Professor Booy, of oseltamivir 
treatment versus treatment-+- prophylaxis, and will use the findings to guide the statistical 
inputs of this trial, further. 
Immediately, we ran into problems achieving consensus on the issue of informed consent of 
study participants. The ethical principle that underlies the practice of obtaining informed 
consent is “respect for individual autonomy” (19). Autonomy is defined as “independence of 
self determination, freedom from external control” (20). Therefore, to preserve their 
autonomy, it is usually an ethical requirement to obtain informed consent from each 
participant in a study of either untested or off guideline treatment or treatment regimens (21). 
This protocol, however, had several specific features that complicated the issue of obtaining 
consent. Firstly, oseltamivir is already a registered medication that has been extensively 
studied for safety and efficacy, albeit with controversial findings (22). Thus, the question of 
whether consent needed to be obtained arose. Secondly, the two regimens being compared 
were both outlined as alternative options in the 2017 guidelines for management of influenza 
outbreaks in residential care facilities, which makes our proposed regimens both ‘on-guide-
line’, hence the requirement for consent was unclear (23). The reason for not advising one 
option over the other is due to a paucity of data with which to make firmer recommendations, 
a matter that this study sought to address. Thirdly, residents of ACFs are often vulnerable, 
with a high level of dementia as well as hearing and visual deficits, hindering communication 
of information with which to obtain consent (24,25). This would require identifying next of kin 
or those with guardianship arrangements for many residents. Fourthly, the huge number of 
participants, residents and staff of approximately 100 ACFs make obtaining individual 
consent impractical. Obtaining consent in advance of an influenza outbreak from thousands 
of potential participants was unrealistic with the resources available to conduct such a study, 
particularly given that it is likely that the majority of them would not ultimately be involved in 
an influenza outbreak. Personal discussions with the Booy et al study authors indicated 
certain pitfalls in the prospective, real time consent process. There is a need to act rapidly  
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during an influenza outbreak to manage it effectively, with oseltamivir being most effective 
within the first 48 hours of symptom onset to reduce both individual duration of illness and 
transmissibility (22). Obtaining consent from the elderly is a time-consuming process.  
“Catch up” consent during outbreaks reduced the ability to treat in a timely manner. ”Time 
to consent” reduced time to check renal function and added to delays. During serious 
outbreaks, the risk-benefit assessments of participants or their guardians changed; 
residents who previously declined consent changed their minds, requiring re-consent. Con-
sent procedure reduced implementation of trial intervention, and led to differential consent 
rates. This was the main source of criticism by reviewers.  
A prolonged process of communication, negotiation, concession and compromise was 
employed to attempt to obtain a workable consensus. In summary, the proposed consent 
processes included: (a) obtaining consent from each participant either before, or at time of, an 
outbreak; (b) obtaining consent to dispense oseltamivir only from contacts of cases, and 
treating cases without obtaining consent; (c) obtaining consent from ACF managers to be 
randomised into one of two guideline-recommended treatments; (d) obtaining consent from 
general practitioners sub-serving both ACFs and individual residents. The first two were 
unworkable and not seen as consistent with the idea that oseltamivir for treatment and 
prophylaxis were both on-guideline measures. The last two measures were essentially 
vetoed, as consent by ACF staff or general practitioners on behalf of residents were not 
considered appropriate. Ultimately it was decided that, as both regimens were on-guideline 
and oseltamivir is a registered medication, we would seek from the Ethics Committee a 
waiver of the requirement for individual consent. Instead, we would seek agreement from the 
treating general practitioners to institute one or the other of the two arms of the study in the 
event of an influenza outbreak. The public health bodies that would oversee outbreak 
management were already included as study co-authors, ensuring their co-operation. Study 
staff would provide no hindrance to any decisions to change outbreak management at any 
time, e.g., to withhold treatment from individuals, or to change treatment of cases, only to 
treatment of cases plus prophylaxis of contacts. We were unable to get agreement from all 
stakeholders to this decision. In the post-PhD period, we will continue these discussions. One 
possible solution is to evaluate prospectively collected observational data; funding and staff 
have been obtained to perform such a study at the Kidney Research Centre at the Children’s 
Hospital, Westmead and the study is underway.  
The other extreme of age, infancy, is also a vulnerable period for influenza with higher rates 
of hospitalisation, Intensive Care Unit admission, and death (26). This is complicated by lack 
of universal vaccination, and barriers to vaccinating pregnant women. With vaccine coverage 
in pregnant women only 20-50% in Australia and the US, infants vulnerability to influenza is 
compounded by lack of transplacental antibody transfer from mothers who are not recently 
infected (27, 28). Once infected, infants are treated with oseltamivir, the only registered 
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treatment for infants, despite a paucity of data in this age group (29). There is only one other 
trial of oseltamivir in infants, and registration only down to 1 year of age (30). We conducted a 
pharmacokinetic and pharmacodynamics analysis of infants on oseltamivir in the Intensive 
Care Unit. Recruitment of cases was limited by several factors including: (a) ethical 
constraints requiring infants to be cannulated for another purpose to collect blood samples. 
Given that oseltamivir is administered via nasogastric route or orally, most babies treated with 
oseltamivir did not require intravenous cannulation; (b) low rates of influenza in infants in one 
of the seasons over which the study was conducted; (c) inability to easily bleed back from the 
cannula in one child. Recruitment of cases was complicated by the fact that many babies 
didn't require cannulation. Some babies were cannulated for only a few hours, too short for 
our sampling time frame. One of the influenza seasons over which the study was conducted 
resulted in no suitable cases admitted to the paediatric infective care unit from which we were 
recruiting. On one occasion we were unable to obtain blood through the cannula. Even so, we 
were able to obtain a complete data set from two cases and a partial data set from two 
patients, for a total of four cases. We obtained our drug and metabolite exposure value target 
from recommendations by Kimberlin et al. (30). Overall, oseltamivir was well tolerated at a 
dose of 2.35–3 mg/kg/ dose twice a day in infants under the age of 1 year. These doses were 
confirmed to produce a target oseltamivir carboxylate plasma exposure in excess of the pro-
posed 12-hour target exposure of AUC 3800 ng/h/ml. Ideally, a greater number of recruited 
cases would have consolidated our findings, but this data contributes to knowledge about 
oseltamivir in infancy due to a lack of published data to confirm the only other published 
study, and may be helpful in meta-analyses of oseltamivir pharmacokinetics in infancy. An 
expanded study over several facilities and several influenza seasons would probably result in 
more recruits and be useful in improving the reliability of the results, but funding would be a 
limitation, given the cost of transporting the specimens to the United States and paying for 
laboratory analysis. Nonetheless, at the time of publication, our data was the only other 
published analysis of oseltamivir pharmacokinetics in infants, confirming the findings of insulin 
and providing data for the current guidelines.  
Building on the theme of obtaining consent in populations that are vulnerable, obtaining con-
sent for analysing influenza and chronic disease data on Indigenous Australians provided a 
steep learning curve. An Aboriginal advisor became unavailable for collaboration. Ethics 
committees rightly wanted evidence of consultation from the outset with key stakeholders 
within the Australian Indigenous community. My own ignorance and naivety in this regard 
resulted in missteps, and my possibly offending the Spirits of the Elders, and there were 
many setbacks. Eventually, we were able to interest Professor Jakelin Troy, Director of 
Aboriginal and Torres Strait Islander Research and Deputy Vice-Chancellor of Indigenous 
Strategy and Services, from the University of Sydney. She endorsed my research, 
commenting that “the publication is an important issue in Indigenous health, I support her 
desktop research program using extant, publicly available, de-identified data sets and look 
forward to further discussion about areas of mutual interest in Indigenous health”. An 
affiliation for 
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post-doctoral research possibilities was formed between Professor Troy and myself. The 
Human Research Ethics Committee approved the project in April 2017. Out of all the projects, 
this may have been the most challenging, most detailed, perhaps most educational, and the 
one closest to my passions – the role of proximal and modifiable determinants of health in 
vulnerable populations. This is the first age-standardised analysis of Australian national data 
sets, in contrast to smaller local analyses, which are usually not age-standardised. We 
examined a national data set for notifications, hospitalisations, Intensive Care Unit 
admissions and deaths from influenza by Indigenous status and by presence of a one of five 
common background conditions as coded by the International Classification of Diseases and 
Health Related Problems (ICD-10) (31). Our results confirmed that chronic conditions are 
significantly more common in Indigenous Australians, and that influenza of varying degrees 
of severity was more common in Indigenous Australians, but restricting our analysis to those 
with each chronic condition reduce the difference in influenza rates between Indigenous and 
non-Indigenous Australians. Thus, we did not demonstrate that higher rates of background 
chronic conditions were responsible for more frequent and severe influenza in Indigenous 
Australians. These findings may be partly explained by data limitations. Attention to 
Indigenous status, classification of individuals with either no, one or multiple comorbidities, 
and case identification through consistently applied diagnostic testing would help to reduce 
data artefacts and biases. This would enable accurate elucidation of the role of chronic 
diseases in the gap between Indigenous and non-Indigenous Australians with respect to 
influenza. This study highlighted the importance of rigorous data collection on Indigenous 
status, and the presence or absence of none, one or multiple comorbid chronic diseases to 
perform multivariate analyses. But, if our research results were true, this begs the question: 
what does cause influenza disparities between Indigenous and non-Indigenous Australians? 
Research of the social, cultural, political and psychological impacts of colonisation has in-
dicated that colonised communities who are able to preserve these ties have better discrete 
health outcomes. Could attention to broader, less quantifiable factors help resolve this 
quandary, rather than a modern Western ‘risk-factor’ based approach? Options for further 
research may include an analysis of prospectively collected data with attention to the above 
data limitations, such as synchronising health survey and clinical data more closely, and 
applying influenza testing uniformly. However, there is also a role for researching the impact 
of broader social and cultural factors that communities and individuals exist within. For 
example, the impact on influenza rates and severity of strength of cultural ties and 
identification, markers of economic and educational empowerment, access to ancestral 
homelands and provision of traditional and modern models of health care could be explored 
with qualitative and quantitative research. Whilst the timeline of the PhD did not allow for 
submission for publication to peer review journals, this is the immediate goal, in order to 
disseminate the results to data collection agencies, the broader community, and particularly 
to Aboriginal and Torres Strait Islander healthcare providers, elders and communities.  
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8.1 Conclusion: 
There are a number of considerations that affect the impact of influenza and its management 
strategies in vulnerable populations. These include those particularly susceptible to 
influenza, such as those in infancy, the elderly, and Indigenous populations in colonised 
countries. Oseltamivir-resistant strains render immunologically-compromised cases vulner-
able in the event that resistant strains predominate, or were highly virulent strains such as 
avian influenza to develop effective person-to-person transmissibility. I examined strategies 
to address oseltamivir resistance. Oseltamivir double dose strategies did not show a clinical 
or virological advantage, nor were we able to show an advantage in terms of avoiding 
oseltamivir resistance. Resurgence of old strategies such as heterologous polyclonal 
antibodies look promising – more phase three trials and post-marketing surveillance needs to 
be undertaken to support their introduction to the anti-influenza artillery. These therapies 
indicate the need to think outside of the current pharmaceutical models of care for resistant 
organisms, towards other biologics for therapeutic applications. I then turned my attention to 
discrete risk groups. The protocol we developed on the role of oseltamivir in averting 
outbreaks of influenza among the elderly residing in ACFs would support a 3-year study; 
however, the issue of how to conduct this study ethically requires further discussion amongst 
the proposed study authors until a consensus is reached. Infants are currently treated with 
oseltamivir, although it is licensed for those over 1 year of age. Our small case series on 
pharmacokinetics demonstrated an agreement with the only published data on the 
appropriateness of current doses given to infants. An expanded study on oseltamivir 
pharmacokinetics in infants during an active influenza season would consolidate the findings 
from the current series, were funding available. Lastly, our national, age-standardised data 
analysis on the role of background non-communicable chronic diseases on higher rates of 
severe influenza in Indigenous Australians did not show that higher prevalence of chronic 
conditions influenced influenza rates, and suggests broader socio-political, economic and 
cultural factors may be worth examining – and highlighted the importance of rigorous, 
prospective data collection.  
Influenza is an ancient, highly contagious viral disease, and continues to evade our best 
efforts to prevent it and treat it. This thesis examined aspects of its impact on certain 
circumstances of population susceptibility, and within particular vulnerable populations. It also 
provided insight into further areas of research and analysis into this globally relevant and 
elusive disease. 
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Heterologous Polyclonal Antibodies 
Past and Present, with Future Applications 
to Avian Influenza and Other Neglected Viruses.  
Introduction 
Passive immunisation with highly purified 
polyclonal antibodies against toxins or infection, 
have potential future applications to influenza 
treatment / prophylaxis. 
Such therapy is currently applied to  
 medication overdoses e.g. colchicine & digoxin, 
 poisoning by snake, arachnid, marine and plant 
toxins 
 post-exposure rabies. 
Polyclonal antibodies (immunoglobulins) are 
obtained from plasma of hyper-immunized animals, 
e.g. horses or sheep. 
Allows affinity maturation and thus high affinity 
antibodies, enables a more potent formulation,  
 reduces volume administered, minimising 
allergic reactions from co-administered animal 
proteins 
In the past, use of animal serum has been 
associated with high rates of heterotypic allergic 
and  hypersensitivity reactions (1) 
Modern manufacturing and purification methods 
have greatly improved safety whilst retaining 
efficacy (2) 
Animal products are cheap and fast to produce, an 
important consideration for resource-limited 
settings, and can be produced in large amounts. 
• A meta-analysis of CroFab ® combined incidence immediate 
hypersensitivity 8% & serum sickness 13% 
• Bothrops antivenin anayphylaxis 1-2%; serum sickness 1-4% 
  
Heterotypic Antibodies: Future application 
• Fab’entech propose application of the well known and 
characterized technology to new pathogens achievable by 
substituting one vaccine in horses for another; enabling  9 to 
12 months from emergence of a new viral threat to release of 
new antisera.   
• Convalescent plasma used in two cases of Highly 
Pathogenic Avian Influenza (HPAI) H5N1, both of whom 
survived. 
• Administration of polyclonal anti-influenza F(ab’)2 to mice 
24H post influenza exposure across several studies, 
including H5N1  
 greater viral clearance and less morbidity and mortality 
compared to controls (6).  
• An anti-H5N1 Higly purified F(ab’)2  was specifically 
developped, named Fabenflu® and propose a 5 consecutive 
days daily injection protocol. 
• A phase 1 study in 16 healthy young males of Fabenflu®, 
safe: one minor febrile reaction. 
• Unimmunised hamsters who received West Nile Virus- anti-
sera one hour before and 24 hours after a challenge were 
protected from lethal infection (7).  
• Ducks egg polyclonal F(ab’)2  to Andes virus (pulmonary 
hantavirus syndrome) given to hamsters post-exposure 
intranasal or intramuscular had improved survival compared 
to controls (8). 
• Polyclonal antibodies against the Marburg and Ebola 
filoviruses from nonhuman primates (NHPs) that survived, 
given post-exposure to other NHP and, prevented disease 
and death (9).  
• Other studies of mice, monkeys & guinea pigs demonstrated 
purified equine whole IgG prolonged survival against Ebola 
(10-14).  
• Given difficulty in conduction efficacy trials in humans, non-
traditional regulatory pathways may be needed to register 
these products. Provisions to reduce overall review time 
should include e.g.: 
 utilisation of FDA ‘animal rule’ where animal data is 
assessed. 
 rolling submissions where regulatory review can 
commence whilst data is still being finalised. 
 ‘mock up dossiers’ which enable standing approval of 
manufacturing processes to be applied to 
development of sera against a new pathogen  
  
  
Dixit, Rashmi (1); Herbreteau, Cécile Hélène (2); Herz, Jenny (3); Dalton, Richard (4) Booy, Robert (1); 
Lepine, Bertrand (2) 
1 The Children’s Hospital, Westmead, Sydney (AUSTRALIA) 2. Fab’entech, Lyon (FRANCE)  3: Biointellect, Sydney (AUSTRALIA)    
4: University of Southampton 
Aim 
This review will examine : 
• the history of animal polyclonal antisera 
used in humans. 
• past and current efficacy and safety 
considerations and progress. 
• future potential prophylactic and therapeutic 
applications.   
  
Method 
• Literature searches were undertaken by a 
experienced medical librarian  
 To identify items on both the safety of 
polyclonal antibodies and the use for the 
treatment of rare or neglected diseases.   
• The databases searched included OVID Medline 
and OVID Embase.   
• The searches contained database-specific 
MeSH and EMTREE terms in combination with 
pertinent text-words.  
• To minimise bias, no language limits were 
applied.  
• The final search was completed on 30.05.14. 
Conclusion 
The past precedent and future potential for safe, effective 
serum prophylaxis and therapeutics in viruses provides hope 
for pathogens for which there are limited therapeutic options, 
including for pandemic and resistant influenza strains. 
Results 
Heterotypic Antibodies: Past 
). 
1890 Von Behring & Kitasato discovered rabbit sera 
protected mice from diphtheria & tetanus (3) 
1894 • Animal derived anti-diphtheria serum used in 
humans during a European epidemic (4) 
• Phisalex & Bertrand demonstrated that blood of 
horses immunised with Vipera aspis (Europen 
viper) had antitoxic properties 
1918 Human & animal origin sera were used for measles, 
varicella and 1918 pandemic Spanish influenza 
Pre-antibiotics, serum therapy was applied to 
bacterial infections such as pneumococcus, 
meningococcus and streptococcal A (scarlet fever)  
Anti-rabies polyclonal antibodies from hyper-
immunised horses was developed in the early 20thC 
Crude preparations of heterotypic sera were 
contaminated with large amounts of non-human 
proteins, thus reactions limited safety. 
1960 Fifty years ago,  
- 16%  treated with equine rabies immunoglobulin 
(ERIG) for post-exposure prophylaxis developed 
serum sickness 
- 46% >15 years were affected  
1980s Serum sickness reduced to 0.5-3% by the late 
1980s after introduction of enzymatic digestion, 
ammonium sulphate / caprilyic acid precipitation 
and thermocoagulation to sterilise and purify serum 
Heterotypic Antibodies: Current 
New processes have made allergic reactions rarer 
• e.g. ERIG <0.1% serum sickness / anaphylaxis 
• Initial anion-exchange chromatography isolates horse 
IgGT subclass, excludes non-protective immunoglobulins, 
proteins, cell aggregates,  contaminants. 
• Peptic cleavage obtains F(ab’)2, and destroys enveloped 
viruses.  
• A second anion exchange chromatography removes 
protein aggregates and bacterial endotoxins. 
• Final heat pasteurisation destroys non-enveloped viruses;  
ultrafiltration removes viruses and bacteria 
• High performance liquid chromatography determines 
purity. 
• Preservatives prevent bacteria/ fungi contamination 
• Animals vaccinated and / or chosen from areas with no 
arboviruses. Sera routinely screened / subcultured  
• Nil documented cases of prion acquisition.  
ERIG from reliable sources is now effective and safe e.g. in 
Philippines (5) 
• 144 cases given correct Favirab® as per protocol, (Sanofi 
Pasteur, Lyon, France), no failures 
• 193 Favirab® recipients cases with rabid bites, one failure. 
• 7660 Favirab®  recipients, 0.3% local and 1.2% systemic 
reactions. 
• Globally, Post marketing surveillance > 1 million doses 
Favirab > 8 years, 2 cases serum-sickness / 1 case 
anaphylaxis.  
Snake antivenoms slightly higher rates of AE as greater 
volume / more protein delivered 
• A 1996-2008 review of F(ab’)2 rattlesnake antivenin 
CroFab ®: response rate 77% to severe envenomation 
• 223 African recipients of equine F(ab’)2  snake antivenin 
IPSER AFRICA (Pasteur Merieux Connaught, Lyon, 
France) 
• clinical cure rate 96.8% 
• 1 (0.4%) case each anaphylaxis and serum sickness. 
Contacts 
• The Children’s Hospital  
 Rasmi Dixit rushmi7@gmail.com   
• Fab’entech 
 Cécile Herbreteau-Delale 
 cecile.herbreteau-delale@fabentech.com 
www.fabentech.com 
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Table 6 
Relative Risk of influenza incidence amongst those with the total cohort and chronic diseases – Indirectly Age-standardisation 
 
Chronic Disease State/ Territory 
Notifications Hospitalisations Intensive Care Admissions Deaths 
Relative 
Risk 95% CI 
Relativ
e Risk 95% CI 
Relative 
Risk 95% CI 
Relative 
Risk 95% CI 
Total Cohort 
WA/SA 1.21 1.11 - 1.32 6.32 5.34 - 7.42         
WA/SA/QLD/NT     7.94 7.25 - 8.67         
All Australia         8.59 6.72 - 10.82 7.14 4.48 - 10.82 
Chronic Lower 
Respiratory 
Conditions 
WA/SA 2.88 2.23 - 3.68 5.8 4.21-7.79         
WA/SA/QLD/NT     12.29 10.42 - 14.40 15.65 10.63 - 22.21 8.09 2.61 - 18.89 
Diabetes Mellitus 
WA/SA 13.96 10.67 - 17.93 18.54 13.05 - 25.55         
WA/SA/QLD/NT     41.46 34.76 - 49.08 28.73 17.54 - 44.37 43.28 11.64 - 110.81 
Obesity 
WA/SA 9.46 6.59 - 13.16 13.04 8.35 - 19.41         
WA/SA/QLD/NT     12.09 8.55 - 16.59 6.63 2.66 – 13.66 8.53 0.96 - 30.78 
Renal Disease 
WA/SA 18.06 10.70 - 28.55 16.78 8.92 - 28.69         
WA/SA/QLD/NT     59.86 46.84 - 75.39 49.12 25.35 - 85.81 43.63 4.90 - 157.51 
Cardiac Disease 
WA/SA 16.02 11.44 - 21.81 16.85 11.10–24.52         
WA/SA/QLD/NT     32.14 25.56 - 39.89 33.07 19.60 - 52.27 31.32 8.43 - 80.18 
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Characteristics of a Widespread Community
Cluster of H275Y Oseltamivir-Resistant A
(H1N1)pdm09 Inﬂuenza in Australia
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(See the editorial commentary by Fry and Gubareva, on pages 145-7.)
Background. Oseltamivir resistance in A(H1N1)pdm09 inﬂuenza is rare, particularly in untreated community
cases. Sustained community transmission has not previously been reported.
Methods. Inﬂuenza specimens from the Asia–Paciﬁc region were collected through sentinel surveillance, hos-
pital, and general practitioner networks. Clinical and epidemiological information was collected on patients infect-
ed with oseltamivir-resistant viruses.
Results. Twenty-nine (15%) of 191 A(H1N1)pdm09 viruses collected between May and September 2011 from
Hunter New England (HNE), Australia, contained the H275Y neuraminidase substitution responsible for oselta-
mivir resistance. Only 1 patient had received oseltamivir before specimen collection. The resistant strains were
genetically very closely related, suggesting the spread of a single variant. Ninety percent of cases lived within 50
kilometers. Three genetically similar oseltamivir-resistant variants were detected outside of HNE, including 1
strain from Perth, approximately 4000 kilometers away. Computational analysis predicted that neuraminidase sub-
stitutions V241I, N369K, and N386S in these viruses may offset the destabilizing effect of the H275Y substitution.
Conclusions. This cluster represents the ﬁrst widespread community transmission of H275Y oseltamivir-
resistant A(H1N1)pdm09 inﬂuenza. These cases and data on potential permissive mutations suggest that currently
circulating A(H1N1)pdm09 viruses retain viral ﬁtness in the presence of the H275Y mutation and that widespread
emergence of oseltamivir-resistant strains may now be more likely.
Oseltamivir (Tamiﬂu®) is the most commonly used
drug for the treatment or prophylaxis of inﬂuenza,
and has been widely used in Japan, North America,
and Europe. Oseltamivir has also been stockpiled by
many countries as part of pandemic preparedness and
was widely used during the 2009 inﬂuenza A(H1N1)
pandemic, when it was shown to improve clinical out-
comes in infants, adults, and pregnant women [1–6].
Since the emergence of the pandemic H1N1 2009
virus (A[H1N1]pdm09), oseltamivir resistance has
been detected at a frequency of approximately 1%,
with the majority of resistant viruses being isolated
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from immunocompromised patients undergoing oseltamivir
treatment [7–9]. Virtually all of these resistant viruses have
contained the histidine (H) to tyrosine (Y) substitution at po-
sition 275 of the neuraminidase (NA; N1 numbering—the
same substitution is referred to as H274Y based on N2 num-
bering), which confers highly reduced oseltamivir sensitivity
in vitro [10]. This substitution was also present in the oselta-
mivir-resistant variant of the prepandemic seasonal A(H1N1)
subtype that emerged in Europe and then spread globally in
less than a year in 2008 [11, 12]. This demonstrated the capac-
ity of an A(H1N1) virus to overcome the inherently detrimen-
tal ﬁtness effect of the H275Y substitution [13, 14] and
transmit readily between individuals in the absence of drug
selection pressure. Clinical data have shown that the effective-
ness of oseltamivir was signiﬁcantly reduced during the treat-
ment of the previously circulating seasonal A(H1N1) H275Y
variants [15–18].
Transmission of oseltamivir-resistant H275Y A(H1N1)
pdm09 strains to date has been limited or unsustained. Most
commonly, transmission has occurred in closed, near-contact
settings, such as hospital wards [19–21], or after prolonged
close contact in community settings such as a long train
journey or at a school camp [22, 23]. Oseltamivir-resistant
H275Y variants were detected at a low frequency (<1%) among
community cases during the 2010–2011 northern hemisphere
inﬂuenza season [24, 25] and, based on our testing, this contin-
ues to be the case for most countries in the southern
hemisphere during the current 2011 inﬂuenza season. In con-
trast, between June and August 2011, in the Hunter New
England region around Newcastle, Australia, we detected a sig-
niﬁcantly increased frequency of H275Y oseltamivir-resistant
A(H1N1)pdm09 viruses in community patients, of whom only
1 patient had been treated with oseltamivir [26]. Following our
initial brief report [26], here we describe the virological and
epidemiological aspects of the cluster of H275Y oseltamivir-re-
sistant A(H1N1)pdm09 inﬂuenza and discuss potentially per-
missive NA substitutions that may have enabled the A(H1N1)
pdm09 virus to retain viral ﬁtness in the presence of the
H275Y mutation.
MATERIALS AND METHODS
Sample Collection
Newcastle (population 273 805) is a regional coastal city in
the state of New South Wales (NSW), and the sixth largest
city in Australia, providing tertiary referral specialist services
for northern NSW. It is located approximately 120 kilometers
north of the NSW capital, Sydney (Figure 1). The Hunter
New England (HNE) health district, of which Newcastle is the
major city, stretches from Lake Macquarie in the south to the
Queensland border. The HNE health district is served
by Hunter Area Pathology Services (HAPS), which receive
specimens for inﬂuenza testing from emergency departments,
intensive care units, and general practitioners. Respiratory
Figure 1. Map of the Hunter New England (HNE) health district and Australia. HNE health district is colored in red.
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specimens (swabs and nasopharyngeal aspirates) that were
positive for inﬂuenza A or B by nucleic acid testing at
HAPS in 2011 were referred weekly to the World Health
Organization (WHO) Collaborating Centre for Reference and
Research on Inﬂuenza (WHO CCRRI) for further virological
analysis. A(H1N1)pdm09 viruses from the HNE health district
were compared with viruses obtained from WHO National In-
ﬂuenza Centres that form part of the WHO Global Inﬂuenza
Surveillance and Response System (GISRS), and other labora-
tories both within and outside of Australia.
To enable the review of oseltamivir-resistant viruses in
the HNE health district, the NSW Chief Health Ofﬁcer
granted an ethics waiver and authorized the investigation
under the NSW Public Health Act 2010 as an urgent public
health investigation. For all patients with oseltamivir-resistant
viruses, hospital records were reviewed and treating medical
practices contacted to obtain details of clinical symptoms and
outcomes, antiviral and concomitant treatment administered
during the current and previous treatment episodes, and
medical history. Patients infected with oseltamivir-resistant
inﬂuenza viruses were interviewed using a structured question-
naire to gather data on patient demographics, medical history
of immune-compromising conditions, inﬂuenza vaccination
status in 2011, and antiviral treatment history.
Virological Analysis
Viruses were isolated from original clinical samples and repas-
saged in Madin–Darby canine kidney cells (ATCC CCL-34).
Antigenic characterization was performed using a hemaggluti-
nation-inhibition assay [27]. All virus isolates were analyzed
for oseltamivir, zanamivir, and peramivir sensitivity using a
ﬂuorescence-based NA inhibition assay [28], followed by hem-
agglutinin (HA) and NA sequence analysis of those strains
with elevated inhibitory concentration (IC50) values (the con-
centration of drug required to inhibit the NA activity by 50%).
Where virus isolates could not be obtained, original specimens
were analyzed for the presence or absence of the H275Y NA
substitution using a pyrosequencing assay [29]. The HA and
NA genes were fully sequenced using standard techniques on
an ABI 3500XL sequencer. Sequences from oseltamivir-resis-
tant strains were uploaded to a publically available inﬂuenza
sequence database (GISAID; www.gisaid.org), and given acces-
sion numbers EPI334765-334790 and 335634-335637.
Maximum likelihood phylogenetic trees were constructed with
PhyML (http://www.atgc-montpellier.fr/phyml) using HKY85
as the nucleotides substitution model with bootstrapping
(Geneious Pro 5.1.4 software).
Computational Structural Analysis
Computational structural analysis of combinations of candi-
date permissive mutations in the NA was conducted
using FoldX [31], an empirical all-atom force ﬁeld that
allows the calculation of protein stability changes upon muta-
tion by approximating the free energy of unfolding through
weighted terms. To validate the calculations, more than 1000
mutations representative of most structural environments were
analyzed and achieved a global correlation of 0.8 with experi-
mentally measured thermodynamic data. In this work, the A
(H1N1)pdm09 NA crystal structure (PDB:3nss) was mini-
mized with the RepairPDB function, then mutations were in-
troduced separately or as cumulative combinations using
FoldX in YASARA [32], where the stochastic side chain mini-
mization procedure is repeated 5 times for each mutant and
the averages are taken as ﬁnal predicted free-energy change.
Results
Frequency of Oseltamivir Resistance
From the HNE health district, 2673 respiratory tract speci-
mens were collected for inﬂuenza testing by nucleic acid
testing (NAT) at HAPS in the period 20 May 2011 to 28
October 2011 (23 weeks) from a population of 874 644 (0.3%).
Of the 749 inﬂuenza NAT-positive specimens, 439 (59%) were
A(H1N1)pdm09 viruses (Figure 2) and 191 had sufﬁcient
volume to enable antiviral susceptibility analysis by the WHO
CCRRI. Twenty-nine (15%) of these 191 A(H1N1)pdm09
viruses were found to contain the H275Y NA substitution by
either pyrosequencing of original specimens (n = 18) or con-
ventional NA sequencing of isolates following an NA inhibi-
tion assay (n = 11). H275Y A(H1N1)pdm09 viruses were
obtained from patients between 31 May and 19 August 2011
(Figure 3). The frequency of resistance over time was 4/51
(8%) in June, 20/85 (24%) in July, 4/45 (8%) in August, and
0/4 (0%) in September by which time inﬂuenza activity had
become very low in the region (Figure 2). Twenty-six of the 29
patients infected with oseltamivir-resistant viruses lived in 5
adjacent local municipalities (Cessnock, Lake Macquarie,
Maitland, Newcastle, Port Stephens) within 50 kilometers of
Newcastle. The other 3 patients lived in rural towns 90, 150,
and 490 kilometers away from Newcastle.
In comparison, only 5 oseltamivir-resistant H275Y viruses
were detected out of 737 A(H1N1)pdm09 viruses tested (fre-
quency, 0.7%) from the rest of Australia during 2011
(Figure 3). Two of these strains from January and March 2011
were from other Australian states (Queensland and Western
Australia) and were isolated from hospitalized immunocom-
promised patients undergoing oseltamivir treatment. However,
2 oseltamivir-resistant H275Y viruses from elsewhere in NSW
and 1 from Western Australia were collected during or after
the period of oseltamivir-resistant virus detection in the HNE
health district. One of the NSW oseltamivir-resistant viruses
was detected in July 2011 from a child in Sydney, NSW, 120
kilometers south of Newcastle, while the other was detected in
August 2011 from an infant in Orange, NSW, a town
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approximately 380 kilometers west of Newcastle. The Western
Australian oseltamivir-resistant virus was detected in Septem-
ber 2011, 3 weeks after the last detected case in the HNE
health district, and in a location near Perth, approximately
4000 kilometers west of Newcastle. All 3 of these resistant
viruses were taken from otherwise healthy children who had
not been treated with oseltamivir. Neither they nor their
family members had traveled recently to Newcastle, and in the
Western Australian case, there had been no recent contact
with anyone from NSW.
Figure 2. Number of laboratory-conﬁrmed inﬂuenza positive specimens detected in the Hunter New England health district during 2011.
Figure 3. Frequency of detection of oseltamivir-resistant H275Y variants in Australia in 2011. A red dot represents the sample date of an individual
oseltamivir-resistant A(H1N1)pdm09 H275Y case, and a blue dot indicates the sample date of an individual oseltamivir-sensitive A(H1N1)pdm09 case
detected in the states and territories of Australia in 2011.
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Patient Details for HNE Health District Oseltamivir-Resistant
Cases
Seventeen (59%) of the 29 patients infected with oseltamivir-
resistant viruses were female and 3 (10%) were pregnant. Three
(10%) identiﬁed themselves as Aboriginal. The age range was 4
months to 62 years (median, 31 years) compared with a
median age of 29 years for persons infected with oseltamivir-
sensitive inﬂuenza A(H1N1)pdm09. No cases resided in insti-
tutional care or aged care facilities. Cough was reported by 25
(86%) cases and fever by 22 (76%) cases. One patient was
asymptomatic, but was swabbed and tested for inﬂuenza due to
contact with a laboratory-proven A(H1N1)pdm09 case. Six
(21%) cases reported a history of asthma; none had a history of
chronic obstructive pulmonary disease; 6 (21%) were current
smokers with an average pack-year history of 20 (range, 1–62)
and none were immunosuppressed. Three (10%) cases had re-
ceived trivalent-inactivated inﬂuenza vaccine in 2011. Impor-
tantly, only 1 patient infected with an oseltamivir-resistant
virus had received oseltamivir prior to their specimen being
collected (in this case, received 4 days prior to specimen being
taken). Eleven (38%) were prescribed oseltamivir after speci-
men collection. Seven (24%) patients required hospital admis-
sion with a mean length of stay of 2.3 days (range, 1–7 days).
There were no intensive care admissions and no fatal out-
comes. The median number of days absent from usual duties
was 5. Of the 29 patients infected with an oseltamivir-resistant
virus, 5 pairs of cases were epidemiologically linked. Four
households had 2 affected cases each, while a ﬁfth pair of cases
shared a short car journey. No other links could be identiﬁed
during interviews with cases. Detailed outcomes were not col-
lected for persons infected with oseltamivir-sensitive inﬂuenza.
Virological Analysis of Oseltamivir-Resistant Viruses
For the viruses that were isolated in cell culture, the oseltami-
vir-resistant H275Y strains (n = 11) had a mean (±1 SD) osel-
tamivir IC50 of 205.3 ± 23.5 nM that was 513-fold higher than
the mean IC50 of oseltamivir-sensitive isolates (n = 3579)
(Table 1). The H275Y isolates also demonstrated elevated per-
amivir IC50 values (16.6 ± 1.5 nM) that were approximately
80-fold higher than sensitive strains, but were fully sensitive to
zanamivir (Table 1). The oseltamivir-resistant viruses were
also resistant to the adamantane class of inﬂuenza antiviral
drugs based on M2 sequencing, having the characteristic S31N
substitution. These H275Y variants, including those from the
3 patients that received the inﬂuenza vaccine in 2011, were an-
tigenically indistinguishable from the oseltamivir-sensitive
viruses and were well inhibited by ferret serum samples raised
against the current A(H1N1)pdm09 vaccine strain A/Califor-
nia/7/2009 in a hemagglutination-inhibition assay (Supple-
mentary Table 1).
Phylogenetic analysis of the hemagglutinin and NA se-
quences revealed that the oseltamivir-resistant viruses from
Table 1. NA Inhibitor Sensitivity of Hunter New England Health District Oseltamivir-Resistant H275Y Viruses
Virus
Zanamivir Oseltamivir Carboxylate Peramivir
Mean IC50± SD (nM) Fold Diff
a Mean IC50± SD (nM) Fold Diff
a Mean IC50± SD (nM) Fold Diff
a
Mean of HNE health district
H275Y A(H1N1) pdm09
viruses (n = 11)
0.3 ± 0.02 1 205.3 ± 23.5 513 16.6 ± 1.5 83
Mean of HNE health district
sensitive A(H1N1) pdm09
viruses (n = 65)
0.4 ± 0.2 1 0.5 ± 0.3 1 0.2 ± 0.1 1
Mean of all sensitive A(H1N1)
pdm09 viruses (n = 3579)
0.3 ± 0.2 … 0.4 ± 0.3 … 0.2 ± 0.1b …
A/Newcastle/2/2011 0.3 ± 0.02 1 191.1 ± 19.4 478 18.6 ± 6.8 93
A/Newcastle/17/2011 0.3 ± 0.04 1 223.7 ± 14.2 559 18.0 ± 2.3 90
A/Newcastle/37/2011 0.3 ± 0.1 1 247.9 ± 27.2 620 16.9 ± 0.8 85
A/Newcastle/53/2011 0.2 ± 0.04 1 187.8 ± 30.0 470 13.8 ± 1.2 69
A/Newcastle/62/2011 0.2 ± 0.04 1 199.9 ± 19.7 500 15.9 ± 1.7 79
A/Newcastle/82/2011 0.2 ± 0.1 1 198.5 ± 36.2 496 15.2 ± 1.5 76
A/Newcastle/85/2011 0.2 ± 1.1 1 226.6 ± 11.4 567 16.7 ± 1.3 83
A/Newcastle/89/2011 0.3 ± 0.04 1 227.8 ± 13.1 569 16.9 ± 1.8 85
A/Newcastle/132/2011 0.3 ± 0.04 1 198.1 ± 26.8 495 15.8 ± 1.5 79
A/Newcastle/151/2011 0.2 ± 0.02 1 191.0 ± 46.6 478 15.9 ± 2.2 79
A/Newcastle/129/2011 0.3 ± 0.03 1 165.9 ± 26.1 415 18.8 ± 2.7 94
Abbreviations: Diff, difference; HNE, Hunter New England; IC50, inhibitory concentration.
a Based on comparison with mean IC50 of all sensitive A(H1N1)pdm09 viruses.
b Mean and standard deviation of peramivir IC50 values based on analysis of n = 273 isolates.
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the HNE health district, the 2 other NSW viruses detected in
Sydney and Orange, and the Western Australian strain from
September 2011 were all highly similar (99.9% nucleotide sim-
ilarity across 22 HA and 18 NA sequences) and formed a dis-
tinct subgroup in both the HA and NA phylogenetic trees
(Figure 4). Apart from the H275Y NA substitution, the oselta-
mivir-resistant strains all contained 2 other NA amino acid
substitutions, V62I and N386S, which were absent from all
but 1 of the local oseltamivir-sensitive viruses (A/Newcastle/
84/2011) (Figure 4). In addition to the NA substitutions,
whole-genome sequence comparison of 8 oseltamivir-resistant
strains and 5 oseltamivir-sensitive strains from the HNE
health district revealed 3 further substitutions across 3 other
segments that were speciﬁc to the resistant strains—E129K in
HA, L672F in PA, and S482N in NP. Genetic comparison of
the 2 viruses from each of the linked cases showed 100%
nucleotide similarity across the HA and NA genes, although
sequence data were not available for viruses from 2 of the
paired cases. In addition, other oseltamivir-sensitive A(H1N1)
pdm09 strains, including A/South Australia/24/2011 and
A/Hong Kong/2973/2011, clustered phylogenetically with the
resistant strains (Figure 4), sharing a high degree of genetic
similarity, except for the H275Y NA substitution. Full phylo-
genetic trees comparing the HNE health district sequences
with publically available 2011 A(H1N1)pdm09 HA and NA
sequences are shown in the supplementary data (Supplemen-
tary Figure 1A and 1B).
Computational Analysis of Potentially Permissive NA
Substitutions
To investigate the role of potentially permissive NA mutations
that may be responsible for offsetting the negative effects of
the H275Y substitution, a computational analysis of NA
protein stability was conducted. Since the emergence of the A
(H1N1)pdm09 strain in 2009, a number of NA mutations
have been described and, in some cases, have become ﬁxed
Figure 4. Phylogenetic trees of hemagglutinin (A) and neuraminidase (B) sequences of oseltamivir-resistant H275Y variants and oseltamivir-sensitive
wild type A(H1N1)pdm09 viruses. Hunter New England health district and other NSW and Western Australian H275Y variants are shown in red,
sporadic H275Y mutants from other regions in green, and Hunter New England health district sensitive viruses in blue. Amino acid mutations common
to each clade and bootstrap conﬁdence values >75 are indicated on the trees.
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within globally circulating strains (Figure 5). Based on compu-
tational analysis, 2 of these mutations, V241I and N369K,
both of which emerged in A(H1N1)pdm09 viruses in 2010
and are now present in over 80% of currently circulating
strains (Figure 5), could restore approximately 50% of the
protein stability that was lost as a result of the H275Y muta-
tion (Figure 6). In addition, the HNE health district and other
NSW oseltamivir-resistant viruses contained an N386S NA
substitution. This substitution is less common in other A
(H1N1)pdm09 viruses, but computational analysis suggested
that it would also further stabilize the NA (Figure 6). Another
NA substitution that has been on the rise in recent strains and
was present in the oseltamivir-resistant viruses described here
is N44S. It creates a new potential N-glycosylation site at posi-
tion 42, changing the motif at positions 42–44 from NQN to
NQS. However, this region of the NA is in the stalk and not
part of the globular domain and, therefore, is not known how
it would affect NA structure and stability.
Discussion
The H275Y variants detected in the HNE health district, other
parts of NSW, and in Western Australia represent the largest
and most widespread cluster of oseltamivir-resistant A(H1N1)
pdm09 inﬂuenza identiﬁed since the virus ﬁrst emerged in
humans in 2009. The oseltamivir-resistant strains detected
from these locations were virtually identical genetically, sug-
gesting emergence from a single source.
The rapid global spread of oseltamivir-resistant seasonal A
(H1N1) H275Y viruses during 2007–2008 [11, 12] showed
that A(H1N1) inﬂuenza viruses with this substitution could
retain transmissibility, even though previous in vitro and in
vivo studies found the substitution reduced ﬁtness in other A
(H1N1) strains [13, 14]. A recent study demonstrated that sea-
sonal A(H1N1) oseltamivir-resistant H275Y viruses exhibited
reduced susceptibility to postvaccination antibody inhibition
compared to the cocirculating oseltamivir-sensitive viruses
Figure 5. All human A(H1N1)pdm09 NA sequences containing date information (at least year/month) were downloaded from the National Center for
Biotechnology Information inﬂuenza virus resource [41] (http://www.ncbi.nlm.nih.gov/genomes/FLU/) and GISAID (http://www.gisaid.org) and merged
with the ones reported in this study (keeping only 1 per unique strain identiﬁer). Sequences shorter than 90% of the median length are considered as
fragmentary and were removed from the analysis. The resulting 8085 sequences were then aligned with the multiple sequence alignment program
MAFFT [42] and mutation frequencies relative to the vaccine reference strain A/California/07/2009 counted with a custom perl script. All mutations
with at least 50 occurrences since March 2009 and global frequencies >20% in any month are shown, plus L415M, which is characteristic for an
outbreak with H275Y in Japan in January. Data collected in the month of March 2009 were merged with April 2009, while data collected from
September 2011 were merged with August 2011 as there were less than 10 sequences in those months.
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[30], which may have contributed to the virtual replacement
of the oseltamivir-sensitive seasonal A(H1N1) strain within 1
year. Based on antigenic analyses with postinfection ferret
serum samples, the oseltamivir-resistant A(H1N1)pdm09
H275Y viruses reported here are antigenically similar to osel-
tamivir-sensitive A/California/7/2009-like A(H1N1)pdm09
strains circulating in the HNE health district and elsewhere in
Australia, although future studies using postvaccination
human serum should be performed [30]. The high frequency
of resistance in untreated community patients suggests that
they are not markedly less ﬁt than sensitive viruses. This situa-
tion is similar to the oseltamivir-resistant seasonal A(H1N1)
viruses that emerged in Norway in 2007 where, like Australia,
the use of oseltamivir was low compared to countries such as
Japan and the United States [31].
Recently, it has been shown that certain substitutions in the
NA, V234M and R222Q, enabled the seasonal A(H1N1) virus
to remain fully functional in the presence of the H275Y sub-
stitution [32, 33]. These permissive substitutions are not
present in the A(H1N1)pdm09 oseltamivir-resistant H275Y
variants reported here. Most A(H1N1)pdm09 sequences (in-
cluding the strains reported here) have the nonpermissive V at
position 234, and the most typical amino acid at position 222
among the A(H1N1)pdm09 NAs is N. However, 3 other NA
substitutions, V241I, N369K, and the N386S, which were
present in the oseltamivir-resistant strains from the cluster re-
ported here, may offset the destabilizing effect of the H275Y
substitution. The V241I and N369K substitutions are present
not only in the H275Y variants reported here, but are also in
viral sequences of North American and a large number of Jap-
anese oseltamivir-resistant H275Y strains recently deposited
on the GISAID sequence database (Supplementary Figure 1A
and 1B). Importantly, the N369K substitution, which compu-
tationally was predicted to cause the largest change in protein
stability, has previously been shown experimentally to increase
NA surface expression and activity in combination with
H275Y [32].
Infection with oseltamivir-resistant seasonal A(H1N1)
viruses signiﬁcantly reduced the effectiveness of oseltamivir
during the 2008–2009 season, particularly in younger children
[15–18]. For patients infected with oseltamivir-resistant
viruses, fever levels were comparable between oseltamivir-
treated and untreated patients, but signiﬁcantly reduced in za-
namivir-treated patients [15]. Mean duration of fever after the
start of oseltamivir treatment was also signiﬁcantly longer in
persons infected with oseltamivir-resistant viruses than in
those infected with oseltamivir-sensitive viruses [15, 17, 18],
while treatment of the H275Y viruses with zanamivir reduced
fever duration to normal levels [18]. Although the relationship
between in vitro IC50 of a virus and clinical effectiveness is not
well understood, it is noteworthy that the mean oseltamivir
IC50 of the H275Y A(H1N1)pdm09 viruses is generally lower
than that of the H275Y seasonal A(H1N1) variants [12, 34,
35], and is below the steady-state trough plasma concentra-
tions found in children, adolescents, and adults following rec-
ommended dosing [36]. As a result, oseltamivir treatment may
be more effective for the A(H1N1)pdm09 H275Y variant than
has been reported for the H275Y seasonal A(H1N1) variants.
Figure 6. Computational structural analysis of combinations of candidate permissive mutations in the neuraminidase (NA). Mutations were modeled
with FoldX in the A(H1N1)pdm09 NA crystal structure (PDB:3nss) after minimization and using 5 repetitions.
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More data regarding the effectiveness of oseltamivir for the
treatment of A(H1N1)pdm09 H275Y viruses, and other vari-
ants with reduced oseltamivir sensitivity, are needed. Eleven of
the oseltamivir-resistant HNE health district cases received
oseltamivir after specimen collection but, because the resistant
virus was detected after the patient had recovered and treat-
ment had ceased, it was not possible to investigate the effec-
tiveness of oseltamivir. The effectiveness of peramivir is also
likely to be reduced for the treatment of H275Y A(H1N1)
pdm09 viruses given the 80-fold increase in IC50 [37], as such
current WHO guidelines state that intravenous peramivir
should only be considered for the treatment of such viruses
when intravenous zanamivir is not available [38]. However,
recent animal data suggest that 5 days of therapy with intrave-
nous peramivir may overcome the shift in sensitivity to pera-
mivir caused by the H275Y substitution [39]. Given that the
H275Y variant is fully susceptible to zanamivir in vitro, this
drug remains the recommended alternative antiviral treatment
option when oseltamivir resistance is detected [38].
Of the 29 H275Y A(H1N1)pdm09 viruses detected in the
HNE health district, none caused severe illness or resulted in
patients being admitted to intensive care wards. However,
because detailed clinical or epidemiological information was
not collected at the same time from a comparison group of
patients with oseltamivir-sensitive virus infections, it was not
possible to determine whether there were any differences
between the types of patients infected or the types of illness
caused by oseltamivir-sensitive and -resistant viruses. Another
limitation is that a relatively small number of A(H1N1)pdm09
viruses were available for testing (191 from the HNE health
district and 737 from the rest of Australia). Therefore, not
only may the true prevalence of resistance be different to that
reported here, but the spread of the genetically related oselta-
mivir-resistant virus may also be wider than detected.
Inﬂuenza activity in the HNE health district and the rest of
Australia has now returned to baseline levels, although the
detection of the variant outside the HNE health district is
concerning and demonstrates its capacity to spread widely.
Oseltamivir-resistant strains that were indistinguishable to
those detected in the HNE health district were identiﬁed in
Sydney, the largest city in Australia and a large international
travel hub, and near Perth, Western Australia, on the other
side of the country to Newcastle. To date, there is no indication
that this oseltamivir-resistant A(H1N1)pdm09 strain has
spread into the northern hemisphere, although it will be
important for countries to monitor strains throughout the
upcoming northern hemisphere inﬂuenza season. The most
recent A(H1N1)pdm09 sequences strains deposited on
GISAID at the time of writing are from the United States
(Hawaii, California, Pennsylvania), and although none of them
have the H275Y substitution, they all have the NA substitu-
tions V241I and N369K, which may buffer the detrimental
effect of the H275Y oseltamivir-resistance mutation. The other
non-NA amino acid substitutions in the oseltamivir-resistant
viruses from the cluster (HA, PA, and NP) may also play a role
in viral ﬁtness. In vitro and in vivo studies are currently in
progress to analyze the ﬁtness of the strains from this cluster
and investigate the role of these potentially “permissive” muta-
tions. However, this cluster of cases, along with the recent
reports of increased detection of H275Y A(H1N1)pdm09
viruses in untreated community patients in the United
Kingdom and United States [24, 40] and the large number of
recent sequences with the H275Y substitution deposited on
GISAID from Japan, suggests that the currently circulating A
(H1N1)pdm09 may be becoming more tolerant of the H275Y
mutation than it was when the strain ﬁrst emerged in 2009,
and that widespread emergence of oseltamivir-resistant A
(H1N1)pdm09 viruses may now be more likely.
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